Antibodies to HSDEK49 polypeptides

[0001] This application is a divisional of U.S. application Ser. No. 11/346,470, filed Feb. 3, 2006, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 10/472,532, filed Sep. 20, 2003 and accorded a National Stage filing date of Jun. 23, 2004, now abandoned, which is the 35 U.S.C. §371 National Stage of PCT/US02/08278, filed Mar. 19, 2002, which in turn claims benefit of U.S. patent application Ser. No. 10/100,683 (now U.S. Pat. No. 7,368,531, issued May 6, 2008). U.S. application Ser. No. 11/346,470 is also a continuation-in-part of U.S. patent application Ser. No. 10/100,683, filed Mar. 19, 2002, which in turn claims benefit of the following:

[0002]

			Parent
		Parent	Filing
Application::	Continuity Type::	Application::	Date::
10/100,683	Non-provisional of	60/277,340	Mar. 21, 2001
10/100,683	Non-provisional of	60/306,171	Jul. 19, 2001
10/100,683	Non-provisional of	60/331,287	Nov. 13, 2001
10/100,683	Continuation-in-part of	09/981,876	Oct. 19, 2001
09/981,876	Divisional of	09/621,011	Jul. 20, 2000
09/621,011	Continuation of	09/148,545	Sep. 4, 1998
09/148,545	Continuation-in-part of	PCT/US98/	Mar. 6, 1998
		04482
10/100,683	Continuation-in-part of	09/621,011	Jul. 20, 2000
09/621,011	Continuation of	09/148,545	Sep. 4, 1998
09/148,545	Continuation-in-part of	PCT/US98/	Mar. 6, 1998
		04482
10/100,683	Continuation-in-part of	09/148,545	Sep. 4, 1998
09/148,545	Continuation-in-part of	PCT/US98/	Mar. 6, 1998
		04482
10/100,683	Continuation-in-part of	PCT/US98/	Mar. 6, 1998
		04482
PCT/US98/04482	Non-provisional of	60/040,162	Mar. 7, 1997
PCT/US98/04482	Non-provisional of	60/040,333	Mar. 7, 1997
PCT/US98/04482	Non-provisional of	60/038,621	Mar. 7, 1997
PCT/US98/04482	Non-provisional of	60/040,161	Mar. 7, 1997
PCT/US98/04482	Non-provisional of	60/040,626	Mar. 7, 1997
PCT/US98/04482	Non-provisional of	60/040,334	Mar. 7, 1997
PCT/US98/04482	Non-provisional of	60/040,336	Mar. 7, 1997
PCT/US98/04482	Non-provisional of	60/040,163	Mar. 7, 1997
PCT/US98/04482	Non-provisional of	60/047,615	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,600	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,597	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,502	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,633	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,583	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,617	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,618	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,503	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,592	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,581	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,584	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,500	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,587	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,492	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,598	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,613	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,582	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,596	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,612	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,632	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,601	May 23, 1997
PCT/US98/04482	Non-provisional of	60/043,580	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/043,568	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/043,314	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/043,569	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/043,311	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/043,671	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/043,674	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/043,669	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/043,312	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/043,313	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/043,672	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/043,315	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/048,974	Jun. 6, 1997
PCT/US98/04482	Non-provisional of	60/056,886	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,877	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,889	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,893	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,630	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,878	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,662	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,872	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,882	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,637	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,903	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,888	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,879	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,880	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,894	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,911	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,636	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,874	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,910	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,864	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,631	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,845	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,892	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/047,595	May 23, 1997
PCT/US98/04482	Non-provisional of	60/057,761	Sep. 5, 1997
PCT/US98/04482	Non-provisional of	60/047,599	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,588	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,585	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,586	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,590	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,594	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,589	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,593	May 23, 1997
PCT/US98/04482	Non-provisional of	60/047,614	May 23, 1997
PCT/US98/04482	Non-provisional of	60/043,578	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/043,576	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/047,501	May 23, 1997
PCT/US98/04482	Non-provisional of	60/043,670	Apr. 11, 1997
PCT/US98/04482	Non-provisional of	60/056,632	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,664	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,876	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,881	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,909	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,875	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,862	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,887	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/056,908	Aug. 22, 1997
PCT/US98/04482	Non-provisional of	60/048,964	Jun. 6, 1997
PCT/US98/04482	Non-provisional of	60/057,650	Sep. 5, 1997
PCT/US98/04482	Non-provisional of	60/056,884	Aug. 22, 1997
10/100,683	Continuation-in-part of	09/882,171	Jun. 18, 2001
09/882,171	Non-provisional of	60/190,068	Mar. 17, 2000
09/882,171	Continuation of	09/809,391	Mar. 16, 2001
09/809,391	Continuation-in-part of	09/149,476	Sep. 8, 1998
09/149,476	Continuation-in-part of	PCT/US98/	Mar. 6, 1998
		04493
10/100,683	Continuation-in-part of	09/809,391	Mar. 16, 2001
09/809,391	Non-provisional of	60/190,068	Mar. 17, 2000
09/809,391	Continuation-in-part of	09/149,476	Sep. 8, 1998
09/149,476	Continuation-in-part of	PCT/US98/	Mar. 6, 1998
		04493
10/100,683	Continuation-in-part of	09/149,476	Sep. 8, 1998
09/149,476	Continuation-in-part of	PCT/US98/	Mar. 6, 1998
		04493
10/100,683	Continuation-in-part of	PCT/US98/	Mar. 6, 1998
		04493
PCT/US98/04493	Non-provisional of	60/040,161	Mar. 7, 1997
PCT/US98/04493	Non-provisional of	60/040,162	Mar. 7, 1997
PCT/US98/04493	Non-provisional of	60/040,333	Mar. 7, 1997
PCT/US98/04493	Non-provisional of	60/038,621	Mar. 7, 1997
PCT/US98/04493	Non-provisional of	60/040,626	Mar. 7, 1997
PCT/US98/04493	Non-provisional of	60/040,334	Mar. 7, 1997
PCT/US98/04493	Non-provisional of	60/040,336	Mar. 7, 1997
PCT/US98/04493	Non-provisional of	60/040,163	Mar. 7, 1997
PCT/US98/04493	Non-provisional of	60/047,600	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,615	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,597	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,502	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,633	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,583	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,617	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,618	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,503	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,592	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,581	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,584	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,500	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,587	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,492	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,598	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,613	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,582	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,596	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,612	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,632	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,601	May 23, 1997
PCT/US98/04493	Non-provisional of	60/043,580	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/043,568	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/043,314	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/043,569	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/043,311	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/043,671	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/043,674	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/043,669	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/043,312	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/043,313	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/043,672	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/043,315	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/048,974	Jun. 6, 1997
PCT/US98/04493	Non-provisional of	60/056,886	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,877	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,889	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,893	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,630	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,878	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,662	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,872	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,882	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,637	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,903	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,888	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,879	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,880	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,894	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,911	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,636	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,874	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,910	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,864	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,631	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,845	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,892	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/057,761	Sep. 5, 1997
PCT/US98/04493	Non-provisional of	60/047,595	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,599	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,588	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,585	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,586	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,590	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,594	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,589	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,593	May 23, 1997
PCT/US98/04493	Non-provisional of	60/047,614	May 23, 1997
PCT/US98/04493	Non-provisional of	60/043,578	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/043,576	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/047,501	May 23, 1997
PCT/US98/04493	Non-provisional of	60/043,670	Apr. 11, 1997
PCT/US98/04493	Non-provisional of	60/056,632	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,664	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,876	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,881	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,909	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,875	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,862	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,887	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/056,908	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/048,964	Jun. 6, 1997
PCT/US98/04493	Non-provisional of	60/057,650	Sep. 5, 1997
PCT/US98/04493	Non-provisional of	60/056,884	Aug. 22, 1997
PCT/US98/04493	Non-provisional of	60/057,669	Sep. 5, 1997
PCT/US98/04493	Non-provisional of	60/049,610	Jun. 13, 1997
PCT/US98/04493	Non-provisional of	60/061,060	Oct. 2, 1997
PCT/US98/04493	Non-provisional of	60/051,926	Jul. 8, 1997
PCT/US98/04493	Non-provisional of	60/052,874	Jul. 16, 1997
PCT/US98/04493	Non-provisional of	60/058,785	Sep. 12, 1997
PCT/US98/04493	Non-provisional of	60/055,724	Aug. 18, 1997
10/100,683	Continuation-in-part of	10/058,993	Jan. 30, 2002
10/058,993	Non-provisional of	60/265,583	Feb. 2, 2001
10/058,993	Continuation-in-part of	09/852,659	May 11, 2001
09/852,659	Continuation-in-part of	09/152,060	Sep. 11, 1998
09/152,060	Continuation-in-part of	PCT/US98/	Mar. 12, 1998
		04858
10/058,993	Continuation-in-part of	09/853,161	May 11, 2001
09/853,161	Continuation-in-part of	09/152,060	Sep. 11, 1998
09/152,060	Continuation-in-part of	PCT/US98/	Mar. 12, 1998
		04858
10/058,993	Continuation-in-part of	09/852,797	May 11, 2001
09/852,797	Continuation-in-part of	09/152,060	Sep. 11, 1998
09/152,060	Continuation-in-part of	PCT/US98/	Mar. 12, 1998
		04858
10/100,683	Continuation-in-part of	09/852,659	May 11, 2001
09/852,659	Non-provisional of	60/265,583	Feb. 2, 2001
09/852,659	Continuation-in-part of	09/152,060	Sep. 11, 1998
09/152,060	Continuation-in-part of	PCT/US98/	Mar. 12, 1998
		04858
10/100,683	Continuation-in-part of	09/853,161	May 11, 2001
09/853,161	Non-provisional of	60/265,583	Feb. 2, 2001
09/853,161	Continuation-in-part of	09/152,060	Sep. 11, 1998
09/152,060	Continuation-in-part of	PCT/US98/	Mar. 12, 1998
		04858
10/100,683	Continuation-in-part of	09/852,797	May 11, 2001
09/852,797	Non-provisional of	60/265,583	Feb. 2, 2001
09/852,797	Continuation-in-part of	09/152,060	Sep. 11, 1998
09/152,060	Continuation-in-part of	PCT/US98/	Mar. 12, 1998
		04858
10/100,683	Continuation-in-part of	09/152,060	Sep. 11, 1998
09/152,060	Continuation-in-part of	PCT/US98/	Mar. 12, 1998
		04858
10/100,683	Continuation-in-part of	PCT/US98/	Mar. 12, 1998
		04858
PCT/US98/04858	Non-provisional of	60/040,762	Mar. 14, 1997
PCT/US98/04858	Non-provisional of	60/040,710	Mar. 14, 1997
PCT/US98/04858	Non-provisional of	60/050,934	May 30, 1997
PCT/US98/04858	Non-provisional of	60/048,100	May 30, 1997
PCT/US98/04858	Non-provisional of	60/048,357	May 30, 1997
PCT/US98/04858	Non-provisional of	60/048,189	May 30, 1997
PCT/US98/04858	Non-provisional of	60/057,765	Sep. 5, 1997
PCT/US98/04858	Non-provisional of	60/048,970	Jun. 6, 1997
PCT/US98/04858	Non-provisional of	60/068,368	Dec. 19, 1997
10/100,683	Continuation-in-part of	10/059,395	Jan. 31, 2002
10/059,395	Divisional of	09/966,262	Oct. 1, 2001
09/966,262	Continuation of	09/154,707	Sep. 17, 1998
09/154,707	Continuation-in-part of	PCT/US98/	Mar. 19, 1998
		05311
10/100,683	Continuation-in-part of	09/984,245	Oct. 29, 2001
09/984,245	Divisional of	09/154,707	Sep. 17, 1998
09/154,707	Continuation-in-part of	PCT/US98/	Mar. 19, 1998
		05311
10/100,683	Continuation-in-part of	09/983,966	Oct. 26, 2001
09/983,966	Divisional of	09/154,707	Sep. 17, 1998
09/154,707	Continuation-in-part of	PCT/US98/	Mar. 19, 1998
		05311
10/100,683	Continuation-in-part of	09/966,262	Oct. 1, 2001
09/966,262	Continuation of	09/154,707	Sep. 17, 1998
09/154,707	Continuation-in-part of	PCT/US98/	Mar. 19, 1998
		05311
10/100,683	Continuation-in-part of	09/154,707	Sep. 17, 1998
09/154,707	Continuation-in-part of	PCT/US98/	Mar. 19, 1998
		05311
10/100,683	Continuation-in-part of	PCT/US98/	Mar. 3, 1998
		05311
PCT/US98/05311	Non-provisional of	60/041,277	Mar. 21, 1997
PCT/US98/05311	Non-provisional of	60/042,344	Mar. 21, 1997
PCT/US98/05311	Non-provisional of	60/041,276	Mar. 21, 1997
PCT/US98/05311	Non-provisional of	60/041,281	Mar. 21, 1997
PCT/US98/05311	Non-provisional of	60/048,094	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,350	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,188	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,135	May 30, 1997
PCT/US98/05311	Non-provisional of	60/050,937	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,187	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,099	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,352	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,186	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,069	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,095	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,131	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,096	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,355	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,160	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,351	May 30, 1997
PCT/US98/05311	Non-provisional of	60/048,154	May 30, 1997
PCT/US98/05311	Non-provisional of	60/054,804	Aug. 5, 1997
PCT/US98/05311	Non-provisional of	60/056,370	Aug. 19, 1997
PCT/US98/05311	Non-provisional of	60/060,862	Oct. 2, 1997
10/100,683	Continuation-in-part of	09/814,122	Mar. 22, 2001
09/814,122	Continuation of	09/577,145	May 24, 2000
09/577,145	Continuation of	09/166,780	Oct. 6, 1998
09/166,780	Continuation-in-part of	PCT/US98/	Apr. 7, 1998
		06801
10/100,683	Continuation-in-part of	PCT/US98/	Apr. 7, 1998
		06801
PCT/US98/06801	Non-provisional of	60/042,726	Apr. 8, 1997
PCT/US98/06801	Non-provisional of	60/042,727	Apr. 8, 1997
PCT/US98/06801	Non-provisional of	60/042,728	Apr. 8, 1997
PCT/US98/06801	Non-provisional of	60/042,754	Apr. 8, 1997
PCT/US98/06801	Non-provisional of	60/042,825	Apr. 8, 1997
PCT/US98/06801	Non-provisional of	60/048,068	May 30, 1997
PCT/US98/06801	Non-provisional of	60/048,070	May 30, 1997
PCT/US98/06801	Non-provisional of	60/048,184	May 30, 1997
10/100,683	Continuation-in-part of	PCT/US98/	Apr. 7, 1997
		06801
PCT/US98/06801	Non-provisional of	60/042,726	Apr. 8, 1997
PCT/US98/06801	Non-provisional of	60/042,727	Apr. 8, 1997
PCT/US98/06801	Non-provisional of	60/042,728	Apr. 8, 1997
PCT/US98/06801	Non-provisional of	60/042,754	Apr. 8, 1997
PCT/US98/06801	Non-provisional of	60/042,825	Apr. 8, 1997
PCT/US98/06801	Non-provisional of	60/048,068	May 30, 1997
PCT/US98/06801	Non-provisional of	60/048,070	May 30, 1997
PCT/US98/06801	Non-provisional of	60/048,184	May 30, 1997
10/100,683	Continuation-in-part of	PCT/US98/	May 28, 1998
		10868
PCT/US98/10868	Non-provisional of	60/044,039	May 30, 1997
PCT/US98/10868	Non-provisional of	60/048,093	May 30, 1997
PCT/US98/10868	Non-provisional of	60/048,190	May 30, 1997
PCT/US98/10868	Non-provisional of	60/050,935	May 30, 1997
PCT/US98/10868	Non-provisional of	60/048,101	May 30, 1997
PCT/US98/10868	Non-provisional of	60/048,356	May 30, 1997
PCT/US98/10868	Non-provisional of	60/056,250	Aug. 29, 1997
PCT/US98/10868	Non-provisional of	60/056,296	Aug. 29, 1997
PCT/US98/10868	Non-provisional of	60/056,293	Aug. 29, 1997
10/100,683	Continuation-in-part of	PCT/US98/	Jun. 4, 1998
		11422
PCT/US98/11422	Non-provisional of	60/048,885	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/049,375	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,881	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,880	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,896	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/049,020	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,876	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,895	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,884	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,894	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,971	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,964	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,882	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,899	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,893	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,900	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,901	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,892	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,915	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/049,019	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,970	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,972	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,916	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/049,373	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,875	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/049,374	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,917	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,949	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,974	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,883	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,897	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,898	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,962	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,963	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,877	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/048,878	Jun. 6, 1997
PCT/US98/11422	Non-provisional of	60/057,645	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,642	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,668	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,635	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,627	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,667	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,666	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,764	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,643	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,769	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,763	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,650	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,584	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,647	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,661	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,662	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,646	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,654	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,651	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,644	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,765	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,762	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,775	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,648	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,774	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,649	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,770	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,771	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,761	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,760	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,776	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,778	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,629	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,628	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,777	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/057,634	Sep. 5, 1997
PCT/US98/11422	Non-provisional of	60/070,923	Dec. 18, 1997
10/100,683	Continuation-in-part of	PCT/US01/	Feb. 21, 2001
		05614
PCT/US01/05614	Non-provisional of	60/184,836	Feb. 24, 2000
PCT/US01/05614	Non-provisional of	60/193,170	Mar. 29, 2000
10/100,683	Continuation-in-part of	PCT/US98/	Jun. 11, 1998
		12125
PCT/US98/12125	Non-provisional of	60/049,547	Jun. 13, 1997
PCT/US98/12125	Non-provisional of	60/049,548	Jun. 13, 1997
PCT/US98/12125	Non-provisional of	60/049,549	Jun. 13, 1997
PCT/US98/12125	Non-provisional of	60/049,550	Jun. 13, 1997
PCT/US98/12125	Non-provisional of	60/049,566	Jun. 13, 1997
PCT/US98/12125	Non-provisional of	60/049,606	Jun. 13, 1997
PCT/US98/12125	Non-provisional of	60/049,607	Jun. 13, 1997
PCT/US98/12125	Non-provisional of	60/049,608	Jun. 13, 1997
PCT/US98/12125	Non-provisional of	60/049,609	Jun. 13, 1997
PCT/US98/12125	Non-provisional of	60/049,610	Jun. 13, 1997
PCT/US98/12125	Non-provisional of	60/049,611	Jun. 13, 1997
PCT/US98/12125	Non-provisional of	60/050,901	Jun. 13, 1997
PCT/US98/12125	Non-provisional of	60/052,989	Jun. 13, 1997
PCT/US98/12125	Non-provisional of	60/051,919	Jul. 8, 1997
PCT/US98/12125	Non-provisional of	60/055,984	Aug. 18, 1997
PCT/US98/12125	Non-provisional of	60/058,665	Sep. 12, 1997
PCT/US98/12125	Non-provisional of	60/058,668	Sep. 12, 1997
PCT/US98/12125	Non-provisional of	60/058,669	Sep. 12, 1997
PCT/US98/12125	Non-provisional of	60/058,750	Sep. 12, 1997
PCT/US98/12125	Non-provisional of	60/058,971	Sep. 12, 1997
PCT/US98/12125	Non-provisional of	60/058,972	Sep. 12, 1997
PCT/US98/12125	Non-provisional of	60/058,975	Sep. 12, 1997
PCT/US98/12125	Non-provisional of	60/060,834	Oct. 2, 1997
PCT/US98/12125	Non-provisional of	60/060,841	Oct. 2, 1997
PCT/US98/12125	Non-provisional of	60/060,844	Oct. 2, 1997
PCT/US98/12125	Non-provisional of	60/060,865	Oct. 2, 1997
PCT/US98/12125	Non-provisional of	60/061,059	Oct. 2, 1997
PCT/US98/12125	Non-provisional of	60/061,060	Oct. 2, 1997
10/100,683	Continuation-in-part of	09/627,081	Jul. 27, 2000
09/627,081	Continuation of	09/213,365	Dec. 17, 1998
09/213,365	Continuation-in-part of	PCT/US98/	Jun. 30, 1998
		13608
10/100,683	Continuation-in-part of	PCT/US98/	Jun. 30, 1998
		13608
PCT/US98/13608	Non-provisional of	60/051,480	Jul. 1, 1997
PCT/US98/13608	Non-provisional of	60/051,381	Jul. 1, 1997
PCT/US98/13608	Non-provisional of	60/058,663	Sep. 12, 1997
PCT/US98/13608	Non-provisional of	60/058,598	Sep. 12, 1997
10/100,683	Continuation-in-part of	09/984,490	Oct. 30, 2001
09/984,490	Divisional of	09/227,357	Jan. 8, 1999
09/227,357	Continuation-in-part of	PCT/US98/	Jul. 7, 1998
		13684
10/100,683	Continuation-in-part of	09/983,802	Oct. 25, 2001
09/983,802	Continuation of	09/227,357	Oct. 10, 2001
09/227,357	Continuation-in-part of	PCT/US98/	Jul. 7, 1998
		13684
10/100,683	Continuation-in-part of	09/973,278	Oct. 10, 2001
09/973,278	Non-provisional of	60/239,899	Oct. 13, 2000
09/973,278	Continuation-in-part of	09/227,357	Jan. 8, 1999
09/227,357	Continuation-in-part of	PCT/US98/	Jul. 7, 1998
		13684
10/100,683	Continuation-in-part of	PCT/US98/	Jul. 7, 1998
		13684
PCT/US98/13684	Non-provisional of	60/051,926	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/052,793	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/051,925	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/051,929	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/052,803	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/052,732	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/051,931	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/051,932	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/051,916	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/051,930	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/051,918	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/051,920	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/052,733	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/052,795	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/051,919	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/051,928	Jul. 8, 1997
PCT/US98/13684	Non-provisional of	60/055,722	Aug. 18, 1997
PCT/US98/13684	Non-provisional of	60/055,723	Aug. 18, 1997
PCT/US98/13684	Non-provisional of	60/055,948	Aug. 18, 1997
PCT/US98/13684	Non-provisional of	60/055,949	Aug. 18, 1997
PCT/US98/13684	Non-provisional of	60/055,953	Aug. 18, 1997
PCT/US98/13684	Non-provisional of	60/055,950	Aug. 18, 1997
PCT/US98/13684	Non-provisional of	60/055,947	Aug. 18, 1997
PCT/US98/13684	Non-provisional of	60/055,964	Aug. 18, 1997
PCT/US98/13684	Non-provisional of	60/056,360	Aug. 18, 1997
PCT/US98/13684	Non-provisional of	60/055,684	Aug. 18, 1997
PCT/US98/13684	Non-provisional of	60/055,984	Aug. 18, 1997
PCT/US98/13684	Non-provisional of	60/055,954	Aug. 18, 1997
PCT/US98/13684	Non-provisional of	60/058,785	Sep. 12, 1997
PCT/US98/13684	Non-provisional of	60/058,664	Sep. 12, 1997
PCT/US98/13684	Non-provisional of	60/058,660	Sep. 12, 1997
PCT/US98/13684	Non-provisional of	60/058,661	Sep. 12, 1997
10/100,683	Continuation-in-part of	09/776,724	Feb. 6, 2001
09/776,724	Non-provisional of	60/180,909	Feb. 8, 2000
09/776,724	Continuation-in-part of	09/669,688	Sep. 26, 2000
09/669,688	Continuation of	09/229,982	Jan. 14, 1999
09/229,982	Continuation-in-part of	PCT/US98/	Jul. 15, 1998
		14613
10/100,683	Continuation-in-part of	09/669,688	Sep. 26, 2000
09/669,688	Continuation of	09/229,982	Jan. 14, 1999
09/229,982	Continuation-in-part of	PCT/US98/	Jul. 15, 1998
		14613
10/100,683	Continuation-in-part of	09/229,982	Jan. 14, 1999
09/229,982	Continuation-in-part of	PCT/US98/	Jul. 15, 1998
		14613
10/100,683	Continuation-in-part of	PCT/US98/	Jul. 15, 1998
		14613
PCT/US98/14613	Non-provisional of	60/052,661	Jul. 16, 1997
PCT/US98/14613	Non-provisional of	60/052,872	Jul. 16, 1997
PCT/US98/14613	Non-provisional of	60/052,871	Jul. 16, 1997
PCT/US98/14613	Non-provisional of	60/052,874	Jul. 16, 1997
PCT/US98/14613	Non-provisional of	60/052,873	Jul. 16, 1997
PCT/US98/14613	Non-provisional of	60/052,870	Jul. 16, 1997
PCT/US98/14613	Non-provisional of	60/052,875	Jul. 16, 1997
PCT/US98/14613	Non-provisional of	60/053,440	Jul. 22, 1997
PCT/US98/14613	Non-provisional of	60/053,441	Jul. 22, 1997
PCT/US98/14613	Non-provisional of	60/053,442	Jul. 22, 1997
PCT/US98/14613	Non-provisional of	60/056,359	Aug. 18, 1997
PCT/US98/14613	Non-provisional of	60/055,725	Aug. 18, 1997
PCT/US98/14613	Non-provisional of	60/055,985	Aug. 18, 1997
PCT/US98/14613	Non-provisional of	60/055,952	Aug. 18, 1997
PCT/US98/14613	Non-provisional of	60/055,989	Aug. 18, 1997
PCT/US98/14613	Non-provisional of	60/056,361	Aug. 18, 1997
PCT/US98/14613	Non-provisional of	60/055,726	Aug. 18, 1997
PCT/US98/14613	Non-provisional of	60/055,724	Aug. 18, 1997
PCT/US98/14613	Non-provisional of	60/055,946	Aug. 18, 1997
PCT/US98/14613	Non-provisional of	60/055,683	Aug. 18, 1997
10/100,683	Non-provisional of	60/295,558	Jun. 5, 2001
10/100,683	Continuation-in-part of	09/820,649	Mar. 30, 2001
09/820,649	Continuation of	09/666,984	Sep. 21, 2000
09/666,984	Continuation of	09/236,557	Jan. 26, 1999
09/236,557	Continuation-in-part of	PCT/US98/	Jul. 29, 1998
		15949
10/100,683	Continuation-in-part of	PCT/US98/	Jul. 29, 1998
		15949
PCT/US98/15949	Non-provisional of	60/054,212	Jul. 30, 1997
PCT/US98/15949	Non-provisional of	60/054,209	Jul. 30, 1997
PCT/US98/15949	Non-provisional of	60/054,234	Jul. 30, 1997
PCT/US98/15949	Non-provisional of	60/054,218	Jul. 30, 1997
PCT/US98/15949	Non-provisional of	60/054,214	Jul. 30, 1997
PCT/US98/15949	Non-provisional of	60/054,236	Jul. 30, 1997
PCT/US98/15949	Non-provisional of	60/054,215	Jul. 30, 1997
PCT/US98/15949	Non-provisional of	60/054,211	Jul. 30, 1997
PCT/US98/15949	Non-provisional of	60/054,217	Jul. 30, 1997
PCT/US98/15949	Non-provisional of	60/054,213	Jul. 30, 1997
PCT/US98/15949	Non-provisional of	60/055,968	Aug. 18, 1997
PCT/US98/15949	Non-provisional of	60/055,969	Aug. 18, 1997
PCT/US98/15949	Non-provisional of	60/055,972	Aug. 18, 1997
PCT/US98/15949	Non-provisional of	60/056,561	Aug. 19, 1997
PCT/US98/15949	Non-provisional of	60/056,534	Aug. 19, 1997
PCT/US98/15949	Non-provisional of	60/056,729	Aug. 19, 1997
PCT/US98/15949	Non-provisional of	60/056,543	Aug. 19, 1997
PCT/US98/15949	Non-provisional of	60/056,727	Aug. 19, 1997
PCT/US98/15949	Non-provisional of	60/056,554	Aug. 19, 1997
PCT/US98/15949	Non-provisional of	60/056,730	Aug. 19, 1997
10/100,683	Continuation-in-part of	09/969,730	Oct. 4, 2001
09/969,730	Continuation-in-part of	09/774,639	Feb. 1, 2001
09/774,639	Continuation of	09/244,112	Feb. 4, 1999
09/244,112	Continuation-in-part of	PCT/US98/	Aug. 4, 1998
		16235
10/100,683	Continuation-in-part of	09/774,639	Feb. 1, 2001
09/774,639	Continuation of	09/244,112	Feb. 4, 1999
09/244,112	Continuation-in-part of	PCT/US98/	Aug. 4, 1998
		16235
10/100,683	Continuation-in-part of	09/969,730	Oct. 4, 2001
09/969,730	Non-provisional of	60/238,291	Oct. 6, 2000
10/100,683	Continuation-in-part of	PCT/US98/	Aug. 4, 1998
		16235
PCT/US98/16235	Non-provisional of	60/055,386	Aug. 5, 1997
PCT/US98/16235	Non-provisional of	60/054,807	Aug. 5, 1997
PCT/US98/16235	Non-provisional of	60/055,312	Aug. 5, 1997
PCT/US98/16235	Non-provisional of	60/055,309	Aug. 5, 1997
PCT/US98/16235	Non-provisional of	60/054,798	Aug. 5, 1997
PCT/US98/16235	Non-provisional of	60/055,310	Aug. 5, 1997
PCT/US98/16235	Non-provisional of	60/054,806	Aug. 5, 1997
PCT/US98/16235	Non-provisional of	60/054,809	Aug. 5, 1997
PCT/US98/16235	Non-provisional of	60/054,804	Aug. 5, 1997
PCT/US98/16235	Non-provisional of	60/054,803	Aug. 5, 1997
PCT/US98/16235	Non-provisional of	60/054,808	Aug. 5, 1997
PCT/US98/16235	Non-provisional of	60/055,311	Aug. 5, 1997
PCT/US98/16235	Non-provisional of	60/055,986	Aug. 18, 1997
PCT/US98/16235	Non-provisional of	60/055,970	Aug. 18, 1997
PCT/US98/16235	Non-provisional of	60/056,563	Aug. 19, 1997
PCT/US98/16235	Non-provisional of	60/056,557	Aug. 19, 1997
PCT/US98/16235	Non-provisional of	60/056,731	Aug. 19, 1997
PCT/US98/16235	Non-provisional of	60/056,365	Aug. 19, 1997
PCT/US98/16235	Non-provisional of	60/056,367	Aug. 19, 1997
PCT/US98/16235	Non-provisional of	60/056,370	Aug. 19, 1997
PCT/US98/16235	Non-provisional of	60/056,364	Aug. 19, 1997
PCT/US98/16235	Non-provisional of	60/056,366	Aug. 19, 1997
PCT/US98/16235	Non-provisional of	60/056,732	Aug. 19, 1997
PCT/US98/16235	Non-provisional of	60/056,371	Aug. 19, 1997
10/100,683	Continuation-in-part of	09/716,128	Nov. 17, 2000
09/716,128	Continuation of	09/251,329	Feb. 17, 1999
09/251,329	Continuation-in-part of	PCT/US98/	Aug. 18, 1998
		17044
10/100,683	Continuation-in-part of	PCT/US98/	Aug. 18, 1998
		17044
PCT/US98/17044	Non-provisional of	60/056,555	Aug. 19, 1997
PCT/US98/17044	Non-provisional of	60/056,556	Aug. 19, 1997
PCT/US98/17044	Non-provisional of	60/056,535	Aug. 19, 1997
PCT/US98/17044	Non-provisional of	60/056,629	Aug. 19, 1997
PCT/US98/17044	Non-provisional of	60/056,369	Aug. 19, 1997
PCT/US98/17044	Non-provisional of	60/056,628	Aug. 19, 1997
PCT/US98/17044	Non-provisional of	60/056,728	Aug. 19, 1997
PCT/US98/17044	Non-provisional of	60/056,368	Aug. 19, 1997
PCT/US98/17044	Non-provisional of	60/056,726	Aug. 19, 1997
PCT/US98/17044	Non-provisional of	60/089,510	Jun. 16, 1998
PCT/US98/17044	Non-provisional of	60/092,956	Jul. 15, 1998
10/100,683	Continuation-in-part of	09/729,835	Dec. 6, 2000
09/729,835	Divisional of	09/257,179	Feb. 25, 1999
09/257,179	Continuation-in-part of	PCT/US98/	Aug. 27, 1998
		17709
10/100,683	Continuation-in-part of	09/257,179	Feb. 25, 1999
09/257,179	Continuation-in-part of	PCT/US98/	Aug. 27, 1998
		17709
10/100,683	Continuation-in-part of	PCT/US98/	Aug. 27, 1998
		17709
PCT/US98/17709	Non-provisional of	60/056,270	Aug. 29, 1997
PCT/US98/17709	Non-provisional of	60/056,271	Aug. 29, 1997
PCT/US98/17709	Non-provisional of	60/056,247	Aug. 29, 1997
PCT/US98/17709	Non-provisional of	60/056,073	Aug. 29, 1997
10/100,683	Continuation-in-part of	10/047,021	Jan. 17, 2002
10/047,021	Continuation-in-part of	09/722,329	Nov. 28, 2000
09/722,329	Continuation of	09/262,109	Mar. 4, 1999
09/262,109	Continuation-in-part of	PCT/US98/	Sep. 3, 1998
		18360
10/100,683	Continuation-in-part of	09/722,329	Nov. 28, 2000
09/722,329	Continuation of	09/262,109	Mar. 4, 1999
09/262,109	Continuation-in-part of	PCT/US98/	Sep. 3, 1998
		18360
10/100,683	Continuation-in-part of	PCT/US02/	Jan. 17, 2002
		01109
PCT/US02/01109	Non-provisional of	60/262,066	Jan. 18, 2001
10/100,683	Continuation-in-part of	PCT/US98/	Sep. 3, 1998
		18360
PCT/US98/18360	Non-provisional of	60/057,626	Sep. 5, 1997
PCT/US98/18360	Non-provisional of	60/057,663	Sep. 5, 1997
PCT/US98/18360	Non-provisional of	60/057,669	Sep. 5, 1997
PCT/US98/18360	Non-provisional of	60/058,667	Sep. 12, 1997
PCT/US98/18360	Non-provisional of	60/058,974	Sep. 12, 1997
PCT/US98/18360	Non-provisional of	60/058,973	Sep. 12, 1997
PCT/US98/18360	Non-provisional of	60/058,666	Sep. 12, 1997
PCT/US98/18360	Non-provisional of	60/090,112	Jun. 22, 1998
10/100,683	Continuation-in-part of	09/281,976	Mar. 31, 1999
09/281,976	Continuation-in-part of	PCT/US98/	Oct. 1, 1998
		20775
10/100,683	Continuation-in-part of	PCT/US98/	Oct. 1, 1998
		20775
PCT/US98/20775	Non-provisional of	60/060,837	Oct. 2, 1997
PCT/US98/20775	Non-provisional of	60/060,862	Oct. 2, 1997
PCT/US98/20775	Non-provisional of	60/060,839	Oct. 2, 1997
PCT/US98/20775	Non-provisional of	60/060,866	Oct. 2, 1997
PCT/US98/20775	Non-provisional of	60/060,843	Oct. 2, 1997
PCT/US98/20775	Non-provisional of	60/060,836	Oct. 2, 1997
PCT/US98/20775	Non-provisional of	60/060,838	Oct. 2, 1997
PCT/US98/20775	Non-provisional of	60/060,874	Oct. 2, 1997
PCT/US98/20775	Non-provisional of	60/060,833	Oct. 2, 1997
PCT/US98/20775	Non-provisional of	60/060,884	Oct. 2, 1997
PCT/US98/20775	Non-provisional of	60/060,880	Oct. 2, 1997
10/100,683	Continuation-in-part of	09/984,429	Oct. 30, 2001
09/984,429	Non-provisional of	60/244,591	Nov. 1, 2000
09/984,429	Continuation-in-part of	09/288,143	Apr. 8, 1999
09/288,143	Continuation-in-part of	PCT/US98/	Oct. 8, 1998
		21142
10/100,683	Non-provisional of	60/244,591	Nov. 1, 2000
10/100,683	Continuation-in-part of	09/288,143	Apr. 8, 1999
09/288,143	Continuation-in-part of	PCT/US98/	Oct. 8, 1998
		21142
10/100,683	Continuation-in-part of	PCT/US98/	Oct. 8, 1998
		21142
PCT/US98/21142	Non-provisional of	60/061,463	Oct. 9, 1997
PCT/US98/21142	Non-provisional of	60/061,529	Oct. 9, 1997
PCT/US98/21142	Non-provisional of	60/071,498	Oct. 9, 1997
PCT/US98/21142	Non-provisional of	60/061,527	Oct. 9, 1997
PCT/US98/21142	Non-provisional of	60/061,536	Oct. 9, 1997
PCT/US98/21142	Non-provisional of	60/061,532	Oct. 9, 1997
10/100,683	Continuation-in-part of	09/296,622	Apr. 23, 1999
09/296,622	Continuation-in-part of	PCT/US98/	Oct. 23, 1998
		22376
10/100,683	Continuation-in-part of	PCT/US98/	Oct. 23, 1998
		22376
PCT/US98/22376	Non-provisional of	60/063,099	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,088	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,100	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,387	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,148	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,386	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/062,784	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,091	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,090	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,089	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,092	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,111	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,101	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,109	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,110	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,098	Oct. 24, 1997
PCT/US98/22376	Non-provisional of	60/063,097	Oct. 24, 1997
10/100,683	Continuation-in-part of	09/974,879	Oct. 12, 2001
09/974,879	Non-provisional of	60/239,893	Oct. 13, 2000
09/974,879	Continuation-in-part of	09/818,683	Mar. 28, 2001
09/818,683	Continuation of	09/305,736	May 5, 1999
09/305,736	Continuation-in-part of	PCT/US98/	Nov. 4, 1998
		23435
10/100,683	Continuation-in-part of	09/818,683	Mar. 28, 2001
09/818,683	Continuation of	09/305,736	May 5, 1999
09/305,736	Continuation-in-part of	PCT/US98/	Nov. 4, 1998
		23435
10/100,683	Continuation-in-part of	09/305,736	May 5, 1999
09/305,736	Continuation-in-part of	PCT/US98/	Nov. 4, 1998
		23435
10/100,683	Continuation-in-part of	PCT/US98/	Nov. 4, 1998
		23435
PCT/US98/23435	Non-provisional of	60/064,911	Nov. 7, 1997
PCT/US98/23435	Non-provisional of	60/064,912	Nov. 7, 1997
PCT/US98/23435	Non-provisional of	60/064,983	Nov. 7, 1997
PCT/US98/23435	Non-provisional of	60/064,900	Nov. 7, 1997
PCT/US98/23435	Non-provisional of	60/064,988	Nov. 7, 1997
PCT/US98/23435	Non-provisional of	60/064,987	Nov. 7, 1997
PCT/US98/23435	Non-provisional of	60/064,908	Nov. 7, 1997
PCT/US98/23435	Non-provisional of	60/064,984	Nov. 7, 1997
PCT/US98/23435	Non-provisional of	60/064,985	Nov. 7, 1997
PCT/US98/23435	Non-provisional of	60/066,094	Nov. 17, 1997
PCT/US98/23435	Non-provisional of	60/066,100	Nov. 17, 1997
PCT/US98/23435	Non-provisional of	60/066,089	Nov. 17, 1997
PCT/US98/23435	Non-provisional of	60/066,095	Nov. 17, 1997
PCT/US98/23435	Non-provisional of	60/066,090	Nov. 17, 1997
10/100,683	Continuation-in-part of	09/334,595	Jun. 17, 1999
09/334,595	Continuation-in-part of	PCT/US98/	Dec. 17, 1998
		27059
10/100,683	Continuation-in-part of	PCT/US98/	Dec. 17, 1998
		27059
PCT/US98/27059	Non-provisional of	60/070,923	Dec. 18, 1997
PCT/US98/27059	Non-provisional of	60/068,007	Dec. 18, 1997
PCT/US98/27059	Non-provisional of	60/068,057	Dec. 18, 1997
PCT/US98/27059	Non-provisional of	60/068,006	Dec. 18, 1997
PCT/US98/27059	Non-provisional of	60/068,369	Dec. 19, 1997
PCT/US98/27059	Non-provisional of	60/068,367	Dec. 19, 1997
PCT/US98/27059	Non-provisional of	60/068,368	Dec. 19, 1997
PCT/US98/27059	Non-provisional of	60/068,169	Dec. 19, 1997
PCT/US98/27059	Non-provisional of	60/068,053	Dec. 18, 1997
PCT/US98/27059	Non-provisional of	60/068,064	Dec. 18, 1997
PCT/US98/27059	Non-provisional of	60/068,054	Dec. 18, 1997
PCT/US98/27059	Non-provisional of	60/068,008	Dec. 18, 1997
PCT/US98/27059	Non-provisional of	60/068,365	Dec. 19, 1997
10/100,683	Continuation-in-part of	09/938,671	Aug. 27, 2001
09/938,671	Continuation of	09/739,907	Dec. 20, 2000
09/739,907	Continuation of	09/348,457	Jul. 7, 1999
09/348,457	Continuation-in-part of	PCT/US99/	Jan. 6, 1999
		00108
10/100,683	Continuation-in-part of	09/739,907	Dec. 20, 2000
09/739,907	Continuation of	09/348,457	Jul. 7, 1999
09/348,457	Continuation-in-part of	PCT/US99/	Jan. 6, 1999
		00108
10/100,683	Continuation-in-part of	09/348,457	Jul. 7, 1999
09/348,457	Continuation-in-part of	PCT/US99/	Jan. 6, 1999
		00108
10/100,683	Continuation-in-part of	PCT/US99/	Jan. 6, 1999
		00108
PCT/US99/00108	Non-provisional of	60/070,704	Jan. 7, 1998
PCT/US99/00108	Non-provisional of	60/070,658	Jan. 7, 1998
PCT/US99/00108	Non-provisional of	60/070,692	Jan. 7, 1998
PCT/US99/00108	Non-provisional of	60/070,657	Jan. 7, 1998
10/100,683	Continuation-in-part of	09/949,925	Sep. 12, 2001
09/949,925	Non-provisional of	60/232,150	Sep. 12, 2000
09/949,925	Continuation-in-part of	PCT/US99/	Jan. 27, 1999
		01621
09/949,925	Continuation-in-part of	09/363,044	Jul. 29, 1999
09/363,044	Continuation-in-part of	PCT/US99/	Jan. 27, 1999
		01621
10/100,683	Continuation-in-part of	09/813,153	Mar. 21, 2001
09/813,153	Continuation of	09/363,044	Jul. 29, 1999
09/363,044	Continuation-in-part of	PCT/US99/	Jan. 27, 1999
		01621
10/100,683	Continuation-in-part of	09/363,044	Jul. 29, 1999
09/363,044	Continuation-in-part of	PCT/US99/	Jan. 27, 1999
		01621
10/100,683	Continuation-in-part of	PCT/US99/	Jan. 27, 1999
		01621
PCT/US99/01621	Non-provisional of	60/073,170	Jan. 30, 1998
PCT/US99/01621	Non-provisional of	60/073,167	Jan. 30, 1998
PCT/US99/01621	Non-provisional of	60/073,165	Jan. 30, 1998
PCT/US99/01621	Non-provisional of	60/073,164	Jan. 30, 1998
PCT/US99/01621	Non-provisional of	60/073,162	Jan. 30, 1998
PCT/US99/01621	Non-provisional of	60/073,161	Jan. 30, 1998
PCT/US99/01621	Non-provisional of	60/073,160	Jan. 30, 1998
PCT/US99/01621	Non-provisional of	60/073,159	Jan. 30, 1998
10/100,683	Continuation-in-part of	10/062,548	Feb. 5, 2002
10/062,548	Continuation of	09/369,247	Aug. 5, 1999
09/369,247	Continuation-in-part of	PCT/US99/	Feb. 4, 1999
		02293
10/100,683	Continuation-in-part of	09/369,247	Aug. 5, 1999
09/369,247	Continuation-in-part of	PCT/US99/	Feb. 4, 1999
		02293
10/100,683	Continuation-in-part of	PCT/US99/	Feb. 4, 1999
		02293
PCT/US99/02293	Non-provisional of	60/074,118	Feb. 9, 1998
PCT/US99/02293	Non-provisional of	60/074,157	Feb. 9, 1998
PCT/US99/02293	Non-provisional of	60/074,037	Feb. 9, 1998
PCT/US99/02293	Non-provisional of	60/074,141	Feb. 9, 1998
PCT/US99/02293	Non-provisional of	60/074,341	Feb. 9, 1998
10/100,683	Continuation-in-part of	09/716,129	Nov. 17, 2000
09/716,129	Continuation-in-part of	PCT/US99/	Feb. 24, 1999
		03939
09/716,129	CON	09/382,572	Aug. 25, 1999
09/382,572	Continuation-in-part of	PCT/US99/	Feb. 24, 1999
		03939
10/100,683	Continuation-in-part of	PCT/US99/	Feb. 24, 1999
		03939
PCT/US99/03939	Non-provisional of	60/076,053	Feb. 26, 1998
PCT/US99/03939	Non-provisional of	60/076,051	Feb. 26, 1998
PCT/US99/03939	Non-provisional of	60/076,054	Feb. 26, 1998
PCT/US99/03939	Non-provisional of	60/076,052	Feb. 26, 1998
PCT/US99/03939	Non-provisional of	60/076,057	Feb. 26, 1998
10/100,683	Continuation-in-part of	09/798,889	Mar. 6, 2001
09/798,889	CON	09/393,022	Sep. 9, 1999
09/393,022	Continuation-in-part of	PCT/US99/	Mar. 11, 1999
		05721
10/100,683	Continuation-in-part of	PCT/US99/	Mar. 11, 1999
		05721
PCT/US99/05721	Non-provisional of	60/077,714	Mar. 12, 1998
PCT/US99/05721	Non-provisional of	60/077,686	Mar. 12, 1998
PCT/US99/05721	Non-provisional of	60/077,687	Mar. 12, 1998
PCT/US99/05721	Non-provisional of	60/077,696	Mar. 12, 1998
10/100,683	Continuation-in-part of	09/397,945	Sep. 17, 1999
09/397,945	Continuation-in-part of	PCT/US99/	Mar. 18, 1999
		05804
10/100,683	Continuation-in-part of	PCT/US99/	Mar. 18, 1999
		05804
PCT/US99/05804	Non-provisional of	60/078,566	Mar. 19, 1998
PCT/US99/05804	Non-provisional of	60/078,576	Mar. 19, 1998
PCT/US99/05804	Non-provisional of	60/078,573	Mar. 19, 1998
PCT/US99/05804	Non-provisional of	60/078,574	Mar. 19, 1998
PCT/US99/05804	Non-provisional of	60/078,579	Mar. 19, 1998
PCT/US99/05804	Non-provisional of	60/080,314	Apr. 1, 1998
PCT/US99/05804	Non-provisional of	60/080,312	Apr. 1, 1998
PCT/US99/05804	Non-provisional of	60/078,578	Mar. 19, 1998
PCT/US99/05804	Non-provisional of	60/078,581	Mar. 19, 1998
PCT/US99/05804	Non-provisional of	60/078,577	Mar. 19, 1998
PCT/US99/05804	Non-provisional of	60/078,563	Mar. 19, 1998
PCT/US99/05804	Non-provisional of	60/080,313	Apr. 1, 1998
10/100,683	Continuation-in-part of	09/948,783	Sep. 10, 2001
09/948,783	Non-provisional of	60/231,846	Sep. 11, 2000
09/948,783	Continuation-in-part of	09/892,877	Jun. 28, 2001
09/892,877	Continuation of	09/437,658	Nov. 10, 1999
09/437,658	Continuation-in-part of	PCT/US99/	May 6, 1999
		09847
10/100,683	Continuation-in-part of	09/892,877	Jun. 28, 2001
09/892,877	Continuation of	09/437,658	Nov. 10, 1999
09/437,658	Continuation-in-part of	PCT/US99/	May 6, 1999
		09847
10/100,683	Continuation-in-part of	PCT/US99/	May 6, 1999
		09847
PCT/US99/09847	Non-provisional of	60/085,093	May 12, 1998
PCT/US99/09847	Non-provisional of	60/085,094	May 12, 1998
PCT/US99/09847	Non-provisional of	60/085,105	May 12, 1998
PCT/US99/09847	Non-provisional of	60/085,180	May 12, 1998
PCT/US99/09847	Non-provisional of	60/085,927	May 18, 1998
PCT/US99/09847	Non-provisional of	60/085,906	May 18, 1998
PCT/US99/09847	Non-provisional of	60/085,920	May 18, 1998
PCT/US99/09847	Non-provisional of	60/085,924	May 18, 1998
PCT/US99/09847	Non-provisional of	60/085,922	May 18, 1998
PCT/US99/09847	Non-provisional of	60/085,923	May 18, 1998
PCT/US99/09847	Non-provisional of	60/085,921	May 18, 1998
PCT/US99/09847	Non-provisional of	60/085,925	May 18, 1998
PCT/US99/09847	Non-provisional of	60/085,928	May 18, 1998
10/100,683	Continuation-in-part of	10/050,873	Jan. 18, 2002
10/050,873	Non-provisional of	60/263,681	Jan. 24, 2001
10/050,873	Non-provisional of	60/263,230	Jan. 23, 2001
10/050,873	Continuation-in-part of	09/461,325	Dec. 14, 1999
09/461,325	Continuation-in-part of	PCT/US99/	Jun. 15, 1999
		13418
10/100,683	Continuation-in-part of	10/012,542	Dec. 12, 2001
10/012,542	Divisional of	09/461,325	Dec. 14, 1999
09/461,325	Continuation-in-part of	PCT/US99/	Jun. 15, 1999
		13418
10/100,683	Continuation-in-part of	09/461,325	Dec. 14, 1999
09/461,325	Continuation-in-part of	PCT/US99/	Jun. 15, 1999
		13418
10/100,683	Continuation-in-part of	PCT/US99/	Jun. 15, 1999
		13418
PCT/US99/13418	Non-provisional of	60/089,507	Jun. 16, 1998
PCT/US99/13418	Non-provisional of	60/089,508	Jun. 16, 1998
PCT/US99/13418	Non-provisional of	60/089,509	Jun. 16, 1998
PCT/US99/13418	Non-provisional of	60/089,510	Jun. 16, 1998
PCT/US99/13418	Non-provisional of	60/090,112	Jun. 22, 1998
PCT/US99/13418	Non-provisional of	60/090,113	Jun. 22, 1998
10/100,683	Continuation-in-part of	09/984,271	Oct. 29, 2001
09/984,271	Divisional of	09/482,273	Jan. 13, 2000
09/482,273	Continuation-in-part of	PCT/US99/	Jul. 14, 1999
		15849
10/100,683	Continuation-in-part of	09/984,276	Oct. 29, 2001
09/984,276	Divisional of	09/482,273	Jan. 13, 2000
09/482,273	Continuation-in-part of	PCT/US99/	Jul. 14, 1999
		15849
10/100,683	Continuation-in-part of	09/482,273	Jan. 13, 2000
09/482,273	Continuation-in-part of	PCT/US99/	Jul. 14, 1999
		15849
10/100,683	Continuation-in-part of	PCT/US99/	Jul. 14, 1999
		15849
PCT/US99/15849	Non-provisional of	60/092,921	Jul. 15, 1998
PCT/US99/15849	Non-provisional of	60/092,922	Jul. 15, 1998
PCT/US99/15849	Non-provisional of	60/092,956	Jul. 15, 1998
10/100,683	Continuation-in-part of	PCT/US01/	Sep. 24, 2001
		29871
PCT/US01/29871	Non-provisional of	60/234,925	Sep. 25, 2000
PCT/US01/29871	Continuation-in-part of	PCT/US01/	Jan. 12, 2001
		00911
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 12, 2001
		00911
PCT/US01/00911	Continuation-in-part of	09/482,273	Jan. 13, 2000
10/100,683	Non-provisional of	60/350,898	Jan. 25, 2002
10/100,683	Continuation-in-part of	09/489,847	Jan. 24, 2000
09/489,847	Continuation-in-part of	PCT/US99/	Jul. 29, 1999
		17130
10/100,683	Continuation-in-part of	PCT/US99/	Jul. 29, 1999
		17130
PCT/US99/17130	Non-provisional of	60/094,657	Jul. 30, 1998
PCT/US99/17130	Non-provisional of	60/095,486	Aug. 5, 1998
PCT/US99/17130	Non-provisional of	60/096,319	Aug. 12, 1998
PCT/US99/17130	Non-provisional of	60/095,454	Aug. 6, 1998
PCT/US99/17130	Non-provisional of	60/095,455	Aug. 6, 1998
10/100,683	Continuation-in-part of	10/054,988	Jan. 25, 2002
10/054,988	Continuation of	09/904,615	Jul. 16, 2001
09/904,615	Continuation of	09/739,254	Dec. 19, 2000
09/739,254	Continuation of	09/511,554	Feb. 23, 2000
09/511,554	Continuation-in-part of	PCT/US99/	Aug. 24, 1999
		19330
10/100,683	Continuation-in-part of	09/904,615	Jul. 16, 2001
09/904,615	Continuation of	09/739,254	Dec. 19, 2000
09/739,254	Continuation of	09/511,554	Feb. 23, 2000
09/511,554	Continuation-in-part of	PCT/US99/	Aug. 24, 1999
		19330
10/100,683	Continuation-in-part of	PCT/US99/	Aug. 24, 1999
		19330
PCT/US99/19330	Non-provisional of	60/097,917	Aug. 25, 1998
PCT/US99/19330	Non-provisional of	60/098,634	Aug. 31, 1998
10/100,683	Continuation-in-part of	09/820,893	Mar. 30, 2001
09/820,893	Continuation of	09/531,119	Mar. 20, 2000
09/531,119	Continuation-in-part of	PCT/US99/	Sep. 22, 1999
		22012
10/100,683	Continuation-in-part of	PCT/US99/	Sep. 22, 1999
		22012
PCT/US99/22012	Non-provisional of	60/101,546	Sep. 23, 1998
PCT/US99/22012	Non-provisional of	60/102,895	Oct. 2, 1998
10/100,683	Continuation-in-part of	09/948,820	Sep. 10, 2001
09/948,820	Continuation of	09/565,391	May 5, 2000
09/565,391	Continuation-in-part of	PCT/US99/	Nov. 9, 1999
		26409
10/100,683	Continuation-in-part of	09/565,391	May 5, 2000
09/565,391	Continuation-in-part of	PCT/US99/	Nov. 9, 1999
		26409
10/100,683	Continuation-in-part of	PCT/US99/	Nov. 9, 1999
		26409
PCT/US99/26409	Non-provisional of	60/108,207	Nov. 12, 1998
10/100,683	Continuation-in-part of	09/895,298	Jul. 2, 2001
09/895,298	Continuation of	09/591,316	Jun. 9, 2000
09/591,316	Continuation-in-part of	PCT/US99/	Dec. 16, 1999
		29950
10/100,683	Continuation-in-part of	PCT/US99/	Dec. 16, 1999
		29950
PCT/US99/29950	Non-provisional of	60/113,006	Dec. 18, 1998
PCT/US99/29950	Non-provisional of	60/112,809	Dec. 17, 1998
10/100,683	Continuation-in-part of	09/985,153	Nov. 1, 2001
09/985,153	Continuation of	09/618,150	Jul. 17, 2000
09/618,150	Continuation-in-part of	PCT/US00/	Jan. 18, 2000
		00903
10/100,683	Continuation-in-part of	PCT/US00/	Jan. 18, 2000
		00903
PCT/US00/00903	Non-provisional of	60/116,330	Jan. 19, 1999
10/100,683	Continuation-in-part of	09/997,131	Nov. 30, 2001
09/997,131	Continuation of	09/628,508	Jul. 28, 2000
09/628,508	Continuation-in-part of	PCT/US00/	Feb. 8, 2000
		03062
10/100,683	Continuation-in-part of	PCT/US00/	Feb. 8, 2000
		03062
PCT/US00/03062	Non-provisional of	60/119,468	Feb. 10, 1999
10/100,683	Continuation-in-part of	10/050,882	Jan. 18, 2002
10/050,882	Continuation of	09/661,453	Sep. 13, 2000
09/661,453	Continuation-in-part of	PCT/US00/	Mar. 16, 2000
		06783
10/100,683	Continuation-in-part of	09/661,453	Sep. 13, 2000
09/661,453	Continuation-in-part of	PCT/US00/	Mar. 16, 2000
		06783
10/100,683	Continuation-in-part of	PCT/US00/	Mar. 16, 2000
		06783
PCT/US00/06783	Non-provisional of	60/125,055	Mar. 18, 1999
10/100,683	Continuation-in-part of	10/050,704	Jan. 18, 2002
10/050,704	Continuation of	09/684,524	Oct. 10, 2000
09/684,524	Continuation-in-part of	PCT/US00/	Apr. 6, 2000
		08979
10/100,683	Continuation-in-part of	09/684,524	Oct. 10, 2000
09/684,524	Continuation-in-part of	PCT/US00/	Apr. 6, 2000
		08979
10/100,683	Continuation-in-part of	PCT/US00/	Apr. 6, 2000
		08979
PCT/US00/08979	Non-provisional of	60/128,693	Apr. 9, 1999
PCT/US00/08979	Non-provisional of	60/130,991	Apr. 26, 1999
10/100,683	Continuation-in-part of	10/042,141	Jan. 11, 2002
10/042,141	Continuation of	09/726,643	Dec. 1, 2000
09/726,643	Continuation-in-part of	PCT/US00/	Jun. 2, 2000
		15187
10/100,683	Continuation-in-part of	09/726,643	Dec. 1, 2000
09/726,643	Continuation-in-part of	PCT/US00/	Jun. 2, 2000
		15187
10/100,683	Continuation-in-part of	PCT/US00/	Jun. 2, 2000
		15187
PCT/US00/15187	Non-provisional of	60/137,725	Jun. 7, 1999
10/100,683	Continuation-in-part of	09/756,168	Jan. 9, 2001
09/756,168	Continuation-in-part of	PCT/US00/	Jul. 23, 1999
		19735
10/100,683	Continuation-in-part of	PCT/US00/	Jul. 20, 2000
		19735
PCT/US00/19735	Non-provisional of	60/145,220	Jul. 23, 1999
10/100,683	Continuation-in-part of	10/060,255	Feb. 2, 2002
10/060,255	Continuation of	09/781,417	Feb. 13, 2001
09/781,417	Continuation-in-part of	PCT/US00/	Aug. 16, 2000
		22325
10/100,683	Continuation-in-part of	09/781,417	Feb. 13, 2001
09/781,417	Continuation-in-part of	PCT/US00/	Aug. 16, 2000
		22325
10/100,683	Continuation-in-part of	PCT/US00/	Aug. 16, 2000
		22325
PCT/US00/22325	Non-provisional of	60/149,182	Aug. 17, 1999
10/100,683	Continuation-in-part of	09/789,561	Feb. 22, 2001
09/789,561	Continuation-in-part of	PCT/US00/	Aug. 31, 2000
		24008
10/100,683	Continuation-in-part of	PCT/US00/	Aug. 31, 2000
		24008
PCT/US00/24008	Non-provisional of	60/152,315	Sep. 3, 1999
PCT/US00/24008	Non-provisional of	60/152,317	Sep. 3, 1999
10/100,683	Continuation-in-part of	09/800,729	Mar. 8, 2001
09/800,729	Continuation-in-part of	PCT/US00/	Sep. 22, 2000
		26013
10/100,683	Continuation-in-part of	PCT/US00/	Sep. 22, 2000
		26013
PCT/US00/26013	Non-provisional of	60/155,709	Sep. 24, 1999
10/100,683	Continuation-in-part of	09/832,129	Feb. 11, 2001
09/832,129	Continuation-in-part of	PCT/US00/	Oct. 17, 2000
		28664
10/100,683	Continuation-in-part of	PCT/US00/	Oct. 17, 2000
		28664
PCT/US00/28664	Non-provisional of	60/163,085	Nov. 2, 1999
PCT/US00/28664	Non-provisional of	60/172,411	Dec. 17, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Oct. 25, 2000
		29363
PCT/US00/29363	Non-provisional of	60/215,139	Jun. 30, 2000
PCT/US00/29363	Non-provisional of	60/162,239	Oct. 29, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Oct. 25, 2000
		29360
PCT/US00/29360	Non-provisional of	60/215,138	Jun. 30, 2000
PCT/US00/29360	Non-provisional of	60/162,211	Oct. 29, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Oct. 25, 2000
		29362
PCT/US00/29362	Non-provisional of	60/215,131	Jun. 30, 2000
PCT/US00/29362	Non-provisional of	60/162,240	Oct. 29, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Oct. 25, 2000
		29365
PCT/US00/29365	Non-provisional of	60/219,666	Jul. 21, 2000
PCT/US00/29365	Non-provisional of	60/162,237	Oct. 29, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Oct. 25, 2000
		29364
PCT/US00/29364	Non-provisional of	60/215,134	Jun. 30, 2000
PCT/US00/29364	Non-provisional of	60/162,238	Oct. 29, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Nov. 1, 2000
		30040
PCT/US00/30040	Non-provisional of	60/215,130	Jun. 30, 2000
PCT/US00/30040	Non-provisional of	60/163,580	Nov. 5, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Nov. 1, 2000
		30037
PCT/US00/30037	Non-provisional of	60/215,137	Jun. 30, 2000
PCT/US00/30037	Non-provisional of	60/163,577	Nov. 5, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Nov. 1, 2000
		30045
PCT/US00/30045	Non-provisional of	60/215,133	Jun. 30, 2000
PCT/US00/30045	Non-provisional of	60/163,581	Nov. 5, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Nov. 1, 2000
		30036
PCT/US00/30036	Non-provisional of	60/221,366	Jul. 27, 2000
PCT/US00/30036	Non-provisional of	60/163,576	Nov. 5, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Nov. 1, 2000
		30039
PCT/US00/30039	Non-provisional of	60/221,367	Jul. 27, 2000
PCT/US00/30039	Non-provisional of	60/195,296	Feb. 7, 2000
PCT/US00/30039	Non-provisional of	60/164,344	Nov. 9, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Nov. 8, 2000
		30654
PCT/US00/30654	Non-provisional of	60/221,142	Jul. 27, 2000
PCT/US00/30654	Non-provisional of	60/164,835	Nov. 12, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Nov. 8, 2000
		30628
PCT/US00/30628	Non-provisional of	60/215,140	Jun. 30, 2000
PCT/US00/30628	Non-provisional of	60/164,744	Nov. 12, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Nov. 8, 2000
		30653
PCT/US00/30653	Non-provisional of	60/221,193	Jul. 27, 2000
PCT/US00/30653	Non-provisional of	60/164,735	Nov. 12, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Nov. 8, 2000
		30629
PCT/US00/30629	Non-provisional of	60/222,904	Aug. 3, 2000
PCT/US00/30629	Non-provisional of	60/164,825	Nov. 12, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Nov. 8, 2000
		30679
PCT/US00/30679	Non-provisional of	60/224,007	Aug. 4, 2000
PCT/US00/30679	Non-provisional of	60/164,834	Nov. 12, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Nov. 8, 2000
		30674
PCT/US00/30674	Non-provisional of	60/215,128	Jun. 30, 2000
PCT/US00/30674	Non-provisional of	60/164,750	Nov. 12, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Nov. 15, 2000
		31162
60/215,136	Non-provisional of	60/215,136	Jun. 30, 2000
60/215,136	Non-provisional of	60/166,415	Nov. 19, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Nov. 15, 2000
		31282
PCT/US00/31282	Non-provisional of	60/219,665	Jul. 21, 2000
PCT/US00/31282	Non-provisional of	60/166,414	Nov. 19, 1999
10/100,683	Continuation-in-part of	PCT/US00/	Nov. 8, 2000
		30657
PCT/US00/30657	Non-provisional of	60/215,132	Jun. 30, 2000
PCT/US00/30657	Non-provisional of	60/164,731	Nov. 12, 1999
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 17, 2001
		01396
60/256,968	Non-provisional of	60/256,968	Dec. 21, 2000
60/256,968	Non-provisional of	60/226,280	Aug. 18, 2000
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 17, 2001
		01387
60/259,803	Non-provisional of	60/259,803	Jan. 5, 2001
60/259,803	Non-provisional of	60/226,380	Aug. 18, 2000
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 17, 2001
		01567
PCT/US01/01567	Non-provisional of	60/228,084	Aug. 28, 2000
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 17, 2001
		01431
PCT/US01/01431	Non-provisional of	60/231,968	Sep. 12, 2000
PCT/US01/01431	Continuation-in-part of	09/915,582	Jul. 27, 2001
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 17, 2001
		01432
PCT/US01/01432	Non-provisional of	60/236,326	Sep. 29, 2000
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 9, 2001
		00544
PCT/US01/00544	Non-provisional of	60/234,211	Sep. 20, 2000
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 17, 2001
		01435
PCT/US01/01435	Non-provisional of	60/226,282	Aug. 18, 2000
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 17, 2001
		01386
PCT/US01/01386	Non-provisional of	60/232,104	Sep. 12, 2000
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 17, 2001
		01565
PCT/US01/01565	Non-provisional of	60/234,210	Sep. 20, 2000
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 17, 2001
		01394
PCT/US01/01394	Non-provisional of	60/259,805	Jan. 5, 2001
PCT/US01/01394	Non-provisional of	60/226,278	Aug. 18, 2000
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 17, 2001
		01434
PCT/US01/01434	Non-provisional of	60/259,678	Jan. 5, 2001
PCT/US01/01434	Non-provisional of	60/226,279	Aug. 18, 2000
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 17, 2001
		01397
PCT/US01/01397	Non-provisional of	60/226,281	Aug. 18, 2000
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 17, 2001
		01385
PCT/US01/01385	Non-provisional of	60/231,969	Sep. 12, 2000
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 17, 2001
		01384
PCT/US01/01384	Non-provisional of	60/259,516	Jan. 4, 2001
PCT/US01/01384	Non-provisional of	60/228,086	Aug. 28, 2000
10/100,683	Continuation-in-part of	PCT/US01/	Jan. 17, 2001
		01383
PCT/US01/01383	Non-provisional of	60/259,804	Jan. 5, 2001
PCT/US01/01383	Non-provisional of	60/228,083	Aug. 28, 2000
10/100,683	Continuation-in-part of	PCT/US02/	Feb. 21, 2002
		05064
PCT/US02/05064	Non-provisional of	60/304,444	Jul. 12, 2001
PCT/US02/05064	Non-provisional of	60/270,658	Feb. 23, 2001
10/100,683	Continuation-in-part of	PCT/US02/	Feb. 21, 2002
		05301
PCT/US02/05301	Non-provisional of	60/304,417	Jul. 12, 2001
PCT/US02/05301	Non-provisional of	60/270,625	Feb. 23, 2001
10/100,683	Non-provisional of	60/304,121	Jul. 11, 2001
10/100,683	Non-provisional of	60/295,869	Jun. 6, 2001
10/100,683	Non-provisional of	60/325,209	Sep. 28, 2001
10/100,683	Non-provisional of	60/311,085	Aug. 10, 2001
10/100,683	Non-provisional of	60/330,629	Oct. 26, 2001
10/100,683	Non-provisional of	60/331,046	Nov. 7, 2001
10/100,683	Non-provisional of	60/358,554	Feb. 22, 2002
10/100,683	Non-provisional of	60/358,714	Feb. 25, 2002

[0003] This application refers to a “Sequence Listing” listed below, which is provided as a text file. The text file contains a document entitled “PS902P1D1-SeqList.txt” (3,646,557 bytes, created Jun. 27, 2008), which is hereby incorporated by reference in its entirety.

[0004] The present invention relates to human secreted proteins/polypeptides, and isolated nucleic acid molecules encoding said proteins/polypeptides, useful for detecting, preventing, diagnosing, prognosticating, treating, and/or ameliorating immune disorders and diseases. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

[0005] The immune system is an intricate network of cells, tissues and soluble molecules that function to protect the body from invasion by foreign substances and pathogens. The major cells of the immune system are lymphocytes, including B cells and T cells, and myeloid cells, including basophils, eosinophils, neutrophils, mast cells, monocytes, macrophages and dendritic cells. In addition to these cellular components of the immune system, soluble molecules—such as antibodies, complement proteins, and cytokines—circulate in lymph and blood plasma, and play important roles in immunity.

[0006] The immune system can be subdivided into the acquired and innate immune systems. The cells of the innate immune system (e.g., neutrophils, eosinophils, basophils, mast cells) are not antigen specific and their action is not enhanced by repeated exposure to the same antigen. The cells of the acquired immune system (B and T cells) are antigen specific. Repeated exposure of B and T cells to an antigen results in improved immune responses (memory responses) produced by these cell types. The cells and products of the acquired immune system can recruit components of the innate system to mount a focused immune response. For a more extensive review of the immune system, see Fundamental Immunology, 4th edition, Ed. William Paul, Lippincott-Raven Pub. (1998).

[0007] An immune response is seldom carried out by a single cell type, but rather requires the coordinated efforts of several cell types. In order to coordinate an immune response, it is necessary that cells of the immune system communicate with each other and with other cells of the body. Communication between cells may be made by cell-cell contact, between membrane bound molecules on each cell, or by the interaction of soluble components of the immune system with cellular receptors. Signaling between cell types may have one or more of a variety of consequences, including activation, proliferation, differentiation, and apoptosis. Activation and differentiation of immune cells may result in the expression or secretion of polypeptides, or other molecules, which in turn affect the function of other cells and/or molecules of the immune system.

[0008] Molecules which stimulate or suppress immune system function are known as immunomodulators. These molecules, which include endogenous proteins (e.g., cytokines, cytokine receptors, and intracellular signal transduction molecules), molecules derived from microorganisms, and synthetic agents, may exert their modulatory effects at one or more stages of the immune response, such as antigen recognition, stimulation of cytokine production and release, and/or activation/differentiation of lymphocytes and myeloid cells Immunomodulators may enhance (immunoprophylaxis, immunostimulation), restore (immunosubstitution, immunorestoration) or suppress (immunosuppression, immunodeviation) immunological functions or activities.

[0009] Immunomodulatory compounds have many important applications in clinical practice. For example, immunosuppressing agents (which attenuate or prevent unwanted immune responses) can be used to prevent tissue rejection during organ transplantation, to prevent Rh hemolytic disease of the newborn, or to treat autoimmune disorders. A mechanism of action common to many immunosuppressants is the inhibition of T cell activation and/or differentiation. Antilymphocyte antibodies have also been used to attenuate immune system functions. Currently-used immunosuppressive agents can produce a number of side effects which limit their use. Among the most serious secondary effects include kidney and liver toxicity, increased risk of infection, hyperglycemia, neoplasia, and osteoporosis (see, e.g., Freeman, Clin. Biochem. 24(1):9-14 (1991); Mitchison, Dig. Dis. 11(2):78-101 (1993)).

[0010] Immunostimulants, which enhance the activity of immune cells and molecules, comprise another class of immunomodulatory agents with important clinical applications. Such applications include, for example, the treatment of immunodeficiency disorders (e.g. AIDS and severe combined immunodeficiency), chronic infectious diseases (e.g. viral hepatitis, papillomavirus, and herpesvirus), and cancer. An important class of endogenous immunostimulants is the cytokines. These soluble signaling molecules are produced by a number of cell types, and are critical to the regulation of the immune response Immunostimulatory mechanisms can include proliferation, differentiation and/or activation of immune cells or progenitors of immune cells. For example, interleukin-2 (IL-2) binds to IL-2 receptors on T lymphocytes and induces proliferation and differentiation. Another cytokine, interferon alpha, stimulates the immune system through a variety of mechanisms, including activation of macrophages, T lymphocytes, and natural killer cells. Interferon alpha also induces the expression of antiviral proteins (see Chapter 50, The Pharmacological Basis of Therapeutics, 9^th Edition, Eds. Hardman, Limbird, Molinoff, Ruddon, and Gilman, McGraw Hill (1996)). Limitations of current immunostimulant therapies include anaphylaxis, pulmonary edema, and renal toxicity, to name a few.

[0011] The discovery of new human immune related polynucleotides, the polypeptides encoded by them, and antibodies that immunospecifically bind these polypeptides, satisfies a need in the art by providing new compositions which are useful in the diagnosis, treatment, prevention and/or prognosis of disorders of the immune system, including, but not limited to, autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis, idiopathic thrombocytopenic purpura and multiple sclerosis), immunodeficiencies (e.g., X-linked agammaglobulinemia, severe combined immunodeficiency, Wiskott-Aldrich syndrome, and ataxia telangiectasia), chronic infections (e.g., HIV, viral hepatitis, and herpesvirus), and neoplastic disorders. See, e.g. “Immune Activity” section infra. Additionally, immune related molecules would be useful as agents to boost immune responsiveness to pathogens or to suppress immune reactions, for example as is necessary in conjunction with organ transplantation.

[0012] The present invention relates to novel secreted proteins. More specifically, isolated nucleic acid molecules are provided encoding novel secreted polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides, polypeptides, and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for detecting, preventing, diagnosing, prognosticating, treating, and/or ameliorating immune diseases and disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Description of Table 1A

[0013] Table 1A summarizes information concerning certain polynucleotides and polypeptides of the invention. The first column provides the gene number in the application for each clone identifier. The second column provides a unique clone identifier, “Clone ID:”, for a cDNA clone related to each contig sequence disclosed in Table 1A. Third column, the cDNA Clones identified in the second column were deposited as indicated in the third column (i.e. by ATCC™ Deposit No:Z and deposit date). Some of the deposits contain multiple different clones corresponding to the same gene. In the fourth column, “Vector” refers to the type of vector contained in the corresponding cDNA Clone identified in the second column. In the fifth column, the nucleotide sequence identified as “NT SEQ ID NO:X” was assembled from partially homologous (“overlapping”) sequences obtained from the corresponding cDNA clone identified in the second column and, in some cases, from additional related cDNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X. In the sixth column, “Total NT Seq.” refers to the total number of nucleotides in the contig sequence identified as SEQ ID NO:X.” The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as “5′ NT of Clone Seq.” (seventh column) and the “3′ NT of Clone Seq.” (eighth column) of SEQ ID NO:X. In the ninth column, the nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as “5′ NT of Start Codon.” Similarly, in column ten, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as “5′ NT of First AA of Signal Pep.” In the eleventh column, the translated amino acid sequence, beginning with the methionine, is identified as “AA SEQ ID NO:Y,” although other reading frames can also be routinely translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

[0014] In the twelfth and thirteenth columns of Table 1A, the first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as “First AA of Sig Pep” and “Last AA of Sig Pep.” In the fourteenth column, the predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as “Predicted First AA of Secreted Portion”. The amino acid position of SEQ ID NO:Y of the last amino acid encoded by the open reading frame is identified in the fifteenth column as “Last AA of ORF”.

[0015] SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1A and/or elsewhere herein

[0016] Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

[0017] Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X, and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC™, as set forth in Table 1A. The nucleotide sequence of each deposited plasmid can readily be determined by sequencing the deposited plasmid in accordance with known methods

[0018] The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular plasmid can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

[0019] Also provided in Table 1A is the name of the vector which contains the cDNA plasmid. Each vector is routinely used in the art. The following additional information is provided for convenience.

[0020] Vectors Lambda Zap (U.S. Pat. Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Pat. Nos. 5,128,256 and 5,286,636), Zap Express (U.S. Pat. Nos. 5,128,256 and 5,286,636), pBLUESCRIPT™ (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from STRATAGENE™ Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, Calif., 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into E. coli strain XL-1 Blue, also available from STRATAGENET™.

[0021] Vectors pSport1, pCMVSport 1.0, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P.O. Box 6009, Gaithersburg, Md. 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. See, for instance, Gruber, C. E., et al., Focus 15:59 (1993). Vector lafmid BA (Bento Soares, Columbia University, New York, N.Y.) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, Calif. 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).

[0022] The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, and/or a deposited cDNA (cDNA Clone ID). The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include, but are not limited to, preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

[0023] Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X and SEQ ID NO:Y using information from the sequences disclosed herein or the clones deposited with the ATCC™. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

[0024] The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X and/or a cDNA contained in ATCC™ Deposit No.Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, and/or a polypeptide encoded by a cDNA contained in ATCC™ deposit No.Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X and/or a polypeptide encoded by the cDNA contained in ATCC™ Deposit No.Z, are also encompassed by the invention. The present invention further encompasses a polynucleotide comprising, or alternatively consisting of the complement of the nucleic acid sequence of SEQ ID NO:X, and/or the complement of the coding strand of the cDNA contained in ATCC™ Deposit No.Z.

Description of Table 1B (Comprised of Tables 1B.1 and 1B.2)

[0025] Table 1B.1 and Table 1B.2 summarize some of the polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID:), contig sequences (contig identifier (Contig ID:) and contig nucleotide sequence identifiers (SEQ ID NO:X)) and further summarizes certain characteristics of these polynucleotides and the polypeptides encoded thereby. The first column of Tables 1B.1 and 1B.2 provide the gene numbers in the application for each clone identifier. The second column of Tables 1B.1 and 1B.2 provide unique clone identifiers, “Clone ID:”, for cDNA clones related to each contig sequence disclosed in Table 1A and/or Table 1B. The third column of Tables 1B.1 and 1B.2 provide unique contig identifiers, “Contig ID:” for each of the contig sequences disclosed in these tables. The fourth column of Tables 1B.1 and 1B.2 provide the sequence identifiers, “SEQ ID NO:X”, for each of the contig sequences disclosed in Table 1A and/or 1B.

Table 1B.1

[0026] The fifth column of Table 1B.1, “ORF (From-To)”, provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:X that delineates the preferred open reading frame (ORF) that encodes the amino acid sequence shown in the sequence listing and referenced in Table 1B.1 as SEQ ID NO:Y (column 6). Column 7 of Table 1B.1 lists residues comprising predicted epitopes contained in the polypeptides encoded by each of the preferred ORFs (SEQ ID NO:Y). Identification of potential immunogenic regions was performed according to the method of Jameson and Wolf (CABIOS, 4; 181-186 (1988)); specifically, the Genetics Computer Group (GCG) implementation of this algorithm, embodied in the program PEPTIDESTRUCTURE (Wisconsin Package v10.0, Genetics Computer Group (GCG), Madison, Wisc.). This method returns a measure of the probability that a given residue is found on the surface of the protein. Regions where the antigenic index score is greater than 0.9 over at least 6 amino acids are indicated in Table 1B.1 as “Predicted Epitopes”. In particular embodiments, polypeptides of the invention comprise, or alternatively consist of, one, two, three, four, five or more of the predicted epitopes described in Table 1B.1. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly. Column 8 of Table 1B.1 (“Cytologic Band”) provides the chromosomal location of polynucleotides corresponding to SEQ ID NO:X. Chromosomal location was determined by finding exact matches to EST and cDNA sequences contained in the NCBI (National Center for Biotechnology Information) UniGene database. Given a presumptive chromosomal location, disease locus association was determined by comparison with the Morbid Map, derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM™. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.) 2000. If the putative chromosomal location of the Query overlaps with the chromosomal location of a Morbid Map entry, an OMIM identification number is disclosed in Table 1B.1, column 9 labeled “OMIM Disease Reference(s)”. A key to the OMIM reference identification numbers is provided in Table 5.

Table 1B.2

[0027] Column 5 of Table 1B.2, “Tissue Distribution” shows the expression profile of tissue, cells, and/or cell line libraries which express the polynucleotides of the invention. The first code number shown in Table 1B.2 column 5 (preceding the colon), represents the tissue/cell source identifier code corresponding to the key provided in Table 4. Expression of these polynucleotides was not observed in the other tissues and/or cell libraries tested. The second number in column 5 (following the colon), represents the number of times a sequence corresponding to the reference polynucleotide sequence (e.g., SEQ ID NO:X) was identified in the corresponding tissue/cell source. Those tissue/cell source identifier codes in which the first two letters are “AR” designate information generated using DNA array technology. Utilizing this technology, cDNAs were amplified by PCR and then transferred, in duplicate, onto the array. Gene expression was assayed through hybridization of first strand cDNA probes to the DNA array. cDNA probes were generated from total RNA extracted from a variety of different tissues and cell lines. Probe synthesis was performed in the presence of ³³P dCTP, using oligo(dT) to prime reverse transcription. After hybridization, high stringency washing conditions were employed to remove non-specific hybrids from the array. The remaining signal, emanating from each gene target, was measured using a Phosphorimager. Gene expression was reported as Phosphor Stimulating Luminescence (PSL) which reflects the level of phosphor signal generated from the probe hybridized to each of the gene targets represented on the array. A local background signal subtraction was performed before the total signal generated from each array was used to normalize gene expression between the different hybridizations. The value presented after “[array code]:” represents the mean of the duplicate values, following background subtraction and probe normalization. One of skill in the art could routinely use this information to identify normal and/or diseased tissue(s) which show a predominant expression pattern of the corresponding polynucleotide of the invention or to identify polynucleotides which show predominant and/or specific tissue and/or cell expression.

Description of Table 1C

[0028] Table 1C summarizes additional polynucleotides encompassed by the invention (including cDNA clones related to the sequences (Clone ID:), contig sequences (contig identifier (Contig ID:) contig nucleotide sequence identifiers (SEQ ID NO:X)), and genomic sequences (SEQ ID NO:B). The first column provides a unique clone identifier, “Clone ID:”, for a cDNA clone related to each contig sequence. The second column provides the sequence identifier, “SEQ ID NO:X”, for each contig sequence. The third column provides a unique contig identifier, “Contig ID:” for each contig sequence. The fourth column, provides a BAC identifier “BAC ID NO:A” for the BAC clone referenced in the corresponding row of the table. The fifth column provides the nucleotide sequence identifier, “SEQ ID NO:B” for a fragment of the BAC clone identified in column four of the corresponding row of the table. The sixth column, “Exon From-To”, provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).

Description of Tables 1D.1 and 1D.2

[0029] Tables 1D.1 and 1D.2: In preferred embodiments, the present invention encompasses a method of detecting, preventing, diagnosing, prognosticating, treating, and/or ameliorating immune diseases or disorders; comprising administering to a patient in which such treatment, prevention, or amelioration is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) represented by Table 1A, Table 1B, and Table 1C, in an amount effective to detect, prevent, diagnose, prognosticate, treat, and/or ameliorate the disease or disorder.

[0030] As indicated in Tables 1D.1 and 1D.2, the polynucleotides, polypeptides, agonists, or antagonists of the present invention (including antibodies) can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists thereof (including antibodies) could be used to treat the associated disease.

[0031] Tables 1D.1 and 1D.2 provide information related to biological activities for polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof). Tables 1D.1 and 1D.2 also provide information related to assays which may be used to test polynucleotides and polypeptides of the invention (including antibodies, agonists, and/or antagonists thereof) for the corresponding biological activities. The first column of Table 1D.1 (“Gene No.”) provides the gene number in the application for each clone identifier. The second column of Table 1D.1 (“cDNA Clone ID:”) provides the unique clone identifier for each clone as previously described and indicated in Tables 1A, 1B, and 1C. The third column of Table 1D.1 (“AA SEQ ID NO:Y”) indicates the Sequence Listing SEQ ID Number for polypeptide sequences encoded by the corresponding cDNA clones (also as indicated in Tables 1A, 1B, and 2). The fourth column of Table 1D.1 (“Biological Activity”) indicates a biological activity corresponding to the indicated polypeptides (or polynucleotides encoding said polypeptides). The first column of Table 1D.2 (“Biological Activity No.”) provides the biological activity number corresponding to each biological activity recited in the fourth column of Table 1D.1. The second column of Table 1D.2 (“Biological Activity”) indicates the biological activity corresponding to each biological activity number (also as indicated in Table 1D.1). The third column of Table 1D.2 (“Exemplary Activity Assay”) further describes the corresponding biological activity and provides information pertaining to the various types of assays which may be performed to test, demonstrate, or quantify the corresponding biological activity. Tables 1D.1 and 1D.2 describes the use of FMAT technology, inter alia, for testing or demonstrating various biological activities. Fluorometric microvolume assay technology (FMAT) is a fluorescence-based system that provides a means to perform nonradioactive cell- and bead-based assays to detect activation of cell signal transduction pathways. This technology was designed specifically for ligand binding and immunological assays. Using this technology, fluorescent cells or beads at the bottom of the well are detected as localized areas of concentrated fluorescence using a data processing system. Unbound fluorophore comprising the background signal is ignored, allowing for a wide variety of homogeneous assays. FMAT technology may be used for peptide ligand binding assays, immunofluorescence, apoptosis, cytotoxicity, and bead-based immunocapture assays. See, Miraglia S et. al., “Homogeneous cell and bead based assays for high throughput screening using fluorometric microvolume assay technology,” Journal of Biomolecular Screening; 4:193-204 (1999). In particular, FMAT technology may be used to test, confirm, and/or identify the ability of polypeptides (including polypeptide fragments and variants) to activate signal transduction pathways. For example, FMAT technology may be used to test, confirm, and/or identify the ability of polypeptides to upregulate production of immunomodulatory proteins (such as, for example, interleukins, GM-CSF, Rantes, and Tumor Necrosis factors, as well as other cellular regulators (e.g. insulin)).

[0032] Tables 1D.1 and 1D.2 also describe the use of kinase assays for testing, demonstrating, or quantifying biological activity. In this regard, the phosphorylation and de-phosphorylation of specific amino acid residues (e.g. Tyrosine, Serine, Threonine) on cell-signal transduction proteins provides a fast, reversible means for activation and de-activation of cellular signal transduction pathways. Moreover, cell signal transduction via phosphorylation/de-phosphorylation is crucial to the regulation of a wide variety of cellular processes (e.g. proliferation, differentiation, migration, apoptosis, etc.). Accordingly, kinase assays provide a powerful tool useful for testing, confirming, and/or identifying polypeptides (including polypeptide fragments and variants) that mediate cell signal transduction events via protein phosphorylation. See e.g., Forrer, P., Tamaskovic R., and Jaussi, R. “Enzyme-Linked Immunosorbent Assay for Measurement of INK, ERK, and p38 Kinase Activities” Biol. Chem. 379(8-9): 1101-1110 (1998).

Description of Table 1E

[0033] Polynucleotides encoding polypeptides of the present invention can be used in assays to test for one or more biological activities. One such biological activity which may be tested includes the ability of polynucleotides and polypeptides of the invention to stimulate up-regulation or down-regulation of expression of particular genes and proteins. Hence, if polynucleotides and polypeptides of the present invention exhibit activity in altering particular gene and protein expression patterns, it is likely that these polynucleotides and polypeptides of the present invention may be involved in, or capable of effecting changes in, diseases associated with the altered gene and protein expression profiles. Hence, polynucleotides, polypeptides, or antibodies of the present invention could be used to treat said associated diseases.

[0034] TaqMan® assays may be performed to assess the ability of polynucleotides (and polypeptides they encode) to alter the expression pattern of particular “target” genes. TaqMan® reactions are performed to evaluate the ability of a test agent to induce or repress expression of specific genes in different cell types. TaqMan® gene expression quantification assays (“TaqMan® assays”) are well known to, and routinely performed by, those of ordinary skill in the art. TaqMan® assays are performed in a two step reverse transcription/polymerase chain reaction (RT-PCR). In the first (RT) step, cDNA is reverse transcribed from total RNA samples using random hexamer primers. In the second (PCR) step, PCR products are synthesized from the cDNA using gene specific primers.

[0035] To quantify gene expression the Taqman® PCR reaction exploits the 5′ nuclease activity of AmpliTaq Gold® DNA Polymerase to cleave a Taqman® probe (distinct from the primers) during PCR. The Taqman® probe contains a reporter dye at the 5′-end of the probe and a quencher dye at the 3′ end of the probe. When the probe is intact, the proximity of the reporter dye to the quencher dye results in suppression of the reporter fluorescence. During PCR, if the target of interest is present, the probe specifically anneals between the forward and reverse primer sites. AmpliTaq Fold DNA Polymerase then cleaves the probe between the reporter and quencher when the probe hybridizes to the target, resulting in increased fluorescence of the reporter (see Figure 2). Accumulation of PCR products is detected directly by monitoring the increase in fluorescence of the reporter dye.

[0036] After the probe fragments are displaced from the target, polymerization of the strand continues. The 3′-end of the probe is blocked to prevent extension of the probe during PCR. This process occurs in every cycle and does not interfere with the exponential accumulation of product. The increase in fluorescence signal is detected only if the target sequence is complementary to the probe and is amplified during PCR. Because of these requirements, any nonspecific amplification is not detected.

[0037] For test sample preparation, vector controls or constructs containing the coding sequence for the gene of interest are transfected into cells, such as for example 293T cells, and supernatants collected after 48 hours. For cell treatment and RNA isolation, multiple primary human cells or human cell lines are used; such cells may include but are not limited to, Normal Human Dermal Fibroblasts, Aortic Smooth Muscle, Human Umbilical Vein Endothelial Cells, HepG2, Daudi, Jurkat, U937, Caco, and THP-1 cell lines. Cells are plated in growth media and growth is arrested by culturing without media change for 3 days, or by switching cells to low serum media and incubating overnight. Cells are treated for 1, 6, or 24 hours with either vector control supernatant or sample supernatant (or purified/partially purified protein preparations in buffer). Total RNA is isolated; for example, by using Trizol extraction or by using the Ambion RNAqueous™-4PCR RNA isolation system. Expression levels of multiple genes are analyzed using TAQMAN, and expression in the test sample is compared to control vector samples to identify genes induced or repressed. Each of the above described techniques are well known to, and routinely performed by, those of ordinary skill in the art.

[0038] Table 1E indicates particular disease classes and preferred indications for which polynucleotides, polypeptides, or antibodies of the present invention may be used in detecting, diagnosing, preventing, treating and/or ameliorating said diseases and disorders based on “target” gene expression patterns which may be up- or down-regulated by polynucleotides (and the encoded polypeptides) corresponding to each indicated cDNA Clone ID (shown in Table 1E, Column 2).

[0039] Thus, in preferred embodiments, the present invention encompasses a method of detecting, diagnosing, preventing, treating, and/or ameliorating a disease or disorder listed in the “Disease Class” and/or “Preferred Indication” columns of Table 1E; comprising administering to a patient in which such detection, diagnosis, prevention, or treatment is desired a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof) in an amount effective to detect, diagnose, prevent, treat, or ameliorate the disease or disorder. The first and second columns of Table 1D.1 show the “Gene No.” and “cDNA Clone ID No.”, respectively, indicating certain nucleic acids and proteins (or antibodies against the same) of the invention (including polynucleotide, polypeptide, and antibody fragments or variants thereof) that may be used in detecting, diagnosing, preventing, treating, or ameliorating the disease(s) or disorder(s) indicated in the corresponding row in the “Disease Class” or “Preferred Indication” Columns of Table 1E.

[0040] In another embodiment, the present invention also encompasses methods of detecting, diagnosing, preventing, treating, or ameliorating a disease or disorder listed in the “Disease Class” or “Preferred Indication” Columns of Table 1E; comprising administering to a patient combinations of the proteins, nucleic acids, or antibodies of the invention (or fragments or variants thereof), sharing similar indications as shown in the corresponding rows in the “Disease Class” or “Preferred Indication” Columns of Table 1E.

[0041] The “Disease Class” Column of Table 1E provides a categorized descriptive heading for diseases, disorders, and/or conditions (more fully described below) that may be detected, diagnosed, prevented, treated, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).

[0042] The “Preferred Indication” Column of Table 1E describes diseases, disorders, and/or conditions that may be detected, diagnosed, prevented, treated, or ameliorated by a protein, nucleic acid, or antibody of the invention (or fragment or variant thereof).

[0043] The “Cell Line” and “Exemplary Targets” Columns of Table 1E indicate particular cell lines and target genes, respectively, which may show altered gene expression patterns (i.e., up- or down-regulation of the indicated target gene) in Taqman assays, performed as described above, utilizing polynucleotides of the cDNA Clone ID shown in the corresponding row. Alteration of expression patterns of the indicated “Exemplary Target” genes is correlated with a particular “Disease Class” and/or “Preferred Indication” as shown in the corresponding row under the respective column headings.

[0044] The “Exemplary Accessions” Column indicates GenBank Accessions (available online through the National Center for Biotechnology Information (NCBI)) which correspond to the “Exemplary Targets” shown in the adjacent row.

[0045] The recitation of “Cancer” in the “Disease Class” Column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof) may be used for example, to detect, diagnose, prevent, treat, and/or ameliorate neoplastic diseases and/or disorders (e.g., leukemias, cancers, etc., as described below under “Hyperproliferative Disorders”).

[0046] The recitation of “Immune” in the “Disease Class” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to detect, diagnose, prevent, treat, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), blood disorders (e.g., as described below under “Immune Activity” “Cardiovascular Disorders” and/or “Blood-Related Disorders”), and infections (e.g., as described below under “Infectious Disease”).

[0047] The recitation of “Angiogenesis” in the “Disease Class” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to detect, diagnose, treat, prevent, and/or ameliorate diseases and/or disorders relating to neoplastic diseases (e.g., as described below under “Hyperproliferative Disorders”), diseases and/or disorders of the cardiovascular system (e.g., as described below under “Cardiovascular Disorders”), diseases and/or disorders involving cellular and genetic abnormalities (e.g., as described below under “Diseases at the Cellular Level”), diseases and/or disorders involving angiogenesis (e.g., as described below under “Anti-Angiogenesis Activity”), to promote or inhibit cell or tissue regeneration (e.g., as described below under “Regeneration”), or to promote wound healing (e.g., as described below under “Wound Healing and Epithelial Cell Proliferation”).

[0048] The recitation of “Diabetes” in the “Disease Class” column indicates that the corresponding nucleic acid and protein, or antibody against the same, of the invention (or fragment or variant thereof), may be used for example, to detect, diagnose, treat, prevent, and/or ameliorate diabetes (including diabetes mellitus types I and II), as well as diseases and/or disorders associated with, or consequential to, diabetes (e.g. as described below under “Endocrine Disorders,” “Renal Disorders,” and “Gastrointestinal Disorders”).

Description of Table 2

[0049] Table 2 summarizes homology and features of some of the polypeptides of the invention. The first column provides a unique clone identifier, “Clone ID:”, corresponding to a cDNA clone disclosed in Table 1A or Table 1B. The second column provides the unique contig identifier, “Contig ID:” corresponding to contigs in Table 1B and allowing for correlation with the information in Table 1B. The third column provides the sequence identifier, “SEQ ID NO:X”, for the contig polynucleotide sequence. The fourth column provides the analysis method by which the homology/identity disclosed in the Table was determined. Comparisons were made between polypeptides encoded by the polynucleotides of the invention and either a non-redundant protein database (herein referred to as “NR”), or a database of protein families (herein referred to as “PFAM”) as further described below. The fifth column provides a description of the PFAM/NR hit having a significant match to a polypeptide of the invention. Column six provides the accession number of the PFAM/NR hit disclosed in the fifth column. Column seven, “Score/Percent Identity”, provides a quality score or the percent identity, of the hit disclosed in columns five and six. Columns 8 and 9, “NT From” and “NT To” respectively, delineate the polynucleotides in “SEQ ID NO:X” that encode a polypeptide having a significant match to the PFAM/NR database as disclosed in the fifth and sixth columns. In specific embodiments polypeptides of the invention comprise, or alternatively consist of, an amino acid sequence encoded by a polynucleotide in SEQ ID NO:X as delineated in columns 8 and 9, or fragments or variants thereof.

Description of Table 3

[0050] Table 3 provides polynucleotide sequences that may be disclaimed according to certain embodiments of the invention. The first column provides a unique clone identifier, “Clone ID”, for a cDNA clone related to contig sequences disclosed in Table 1B. The second column provides the sequence identifier, “SEQ ID NO:X”, for contig sequences disclosed in Table 1A and/or Table 1B. The third column provides the unique contig identifier, “Contig ID:”, for contigs disclosed in Table 1B. The fourth column provides a unique integer ‘a’ where ‘a’ is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X, and the fifth column provides a unique integer ‘b’ where ‘b’ is any integer between 15 and the final nucleotide of SEQ ID NO:X, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where b is greater than or equal to a +14. For each of the polynucleotides shown as SEQ ID NO:X, the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention. In certain embodiments, preferably excluded from the invention are at least one, two, three, four, five, ten, or more of the polynucleotide sequence(s) having the accession number(s) disclosed in the sixth column of this Table (including for example, published sequence in connection with a particular BAC clone). In further embodiments, preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones corresponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone).

Description of Table 4

[0051] Table 4 provides a key to the tissue/cell source identifier code disclosed in Table 1B.2, column 5 Column 1 provides the tissue/cell source identifier code disclosed in Table 1B.2, Column 5. Columns 2-5 provide a description of the tissue or cell source. Note that “Description” and “Tissue” sources (i.e. columns 2 and 3) having the prefix “a_” indicates organs, tissues, or cells derived from “adult” sources. Codes corresponding to diseased tissues are indicated in column 6 with the word “disease.” The use of the word “disease” in column 6 is non-limiting. The tissue or cell source may be specific (e.g. a neoplasm), or may be disease-associated (e.g., a tissue sample from a normal portion of a diseased organ). Furthermore, tissues and/or cells lacking the “disease” designation may still be derived from sources directly or indirectly involved in a disease state or disorder, and therefore may have a further utility in that disease state or disorder. In numerous cases where the tissue/cell source is a library, column 7 identifies the vector used to generate the library.

Description of Table 5

[0052] Table 5 provides a key to the OMIM reference identification numbers disclosed in Table 1B.1, column 9. OMIM reference identification numbers (Column 1) were derived from Online Mendelian Inheritance in Man (Online Mendelian Inheritance in Man, OMIM. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine, (Bethesda, Md.) 2000. Column 2 provides diseases associated with the cytologic band disclosed in Table 1B.1, column 8, as determined using the Morbid Map database.

Description of Table 6

[0053] Table 6 summarizes some of the ATCC™ Deposits, Deposit dates, and ATCC™ designation numbers of deposits made with the ATCC™ in connection with the present application. These deposits were made in addition to those described in the Table 1A.

Description of Table 7

[0054] Table 7 shows the cDNA libraries sequenced, and ATCC™ designation numbers and vector information relating to these cDNA libraries.

[0055] The first column shows the first four letters indicating the Library from which each library clone was derived. The second column indicates the catalogued tissue description for the corresponding libraries. The third column indicates the vector containing the corresponding clones. The fourth column shows the ATCC™ deposit designation for each library clone as indicated by the deposit information in Table 6.

[0056] The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

[0057] In the present invention, “isolated” refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered “by the hand of man” from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be “isolated” because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term “isolated” does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

[0058] In the present invention, a “secreted” protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a “mature” protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

[0059] As used herein, a “polynucleotide” refers to a molecule having a nucleic acid sequence encoding SEQ ID NO:Y or a fragment or variant thereof (e.g., the polypeptide delineated in columns fourteen and fifteen of Table 1A); a nucleic acid sequence contained in SEQ ID NO:X (as described in column 5 of Table 1A and/or Table 1B) or the complement thereof; a cDNA sequence contained in Clone ID: (as described in column 2 of Table 1A and/or Table 1B and contained within a library deposited with the ATCC™); a nucleotide sequence encoding the polypeptide encoded by a nucleotide sequence in SEQ ID NO:B as defined in column 6 (EXON From-To) of Table 1C or a fragment or variant thereof; or a nucleotide coding sequence in SEQ ID NO:B as defined in column 6 of Table 1C or the complement thereof. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5′ and 3′ untranslated sequences, the coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a “polypeptide” refers to a molecule having an amino acid sequence encoded by a polynucleotide of the invention as broadly defined (obviously excluding poly-Phenylalanine or poly-Lysine peptide sequences which result from translation of a polyA tail of a sequence corresponding to a cDNA).

[0060] In the present invention, “SEQ ID NO:X” was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X is deposited at Human Genome Sciences, Inc. (HGS) in a catalogued and archived library. As shown, for example, in column 2 of Table 1B, each clone is identified by a cDNA Clone ID (identifier generally referred to herein as Clone ID:). Each Clone ID is unique to an individual clone and the Clone ID is all the information needed to retrieve a given clone from the HGS library. Table 7 provides a list of the deposited cDNA libraries. One can use the Clone ID: to determine the library source by reference to Tables 6 and 7. Table 7 lists the deposited cDNA libraries by name and links each library to an ATCC™ Deposit. Library names contain four characters, for example, “HTWE.” The name of a cDNA clone (Clone ID) isolated from that library begins with the same four characters, for example “HTWEP07”. As mentioned below, Table 1A and/or Table 1B correlates the Clone ID names with SEQ ID NO:X. Thus, starting with an SEQ ID NO:X, one can use Tables 1A, 1B, 6, 7, and 9 to determine the corresponding Clone ID, which library it came from and which ATCC™ deposit the library is contained in. Furthermore, it is possible to retrieve a given cDNA clone from the source library by techniques known in the art and described elsewhere herein. The ATCC™ is located at 10801 University Boulevard, Manassas, Va. 20110-2209, USA. The ATCC™ deposits were made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure.

[0061] In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5′ or 3′ to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

[0062] A “polynucleotide” of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, or the complement thereof (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments described herein), the polynucleotide sequence delineated in columns 7 and 8 of Table 1A or the complement thereof, the polynucleotide sequence delineated in columns 8 and 9 of Table 2 or the complement thereof, and/or cDNA sequences contained in Clone ID: (e.g., the complement of any one, two, three, four, or more of the polynucleotide fragments, or the cDNA clone within the pool of cDNA clones deposited with the ATCC™, described herein), and/or the polynucleotide sequence delineated in column 6 of Table 1C or the complement thereof. “Stringent hybridization conditions” refers to an overnight incubation at 42 degree C. in a solution comprising 50% formamide, 5×SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 μg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1×SSC at about 65 degree C.

[0063] Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C. in a solution comprising 6×SSPE (20×SSPE=3M NaCl; 0.2M NaH₂PO₄; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 μg/ml salmon sperm blocking DNA; followed by washes at 50 degree C. with 1×SSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5×SSC).

[0064] Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

[0065] Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3′ terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of “polynucleotide,” since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

[0066] The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. “Modified” bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, “polynucleotide” embraces chemically, enzymatically, or metabolically modified forms.

[0067] In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5′ or 3′ to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

[0068] “SEQ ID NO:X” refers to a polynucleotide sequence described in column 5 of Table 1A, while “SEQ ID NO:Y” refers to a polypeptide sequence described in column 10 of Table 1A. SEQ ID NO:X is identified by an integer specified in column 6 of Table 1A. The polypeptide sequence SEQ ID NO:Y is a translated open reading frame (ORF) encoded by polynucleotide SEQ ID NO:X. The polynucleotide sequences are shown in the sequence listing immediately followed by all of the polypeptide sequences. Thus, a polypeptide sequence corresponding to polynucleotide sequence SEQ ID NO:2 is the first polypeptide sequence shown in the sequence listing. The second polypeptide sequence corresponds to the polynucleotide sequence shown as SEQ ID NO:3, and so on.

[0069] The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS—STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990); Rattan et al., Ann. N.Y. Acad. Sci. 663:48-62 (1992)).

[0070] “SEQ ID NO:X” refers to a polynucleotide sequence described, for example, in Tables 1A, Table 1B, or Table 2, while “SEQ ID NO:Y” refers to a polypeptide sequence described in column 11 of Table 1A and or Table 1B. SEQ ID NO:X is identified by an integer specified in column 4 of Table 1B. The polypeptide sequence SEQ ID NO:Y is a translated open reading frame (ORF) encoded by polynucleotide SEQ ID NO:X. “Clone ID:” refers to a cDNA clone described in column 2 of Table 1A and/or 1B.

[0071] “A polypeptide having functional activity” refers to a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) protein. Such functional activities include, but are not limited to, biological activity (e.g. activity useful in treating, preventing and/or ameliorating immune diseases and disorders), antigenicity (ability to bind [or compete with a polypeptide for binding] to an anti-polypeptide antibody), immunogenicity (ability to generate antibody which binds to a specific polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide.

[0072] The polypeptides of the invention can be assayed for functional activity (e.g. biological activity) using or routinely modifying assays known in the art, as well as assays described herein. Specifically, one of skill in the art may routinely assay secreted polypeptides (including fragments and variants) of the invention for activity using assays as described in the examples section below.

[0073] “A polypeptide having biological activity” refers to a polypeptide exhibiting activity similar to, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention).

Tables

Table 1A

[0074] Table 1A summarizes information concerning certain polynucleotides and polypeptides of the invention. The first column provides the gene number in the application for each clone identifier. The second column provides a unique clone identifier, “Clone ID:”, for a cDNA clone related to each contig sequence disclosed in Table 1A. Third column, the cDNA Clones identified in the second column were deposited as indicated in the third column (i.e. by ATCC™ Deposit No:Z and deposit date). Some of the deposits contain multiple different clones corresponding to the same gene. In the fourth column, “Vector” refers to the type of vector contained in the corresponding cDNA Clone identified in the second column. In the fifth column, the nucleotide sequence identified as “NT SEQ ID NO:X” was assembled from partially homologous (“overlapping”) sequences obtained from the corresponding cDNA clone identified in the second column and, in some cases, from additional related cDNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X. In the sixth column, “Total NT Seq.” refers to the total number of nucleotides in the contig sequence identified as SEQ ID NO:X.” The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as “5′ NT of Clone Seq.” (seventh column) and the “3′ NT of Clone Seq.” (eighth column) of SEQ ID NO:X. In the ninth column, the nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as “5′ NT of Start Codon.” Similarly, in column ten, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as “5′ NT of First AA of Signal Pep.” In the eleventh column, the translated amino acid sequence, beginning with the methionine, is identified as “AA SEQ ID NO:Y,” although other reading frames can also be routinely translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

[0075] In the twelfth and thirteenth columns of Table 1A, the first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as “First AA of Sig Pep” and “Last AA of Sig Pep.” In the fourteenth column, the predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as “Predicted First AA of Secreted Portion”. The amino acid position of SEQ ID NO:Y of the last amino acid encoded by the open reading frame is identified in the fifteenth column as “Last AA of ORF”.

[0076] SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1A and/or elsewhere herein

[0077] Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

[0078] Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X, and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC™, as set forth in Table 1A. The nucleotide sequence of each deposited plasmid can readily be determined by sequencing the deposited plasmid in accordance with known methods

[0079] The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular plasmid can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

[0080] Also provided in Table 1A is the name of the vector which contains the cDNA plasmid. Each vector is routinely used in the art. The following additional information is provided for convenience.

[0081] Vectors Lambda Zap (U.S. Pat. Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Pat. Nos. 5,128,256 and 5,286,636), Zap Express (U.S. Pat. Nos. 5,128,256 and 5,286,636), pBLUESCRIPT™ (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from STRATAGENE™ Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, Calif., 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Phagemid pBS may be excised from the Lambda Zap and Uni-Zap XR vectors, and phagemid pBK may be excised from the Zap Express vector. Both phagemids may be transformed into E. coli strain XL-1 Blue, also available from STRATAGENET™.

[0082] Vectors pSport1, pCMVSport 1.0, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P.O. Box 6009, Gaithersburg, Md. 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. See, for instance, Gruber, C. E., et al., Focus 15:59 (1993). Vector lafmid BA (Bento Soares, Columbia University, New York, N.Y.) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, Calif. 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).

[0083] The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, and/or a deposited cDNA (cDNA Clone ID). The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include, but are not limited to, preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

[0084] Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X and SEQ ID NO:Y using information from the sequences disclosed herein or the clones deposited with the ATCC™. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

[0085] The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X and/or a cDNA contained in ATCC™ Deposit No.Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X, and/or a polypeptide encoded by a cDNA contained in ATCC™ deposit No.Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y, a polypeptide encoded by SEQ ID NO:X and/or a polypeptide encoded by the cDNA contained in ATCC™ Deposit No.Z, are also encompassed by the invention. The present invention further encompasses a polynucleotide comprising, or alternatively consisting of the complement of the nucleic acid sequence of SEQ ID NO:X, and/or the complement of the coding strand of the cDNA contained in ATCC™ Deposit No.Z.

[0086]

TABLE 1A
				NT					5′ NT	AA	First	Last	First
		ATCC ™		SEQ		5′ NT	3′ NT		of First	SEQ	AA	AA	AA	Last
		Deposit		ID	Total	of	of	5′ NT	AA of	ID	of	of	of	AA
Gene	cDNA	No:Z and		NO:	NT	Clone	Clone	of Start	Signal	NO:	Sig	Sig	Secreted	of
No.	Clone ID	Date	Vector	X	Seq.	Seq.	Seq.	Codon	Pep	Y	Pep	Pep	Portion	ORF
1	H2CBG48	209889	pBLUESCRIPT ™	11	2797	1	2797	125	125	908	1	25	26	45
		May 22, 1998	SK-
2	H2MAC30	209299	pBLUESCRIPT ™	12	459	1	459	157	157	909	1	28	29	72
		Sep. 25, 1997	SK-
3	H6EAB28	209511	Uni-ZAP XR	13	1939	1	1939	115	115	910	1	31	32	100
		Dec. 03, 1997
3	H6EAB28	209511	Uni-ZAP XR	603	1547	1	1547	116	116	1500	1	20	21	76
		Dec. 03, 1997
4	H6EDF66	209299	Uni-ZAP XR	14	540	1	540	146	146	911	1	27	28	131
		Sep. 25, 1997
5	H6EDX46	209626	Uni-ZAP XR	15	888	1	888	229	229	912	1	20	21	182
		Feb. 12, 1998
5	H6EDX46	209626	Uni-ZAP XR	604	718	1	718	128	128	1501	1	20	21	84
		Feb. 12, 1998
6	HABAG37	209626	pSport1	16	654	1	639	97	97	913	1	31	32	62
		Feb. 12, 1998
7	HACBD91	209626	Uni-ZAP XR	17	1445	1	1445	117	117	914	1	42	43	49
		Feb. 12, 1998
8	HACCI17	203071	Uni-ZAP XR	18	1722	336	1714	461	461	915	1	24	25	218
		Jul. 27, 1998
8	HACCI17	203071	Uni-ZAP XR	605	1380	12	1380	135	135	1502	1	24	25	72
		Jul. 27, 1998
9	HADAO89	209423	pSport1	19	1453	1	1453	244	244	916	1	22	23	44
		Oct. 30, 1997
10	HADCP14	203027	pSport1	20	1032	1	1032	35	35	917	1	20	21	142
		Jun. 26, 1998
11	HAGAI85	97922	Uni-ZAP XR	21	1752	52	1752	166	166	918	1	23	24	30
		Mar. 07, 1997
		209070
		May 22, 1997
12	HAGAM64	209603	Uni-ZAP XR	22	2321	1	2321	57	57	919	1	31	32	44
		Jan. 29, 1998
13	HAGAN21	PTA-841	Uni-ZAP XR	23	843	1	843	34	34	920	1	17	18	91
		Oct. 13, 1999
13	HAGAN21	PTA-841	Uni-ZAP XR	606	610	294	610	335	335	1503	1	17	18	91
		Oct. 13, 1999
13	HAGAN21	PTA-841	Uni-ZAP XR	607	659	1	659		452	1504	1			4
		Oct. 13, 1999
13	HAGAN21	PTA-841	Uni-ZAP XR	608	189	1	189		146	1505	1	13	14	14
		Oct. 13, 1999
13	HAGAN21	PTA-841	Uni-ZAP XR	609	637	1	637		321	1506	1			6
		Oct. 13, 1999
14	HAGBZ81	209118	Uni-ZAP XR	24	1382	24	1382		65	921	1	30	31	49
		Jun. 12, 1997
15	HAGDG59	209277	Uni-ZAP XR	25	1734	44	1717	124	124	922	1	18	19	300
		Sep. 18, 1997
16	HAGDS20	209299	Uni-ZAP XR	26	919	1	919	11	11	923	1	17	18	66
		Sep. 25, 1997
17	HAGFG51	203364	Uni-ZAP XR	27	1313	1	1313	163	163	924	1	23	24	43
		Oct. 19, 1998
18	HAHDB16	209626	Uni-ZAP XR	28	796	1	796	93	93	925	1	20	21	50
		Feb. 12, 1998
19	HAHDR32	209626	Uni-ZAP XR	29	1256	365	1256	435	435	926	1	25	26	181
		Feb. 12, 1998
20	HAIBO71	209145	Uni-ZAP XR	30	752	172	752	325	325	927	1	28	29	66
		Jul. 17, 1997
21	HAIBP89	209877	Uni-ZAP XR	31	2243	173	2243	311	311	928	1	27	28	317
		May 18, 1998
21	HAIBP89	209877	Uni-ZAP XR	610	1025	1	1025		1	1507	1	1	2	18
		May 18, 1998
22	HAICP19	209009	Uni-ZAP XR	32	1624	89	1483	128	128	929	1	18	19	446
		Apr. 28, 1997
23	HAIFL18	209852	Uni-ZAP XR	33	879	1	879	274	274	930	1	29	30	140
		May 07, 1998
24	HAJAF57	203364	pCMVSport 3.0	34	2761	1	2761	43	43	931	1	1	2	94
		Oct. 19, 1998
25	HAJBR69	209626	pCMVSport 3.0	35	755	1	755	262	262	932	1	19	20	53
		Feb. 12, 1998
26	HAJBZ75	209603	pCMVSport 3.0	36	2089	10	2085	49	49	933	1	22	23	607
		Jan. 29, 1998
27	HAMFC93	PTA-849	pCMVSport 3.0	37	2534	1	2534	136	136	934	1	30	31	191
		Oct. 13, 1999
27	HAMFC93	PTA-849	pCMVSport 3.0	611	824	1	824	115	115	1508	1	30	31	178
		Oct. 13, 1999
27	HAMFC93	PTA-849	pCMVSport 3.0	612	3941	1947	3941		323	1509	1			8
		Oct. 13, 1999
28	HAMFK58	209641	pCMVSport 3.0	38	785	1	785	279	279	935	1	31	32	79
		Feb. 25, 1998
29	HAPNY86	209511	Uni-ZAP XR	39	1280	1	1280	100	100	936	1	25	26	129
		Dec. 03, 1997
30	HAPPW30	209683	Uni-ZAP XR	40	1472	1	1472	59	59	937	1	22	23	264
		Mar. 20, 1998
30	HAPPW30	209683	Uni-ZAP XR	613	1508	14	1501	54	54	1510	1	22	23	91
		Mar. 20, 1998
31	HAPQT22	203070	Uni-ZAP XR	41	635	1	635	132	132	938	1	17	18	72
		Jul. 27, 1998
32	HASAV70	97923	Uni-ZAP XR	42	729	1	729	94	94	939	1	20	21	110
		Mar. 07, 1997
		209071
		May 22, 1997
32	HASAV70	97923	Uni-ZAP XR	614	1412	10	733	103	103	1511	1	20	21	110
		Mar. 07, 1997
		209071
		May 22, 1997
33	HASCG84	209568	Uni-ZAP XR	43	1079	1	1079	216	216	940	1	32	33	53
		Jan. 06, 1998
34	HATAC53	209651	Uni-ZAP XR	44	1959	1	1959	97	97	941	1	21	22	248
		Mar. 04, 1998
34	HATAC53	209651	Uni-ZAP XR	615	1306	13	1306	99	99	1512	1	21	22	189
		Mar. 04, 1998
35	HATBR65	209626	Uni-ZAP XR	45	812	1	812	252	252	942	1	16	17	64
		Feb. 12, 1998
36	HATCB92	209683	Uni-ZAP XR	46	1756	1	1756	247	247	943	1	37	38	56
		Mar. 20, 1998
37	HATCP77	209965	Uni-ZAP XR	47	2098	1	2098	37	37	944	1	21	22	182
		Jun. 11, 1998
38	HATDF29	203858	Uni-ZAP XR	48	1355	1	1355	143	143	945	1	30	31	385
		Mar. 18, 1999
39	HATDM46	PTA-844	Uni-ZAP XR	49	2325	1	2325	130	130	946	1	18	19	68
		Oct. 13, 1999
39	HATDM46	PTA-844	Uni-ZAP XR	616	546	1	546	131	131	1513	1	18	19	68
		Oct. 13, 1999
39	HATDM46	PTA-844	Uni-ZAP XR	617	859	1	859		723	1514	1	10	11	29
		Oct. 13, 1999
39	HATDM46	PTA-844	Uni-ZAP XR	618	1649	1	1649		988	1515	1	15	16	62
		Oct. 13, 1999
39	HATDM46	PTA-844	Uni-ZAP XR	619	675	204	651		1	1516	1	1	2	225
		Oct. 13, 1999
39	HATDM46	PTA-844	Uni-ZAP XR	620	751	563	751		2	1517	1	1	2	211
		Oct. 13, 1999
40	HATEE46	209407	Uni-ZAP XR	50	1675	136	863	241	241	947	1	21	22	53
		Oct. 23, 1997
41	HBAFJ33	209603	pSport1	51	1280	1	1252	60	60	948	1	15	16	110
		Jan. 29, 1998
42	HBAFV19	PTA-1543	pSport1	52	953	1	953	6	6	949	1	1	2	258
		Mar. 21, 2000
43	HBAMB34	209324	pSport1	53	1027	1	1027	87	87	950	1	35	36	48
		Oct. 02, 1997
44	HBCPB32	PTA-2075	pSport1	54	1368	1	1368	88	88	951	1	37	38	202
		Jun. 09, 2000
44	HBCPB32	PTA-2075	pSport1	621	729	1	729	89	89	1518	1	37	38	196
		Jun. 09, 2000
45	HBHAD12	209009	Uni-ZAP XR	55	786	1	786		176	952	1	17	18	23
		Apr. 28, 1997
46	HBHMA23	209782	pSport1	56	1175	2	1175	71	71	953	1	24	25	197
		Apr. 20, 1998
46	HBHMA23	209782	pSport1	622	1172	1	1172	70	70	1519	1	24	25	76
		Apr. 20, 1998
47	HBIBW67	209324	Uni-ZAP XR	57	1404	1	1404	685	685	954	1	33	34	38
		Oct. 02, 1997
48	HBIMB51	209683	pCMVSport 3.0	58	537	1	537	98	98	955	1	21	22	146
		Mar. 20, 1998
48	HBIMB51	209683	pCMVSport 3.0	623	526	1	526	93	93	1520	1	21	22	130
		Mar. 20, 1998
49	HBINS58	PTA-885	pCMVSport 3.0	59	843	1	843	57	57	956	1	30	31	174
		Oct. 28, 1999
49	HBINS58	PTA-885	pCMVSport 3.0	624	1566	1	1566	71	71	1521	1	29	30	173
		Oct. 28, 1999
49	HBINS58	PTA-885	pCMVSport 3.0	625	1067	1	1067	100	100	1522	1	29	30	210
		Oct. 28, 1999
50	HBJFU48	209125	Uni-ZAP XR	60	849	1	849	20	20	957	1	39	40	40
		Jun. 19, 1997
51	HBJID05	209300	Uni-ZAP XR	61	2008	1	2008	157	157	958	1	20	21	199
		Sep. 25, 1997
51	HBJID05	209300	Uni-ZAP XR	626	571	1	571	137	137	1523	1	20	21	111
		Sep. 25, 1997
52	HBJIY92	203071	Uni-ZAP XR	62	2434	487	2366	548	548	959	1	29	30	40
		Jul. 27, 1998
53	HBJJU28	209346	Uni-ZAP XR	63	1160	1	1160	133	133	960	1	18	19	84
		Oct. 09, 1997
54	HBJLC01	209651	Uni-ZAP XR	64	872	1	872	87	87	961	1	34	35	46
		Mar. 04, 1998
55	HBJLF01	209877	Uni-ZAP XR	65	1932	201	1931	217	217	962	1	46	47	244
		May 18, 1998
56	HBJLH40	203499	Uni-ZAP XR	66	1853	1	1853	74	74	963	1	30	31	74
		Dec. 01, 1998
57	HBJNC59	PTA-622	Uni-ZAP XR	67	1061	1	1061	66	66	964	1	22	23	245
		Sep. 02, 1999
57	HBJNC59	PTA-622	Uni-ZAP XR	627	1021	1	1021	66	66	1524	1	22	23	99
		Sep. 02, 1999
57	HBJNC59	PTA-622	Uni-ZAP XR	628	1086	1	1023	64	64	1525	1	22	23	245
		Sep. 02, 1999
58	HBNAW17	209242	Uni-ZAP XR	68	601	1	601	77	77	965	1	37	38	61
		Sep. 12, 1997
59	HBOEG11	PTA-2072	pSport1	69	1356	1	1356	57	57	966	1	22	23	250
		Jun. 09, 2000
59	HBOEG11	PTA-2072	pSport1	629	1352	1	1352	53	53	1526	1	22	23	250
		Jun. 09, 2000
59	HBOEG11	PTA-2072	pSport1	630	1337	1	1289	47	47	1527	1	22	23	250
		Jun. 09, 2000
60	HBOEG69	203081	pSport1	70	1411	1	1411	302	302	967	1	19	20	54
		Jul. 30, 1998
61	HBXFL29	203858	ZAP Express	71	2229	376	2210	560	560	968	1	31	32	57
		Mar. 18, 1999
62	HCACU58	209626	Uni-ZAP XR	72	1554	1	1554	137	137	969	1	30	31	83
		Feb. 12, 1998
63	HCACV51	209551	Uni-ZAP XR	73	2083	1	2083	168	168	970	1	31	32	81
		Dec. 12, 1997
63	HCACV51	209551	Uni-ZAP XR	631	2092	1	2092	173	173	1528	1	31	32	281
		Dec. 12, 1997
64	HCDBW86	209242	Uni-ZAP XR	74	730	1	730	139	139	971	1	18	19	30
		Sep. 12, 1997
65	HCE1Q89	209242	Uni-ZAP XR	75	863	1	863	74	74	972	1	17	18	88
		Sep. 12, 1997
66	HCE2F54	209626	Uni-ZAP XR	76	1276	19	1256	166	166	973	1	19	20	319
		Feb. 12, 1998
67	HCE3G69	209878	Uni-ZAP XR	77	2084	1	2084	165	165	974	1	19	20	336
		May 18, 1998
67	HCE3G69	209878	Uni-ZAP XR	632	2078	1	2078	165	165	1529	1	19	20	105
		May 18, 1998
68	HCEEA88	209626	Uni-ZAP XR	78	1016	1	1016	134	134	975	1	23	24	60
		Feb. 12, 1998
69	HCEFB69	209965	Uni-ZAP XR	79	1430	1	1430	188	188	976	1	24	25	224
		Jun. 11, 1998
70	HCEFB80	PTA-2069	Uni-ZAP XR	80	2494	1	2494	12	12	977	1	35	36	89
		Jun. 09, 2000
70	HCEFB80	PTA-2069	Uni-ZAP XR	633	2494	1	2451	5	5	1530	1	35	36	89
		Jun. 09, 2000
71	HCEGR33	209090	Uni-ZAP XR	81	1630	1	1630	243	243	978	1	18	19	31
		Jun. 05, 1997
72	HCEMP62	209745	Uni-ZAP XR	82	1860	269	1726	352	352	979	1	30	31	187
		Apr. 07, 1998
72	HCEMP62	209745	Uni-ZAP XR	634	1957	582	1823	19	19	1531	1	33	34	335
		Apr. 07, 1998
73	HCENK38	209651	Uni-ZAP XR	83	1509	1	1509	10	10	980	1	28	29	52
		Mar. 04, 1998
74	HCEWE17	PTA-842	Uni-ZAP XR	84	967	1	967	117	117	981	1	23	24	106
		Oct. 13, 1999
74	HCEWE17	PTA-842	Uni-ZAP XR	635	730	247	730	500	500	1532	1	19	20	27
		Oct. 13, 1999
74	HCEWE17	PTA-842	Uni-ZAP XR	636	550	1	550		156	1533	1	1	2	54
		Oct. 13, 1999
75	HCEWE20	209300	Uni-ZAP XR	85	885	13	885	166	166	982	1	18	19	51
		Sep. 25, 1997
76	HCFCU88	209324	pSport1	86	853	1	853	217	217	983	1	18	19	97
		Oct. 02, 1997
77	HCFMV71	209242	pSport1	87	400	1	400	31	31	984	1	24	25	58
		Sep. 12, 1997
78	HCFNN01	209086	pSport1	88	1261	154	1261	254	254	985	1	27	28	43
		May 29, 1997
79	HCFOM18	209324	pSport1	89	639	1	639	28	28	986	1	20	21	63
		Oct. 02, 1997
80	HCHNF25	209651	pSport1	90	3576	1	3576	1130	1130	987	1	30	31	169
		Mar. 04, 1998
80	HCHNF25	209651	pSport1	637	807	1	807	180	180	1534	1	30	31	147
		Mar. 04, 1998
81	HCMSQ56	209877	Uni-ZAP XR	91	1262	1	1262	148	148	988	1	19	20	88
		May 18, 1998
82	HCMST14	209346	Uni-ZAP XR	92	614	1	614	136	136	989	1	24	25	47
		Oct. 09, 1997
83	HCMTB45	209368	Uni-ZAP XR	93	958	1	958	215	215	990	1	20	21	123
		Oct. 16, 1997
83	HCMTB45	209368	Uni-ZAP XR	638	946	1	946	209	209	1535	1	27	28	70
		Oct. 16, 1997
84	HCNSD93	209627	pBLUESCRIPT ™	94	1106	1	1106	139	139	991	1	21	22	46
		Feb. 12, 1998
85	HCOOS80	PTA-2076	pSport1	95	1254	1	1254	36	36	992	1	26	27	158
		Jun. 09, 2000
85	HCOOS80	PTA-2076	pSport1	639	869	15	869	40	40	1536	1	26	27	158
		Jun. 09, 2000
85	HCOOS80	PTA-2076	pSport1	640	692	339	506		1	1537	1	1	2	106
		Jun. 09, 2000
86	HCQCT05	PTA-884	Lambda ZAP II	96	679	1	679		381	993	1			2
		Oct. 28, 1999
86	HCQCT05	PTA-884	Lambda ZAP II	641	2333	1324	2333		1702	1538	1			2
		Oct. 28, 1999
87	HCUBS50	209215	ZAP Express	97	865	1	865	88	88	994	1	34	35	38
		Aug. 21, 1997
88	HCUCK44	209853	ZAP Express	98	1139	573	1133	593	593	995	1	30	31	60
		May 07, 1998
89	HCUE060	209215	ZAP Express	99	1222	1	1222	102	102	996	1	34	35	64
		Aug. 21, 1997
90	HCUGM86	PTA-1544	ZAP Express	100	627	1	627	91	91	997	1	24	25	44
		Mar. 21, 2000
91	HCUHK65	209641	ZAP Express	101	367	1	367	80	80	998	1	26	27	79
		Feb. 25, 1998
91	HCUHK65	209641	ZAP Express	642	3113	2577	2946	770	770	1539	1	30	31	708
		Feb. 25, 1998
92	HCUIM65	209324	ZAP Express	102	875	331	736	557	557	999	1	27	28	47
		Oct. 02, 1997
93	HCWEB58	PTA-883	ZAP Express	103	1283	1	1283	148	148	1000	1	27	28	343
		Oct. 28, 1999
93	HCWEB58	PTA-883	ZAP Express	643	980	1	980	247	247	1540	1	27	28	244
		Oct. 28, 1999
93	HCWEB58	PTA-883	ZAP Express	644	888	1	888	155	155	1541	1	27	28	244
		Oct. 28, 1999
94	HCWGU37	PTA-883	ZAP Express	104	2777	1	2777	194	194	1001	1			10
		Oct. 28, 1999
94	HCWGU37	PTA-883	ZAP Express	645	1651	1	1651	187	187	1542	1			10
		Oct. 28, 1999
95	HCWKC15	209324	ZAP Express	105	710	1	710	37	37	1002	1	18	19	40
		Oct. 02, 1997
96	HCWLD74	209626	ZAP Express	106	1540	1	1540	138	138	1003	1	21	22	65
		Feb. 12, 1998
97	HDHEB60	209215	pCMVSport 2.0	107	1421	235	1421	568	568	1004	1	24	25	108
		Aug. 21, 1997
98	HDHIA94	209627	pCMVSport 2.0	108	1489	1	1489	154	154	1005	1	30	31	168
		Feb. 12, 1998
98	HDHIA94	209627	pCMVSport 2.0	646	2492	1	2492	163	163	1543	1	30	31	48
		Feb. 12, 1998
99	HDHMA45	203331	pCMVSport 2.0	109	2184	1	2184	199	199	1006	1	33	34	413
		Oct. 08, 1998
99	HDHMA45	203331	pCMVSport 2.0	647	2190	1	2190	204	204	1544	1	33	34	413
		Oct. 08, 1998
100	HDHMA72	209324	pCMVSport 2.0	110	4463	216	2158	287	287	1007	1	36	37	315
		Oct. 02, 1997
101	HDLAC10	209745	pCMVSport 2.0	111	1477	1	1477	132	132	1008	1	29	30	81
		Apr. 07, 1998
102	HDLAO28	PTA-499	pCMVSport 2.0	112	1984	1	1984	259	259	1009	1	21	22	76
		Aug. 11, 1999
103	HDPBA28	PTA-163	pCMVSport 3.0	113	3447	197	3447	259	259	1010	1	32	33	941
		Jun. 01, 1999
103	HDPBA28	PTA-163	pCMVSport 3.0	648	4909	1	4909	69	69	1545	1	32	33	941
		Jun. 01, 1999
104	HDPBQ02	209889	pCMVSport 3.0	114	1166	1	1166	461	461	1011	1	24	25	222
		May 22, 1998
104	HDPBQ02	209889	pCMVSport 3.0	649	2191	291	2191	460	460	1546	1	24	25	108
		May 22, 1998
105	HDPBQ71	209877	pCMVSport 3.0	115	2312	1	2312	93	93	1012	1	33	34	612
		May 18, 1998
105	HDPBQ71	209877	pCMVSport 3.0	650	2242	6	2242	24	24	1547	1	33	34	612
		May 18, 1998
105	HDPBQ71	209877	pCMVSport 3.0	651	2381	146	2381	165	165	1548	1	33	34	456
		May 18, 1998
106	HDPCO25	209125	pCMVSport 3.0	116	767	76	767	182	182	1013	1	20	21	53
		Jun. 19, 1997
107	HDPCY37	209568	pCMVSport 3.0	117	1932	45	1932	76	76	1014	1	21	22	578
		Jan. 06, 1998
107	HDPCY37	209568	pCMVSport 3.0	652	1931	45	1931	76	76	1549	1	21	22	264
		Jan. 06, 1998
108	HDPFF39	209511	pCMVSport 3.0	118	1256	1	1256	175	175	1015	1	18	19	196
		Dec. 03, 1997
109	HDPGK25	209877	pCMVSport 3.0	119	703	1	703	345	345	1016	1	33	34	119
		May 18, 1998
110	HDPGP94	203364	pCMVSport 3.0	120	3881	1	3881	256	256	1017	1	18	19	74
		Oct. 19, 1998
111	HDPHI51	209125	pCMVSport 3.0	121	728	1	728	245	245	1018	1	30	31	40
		Jun. 19, 1997
112	HDPJF37	209852	pCMVSport 3.0	122	986	1	986	196	196	1019	1	23	24	57
		May 07, 1998
113	HDPJM30	209563	pCMVSport 3.0	123	1635	308	1633	59	59	1020	1	59	60	525
		Dec. 18, 1997
113	HDPJM30	209563	pCMVSport 3.0	653	1314	1	1313	259	259	1550	1	20	21	59
		Dec. 18, 1997
114	HDPNC61	209627	pCMVSport 3.0	124	1410	1	1410	20	20	1021	1	22	23	94
		Feb. 12, 1998
115	HDPND46	209627	pCMVSport 3.0	125	1727	1	1727	15	15	1022	1	22	23	484
		Feb. 12, 1998
116	HDPOE32	PTA-622	pCMVSport 3.0	126	1353	1	1353	118	118	1023	1	34	35	151
		Sep. 02, 1999
117	HDPOH06	209745	pCMVSport 3.0	127	2504	1	2504	252	252	1024	1	29	30	242
		Apr. 07, 1998
118	HDPOZ56	209889	pCMVSport 3.0	128	1905	1	1905	91	91	1025	1	21	22	567
		May 22, 1998
118	HDPOZ56	209889	pCMVSport 3.0	654	1867	415	1867	103	103	1551	1	21	22	566
		May 22, 1998
118	HDPOZ56	209889	pCMVSport 3.0	655	1722	1	1722	59	59	1552	1	21	22	319
		May 22, 1998
119	HDPPA04	PTA-867	pCMVSport 3.0	129	2406	1	2406	271	271	1026	1	19	20	283
		Oct. 26, 1999
119	HDPPA04	PTA-867	pCMVSport 3.0	656	1675	1	1613		1003	1553	1	11	12	23
		Oct. 26, 1999
119	HDPPA04	PTA-867	pCMVSport 3.0	657	786	1	786	261	261	1554	1	19	20	93
		Oct. 26, 1999
120	HDPPH47	209626	pCMVSport 3.0	130	2080	105	2080	116	116	1027	1	35	36	540
		Feb. 12, 1998
121	HDPSB18	PTA-868	pCMVSport 3.0	131	3408	1	3408	123	123	1028	1	18	19	66
		Oct. 26, 1999
121	HDPSB18	PTA-868	pCMVSport 3.0	658	308	1	308		116	1555	1	17	18	64
		Oct. 26, 1999
121	HDPSB18	PTA-868	pCMVSport 3.0	659	1568	1	1568		1525	1556	1	7	8	14
		Oct. 26, 1999
121	HDPSB18	PTA-868	pCMVSport 3.0	660	865	1	865		345	1557	1	1	2	107
		Oct. 26, 1999
122	HDPSP01	209745	pCMVSport 3.0	132	2343	1	2343	184	184	1029	1	20	21	710
		Apr. 07, 1998
122	HDPSP01	209745	pCMVSport 3.0	661	1752	1	1752	227	227	1558	1	20	21	308
		Apr. 07, 1998
123	HDPSP54	209782	pCMVSport 3.0	133	3091	2304	3091	2356	2356	1030	1	18	19	48
		Apr. 20, 1998
123	HDPSP54	209782	pCMVSport 3.0	662	536	1	536	179	179	1559	1	41	42	55
		Apr. 20, 1998
124	HDPSU13	209627	pCMVSport 3.0	134	1218	1	1218	14	14	1031	1	25	26	114
		Feb. 12, 1998
125	HDPTD15	209782	pCMVSport 3.0	135	1396	1	1396	223	223	1032	1	18	19	200
		Apr. 20, 1998
126	HDPTK41	209965	pCMVSport 3.0	136	1564	1	1564	39	39	1033	1	26	27	369
		Jun. 11, 1998
127	HDPUG50	209745	pCMVSport 3.0	137	1734	1	1734	22	22	1034	1	34	35	526
		Apr. 07, 1998
128	HDPUH26	PTA-163	pCMVSport 3.0	138	2916	1	2916	90	90	1035	1	18	19	549
		Jun. 01, 1999
129	HDPUW68	203331	pCMVSport 3.0	139	1748	1	1748	40	40	1036	1	18	19	467
		Oct. 08, 1998
130	HDPVH60	203105	pCMVSport 3.0	140	3116	1	3100	8	8	1037	1	45	46	51
		Aug. 13, 1998
131	HDPWN93	PTA-868	pCMVSport 3.0	141	2679	1	2669	45	45	1038	1	19	20	802
		Oct. 26, 1999
131	HDPWN93	PTA-868	pCMVSport 3.0	663	716	1	716	35	35	1560	1	19	20	214
		Oct. 26, 1999
131	HDPWN93	PTA-868	pCMVSport 3.0	664	2716	26	2716	27	27	1561	1	19	20	43
		Oct. 26, 1999
132	HDQHD03	203570	pCMVSport 3.0	142	1266	1	1266	274	274	1039	1	20	21	331
		Jan. 11, 1999
132	HDQHD03	203570	pCMVSport 3.0	665	1257	1	1257	259	259	1562	1	20	21	333
		Jan. 11, 1999
133	HDTBP04	209300	pCMVSport 2.0	143	961	1	961	70	70	1040	1	15	16	219
		Sep. 25, 1997
133	HDTBP04	209300	pCMVSport 2.0	666	959	1	959	65	65	1563	1	15	16	220
		Sep. 25, 1997
134	HDTEK44	PTA-867	pCMVSport 2.0	144	2070	20	2070		691	1041	1	12	13	83
		Oct. 26, 1999
134	HDTEK44	PTA-867	pCMVSport 2.0	667	1005	1	1005	175	175	1564	1	17	18	67
		Oct. 26, 1999
134	HDTEK44	PTA-867	pCMVSport 2.0	668	2988	1	2988	116	116	1565	1	17	18	67
		Oct. 26, 1999
134	HDTEK44	PTA-867	pCMVSport 2.0	669	2052	2	2052		673	1566	1	12	13	83
		Oct. 26, 1999
135	HDTEN81	209463	pCMVSport 2.0	145	566	1	566	114	114	1042	1	17	18	85
		Nov. 14, 1997
136	HDTFE17	PTA-868	pCMVSport 2.0	146	1242	1	1242	260	260	1043	1	20	21	29
		Oct. 26, 1999
136	HDTFE17	PTA-868	pCMVSport 2.0	670	628	1	628	251	251	1567	1	20	21	29
		Oct. 26, 1999
136	HDTFE17	PTA-868	pCMVSport 2.0	671	923	29	903		101	1568	1	6	7	80
		Oct. 26, 1999
137	HDTGC73	209627	pCMVSport 2.0	147	712	1	712	386	386	1044	1	31	32	49
		Feb. 12, 1998
138	HDTIT10	203570	pCMVSport 2.0	148	1200	1	813	58	58	1045	1	56	57	297
		Jan. 11, 1999
138	HDTIT10	203570	pCMVSport 2.0	672	1159	1	805	161	161	1569	1	30	31	56
		Jan. 11, 1999
139	HDTMK50	PTA-884	pCMVSport 2.0	149	1352	1	1352	154	154	1046	1	21	22	51
		Oct. 28, 1999
139	HDTMK50	PTA-884	pCMVSport 2.0	673	912	1	912	164	164	1570	1	21	22	51
		Oct. 28, 1999
139	HDTMK50	PTA-884	pCMVSport 2.0	674	321	1	321		200	1571	1			1
		Oct. 28, 1999
140	HE2DY70	209877	Uni-ZAP XR	150	639	1	639	137	137	1047	1	45	46	58
		May 18, 1998
141	HE2EN04	209300	Uni-ZAP XR	151	370	1	370	57	57	1048	1	16	17	50
		Sep. 25, 1997
142	HE2FV03	97955	Uni-ZAP XR	152	2067	1	1251	116	116	1049	1	21	22	42
		Mar. 13, 1997
		209074
		May 22, 1997
143	HE2NV57	209877	Uni-ZAP XR	153	867	1	867	99	99	1050	1	36	37	99
		May 18, 1998
144	HE2PD49	209627	Uni-ZAP XR	154	1422	257	1404	337	337	1051	1	18	19	171
		Feb. 12, 1998
145	HE2PY40	209965	Uni-ZAP XR	155	1288	1	1288	147	147	1052	1	22	23	83
		Jun. 11, 1998
146	HE6EU50	97975	Uni-ZAP XR	156	1152	117	686	237	237	1053	1	20	21	34
		Apr. 04, 1997
		209081
		May 29, 1997
147	HE8MH91	209603	Uni-ZAP XR	157	1761	1	1761	63	63	1054	1	23	24	116
		Jan. 29, 1998
148	HE8QV67	PTA-2072	Uni-ZAP XR	158	1999	643	1999	502	502	1055	1	49	50	80
		Jun. 09, 2000
148	HE8QV67	PTA-2072	Uni-ZAP XR	675	2342	1956	2276		256	1572	1	1	2	415
		Jun. 09, 2000
149	HE8UB86	203570	Uni-ZAP XR	159	1021	1	1021	201	201	1056	1	21	22	250
		Jan. 11, 1999
150	HE9BK23	209683	Uni-ZAP XR	160	1636	1	1636	39	39	1057	1	21	22	309
		Mar. 20, 1998
151	HE9C069	209551	Uni-ZAP XR	161	1077	1	1077	161	161	1058	1	26	27	41
		Dec. 12, 1997
152	HE9CP41	209368	Uni-ZAP XR	162	1392	1	1392	132	132	1059	1	20	21	41
		Oct. 16, 1997
153	HE9DG49	97923	Uni-ZAP XR	163	717	1	717	70	70	1060	1	28	29	201
		Mar. 07, 1997
		209071
		May 22, 1997
153	HE9DG49	97923	Uni-ZAP XR	676	717	1	717	70	70	1573	1	27	28	201
		Mar. 07, 1997
		209071
		May 22, 1997
153	HE9DG49	97923	Uni-ZAP XR	677	713	17	713	78	78	1574	1	28	29	203
		Mar. 07, 1997
		209071
		May 22, 1997
154	HE90W20	203570	Uni-ZAP XR	164	1209	1	1209	129	129	1061	1	33	34	355
		Jan. 11, 1999
154	HE90W20	203570	Uni-ZAP XR	678	1165	1	1165	136	136	1575	1	30	31	313
		Jan. 11, 1999
154	HE90W20	203570	Uni-ZAP XR	679	1160	1	1160	129	129	1576	1	30	31	134
		Jan. 11, 1999
155	HE9RM63	PTA-499	Uni-ZAP XR	165	2149	1	2149	82	82	1062	1	27	28	354
		Aug. 11, 1999
156	HEAAR07	209346	Uni-ZAP XR	166	1084	1	1084	48	48	1063	1	31	32	42
		Oct. 09, 1997
157	HEBAE88	209242	Uni-ZAP XR	167	582	1	582	160	160	1064	1	26	27	42
		Sep. 12, 1997
158	HEBBN36	209141	Uni-ZAP XR	168	1046	470	1046	645	645	1065	1	29	30	53
		Jul. 09, 1997
159	HEBCM63	209141	Uni-ZAP XR	169	558	1	558	246	246	1066	1	26	27	68
		Jul. 09, 1997
160	HEBEJ18	203069	Uni-ZAP XR	170	685	7	649	51	51	1067	1	15	16	139
		Jul. 27, 1998
161	HEEAG23	209745	Uni-ZAP XR	171	1669	25	1280	57	57	1068	1	18	19	46
		Apr. 07, 1998
162	HEEAJ02	209627	Uni-ZAP XR	172	1038	148	1037	387	387	1069	1	40	41	125
		Feb. 12, 1998
163	HEEAQ11	203071	Uni-ZAP XR	173	921	1	921	213	213	1070	1	28	29	147
		Jul. 27, 1998
164	HEGAN94	203071	Uni-ZAP XR	174	582	1	582	52	52	1071	1	23	24	121
		Jul. 27, 1998
164	HEGAN94	203071	Uni-ZAP XR	680	680	1	680	133	133	1577	1	23	24	121
		Jul. 27, 1998
165	HEGBS69	PTA-2082	Uni-ZAP XR	175	809	1	809	260	260	1072	1	20	21	161
		Jun. 09, 2000
165	HEGBS69	PTA-2082	Uni-ZAP XR	681	1188	1	807	253	253	1578	1	20	21	161
		Jun. 09, 2000
166	HELGK31	209878	Uni-ZAP XR	176	1396	25	1334	209	209	1073	1	29	30	344
		May 18, 1998
166	HELGK31	209878	Uni-ZAP XR	682	1342	68	1342	402	402	1579	1	1	2	291
		May 18, 1998
167	HELHD85	PTA-1544	Uni-ZAP XR	177	1886	1	1886	41	41	1074	1	25	26	79
		Mar. 21, 2000
168	HELHL48	209877	Uni-ZAP XR	178	2971	560	2557	629	629	1075	1	16	17	291
		May 18, 1998
168	HELHL48	209877	Uni-ZAP XR	683	1955	1	1955	31	31	1580	1	16	17	184
		May 18, 1998
169	HEMAM41	209010	Uni-ZAP XR	179	1337	60	1328	175	175	1076	1	39	40	190
		Apr. 28, 1997
		209085
		May 29, 1997
169	HEMAM41	209010	Uni-ZAP XR	684	1338	33	1327	175	175	1581	1	32	33	91
		Apr. 28, 1997
		209085
		May 29, 1997
170	HEPAA46	209551	Uni-ZAP XR	180	1129	1	1129	18	18	1077	1	20	21	123
		Dec. 12, 1997
171	HEQAK71	209551	pCMVSport 3.0	181	1689	1	1689	198	198	1078	1	17	18	44
		Dec. 12, 1997
172	HEQCC55	209965	pCMVSport 3.0	182	1000	1	1000	25	25	1079	1	27	28	129
		Jun. 11, 1998
172	HEQCC55	209965	pCMVSport 3.0	685	1052	30	1052	62	62	1582	1	27	28	112
		Jun. 11, 1998
172	HEQCC55	209965	pCMVSport 3.0	686	1037	1	1037	57	57	1583	1	27	28	155
		Jun. 11, 1998
173	HERAD40	209853	Uni-ZAP XR	183	990	1	990	85	85	1080	1	38	39	98
		May 07, 1998
174	HERAR44	209407	Uni-ZAP XR	184	420	1	420	60	60	1081	1	40	41	45
		Oct. 23, 1997
175	HESAJ10	209242	Uni-ZAP XR	185	1090	400	1090	405	405	1082	1	23	24	71
		Sep. 12, 1997
176	HETAB45	209580	Uni-ZAP XR	186	1676	1	1676	123	123	1083	1	30	31	179
		Jan. 14, 1998
177	HETBR16	209877	Uni-ZAP XR	187	1569	1	1569	161	161	1084	1	21	22	64
		May 18, 1998
178	HETEU28	PTA-842	Uni-ZAP XR	188	1381	1	1381	256	256	1085	1	34	35	153
		Oct. 13, 1999
178	HETEU28	PTA-842	Uni-ZAP XR	687	1501	1	1462	331	331	1584	1	34	35	153
		Oct. 13, 1999
179	HETLM70	PTA-2073	Uni-ZAP XR	189	1251	1	1199	336	336	1086	1	27	28	229
		Jun. 09, 2000
179	HETLM70	PTA-2073	Uni-ZAP XR	688	1251	1	1251	336	336	1585	1	27	28	229
		Jun. 09, 2000
179	HETLM70	PTA-2073	Uni-ZAP XR	689	517	161	517		2	1586	1	1	2	85
		Jun. 09, 2000
180	HFABG18	PTA-1544	Uni-ZAP XR	190	1345	1	1345	53	53	1087	1	26	27	87
		Mar. 21, 2000
181	HFABH95	209407	Uni-ZAP XR	191	1347	1	1347	199	199	1088	1	21	22	116
		Oct. 23, 1997
182	HFAMB72	209146	Uni-ZAP XR	192	1323	509	1323	559	559	1089	1	22	23	60
		Jul. 17, 1997
183	HFAMH77	209300	Uni-ZAP XR	193	669	96	669	240	240	1090	1	33	34	61
		Sep. 25, 1997
184	HFCCQ50	209463	Uni-ZAP XR	194	1271	1	1271	47	47	1091	1	20	21	352
		Nov. 14, 1997
185	HFCDK17	97923	Uni-ZAP XR	195	1448	475	1392	567	567	1092	1			30
		Mar. 07, 1997
		209071
		May 22, 1997
186	HFCEW05	209603	Uni-ZAP XR	196	933	1	933	34	34	1093	1	18	19	209
		Jan. 29, 1998
187	HFFAD59	209242	Lambda ZAP II	197	470	1	470	44	44	1094	1	17	18	45
		Sep. 12, 1997
188	HFFAL36	209368	Lambda ZAP II	198	1020	1	1020	68	68	1095	1	35	36	56
		Oct. 16, 1997
189	HFGAD82	209225	Uni-ZAP XR	199	1881	772	1861	1019	1019	1096	1	18	19	38
		Aug. 28, 1997
190	HFIIN69	PTA-846	pSport1	200	1450	1	1450	45	45	1097	1	39	40	43
		Oct. 13, 1999
190	HFIIN69	PTA-846	pSport1	690	559	1	559	52	52	1587	1	39	40	43
		Oct. 13, 1999
190	HFIIN69	PTA-846	pSport1	691	678	1	678		280	1588	1			2
		Oct. 13, 1999
191	HFIIZ70	PTA-846	pSport1	201	1408	1	1408	24	24	1098	1	23	24	47
		Oct. 13, 1999
191	HFIIZ70	PTA-846	pSport1	692	1441	43	1441	74	74	1589	1	23	24	47
		Oct. 13, 1999
192	HFKET18	PTA-622	Uni-ZAP XR	202	2407	1	2407	137	137	1099	1	14	15	74
		Sep. 02, 1999
193	HFLNB64	209463	Uni-ZAP XR	203	648	1	648	62	62	1100	1	39	40	45
		Nov. 14, 1997
194	HFOXA73	209277	pSport1	204	540	1	540	25	25	1101	1	17	18	52
		Sep. 18, 1997
194	HFOXA73	209277	pSport1	693	539	1	539	15	15	1590	1			17
		Sep. 18, 1997
195	HFOXB13	209423	pSport1	205	1169	1	1169	36	36	1102	1	21	22	54
		Oct. 30, 1997
196	HFPAC12	209511	Uni-ZAP XR	206	1088	1	1088	140	140	1103	1	21	22	88
		Dec. 03, 1997
197	HFPA071	209626	Uni-ZAP XR	207	2067	364	2067	414	414	1104	1	33	34	131
		Feb. 12, 1998
198	HFPCX09	209551	Uni-ZAP XR	208	2213	1	2213	185	185	1105	1	26	27	549
		Dec. 12, 1997
198	HFPCX09	209551	Uni-ZAP XR	694	2674	59	2674	249	249	1591	1	26	27	549
		Dec. 12, 1997
198	HFPCX09	209551	Uni-ZAP XR	695	2207	1	2207	185	185	1592	1	26	27	66
		Dec. 12, 1997
199	HFPCX36	209242	Uni-ZAP XR	209	796	1	796	103	103	1106	1	27	28	46
		Sep. 12, 1997
200	HFPCX64	209878	Uni-ZAP XR	210	1076	1	1076	181	181	1107	1	28	29	87
		May 18, 1998
200	HFPCX64	209878	Uni-ZAP XR	696	1069	1	1069	181	181	1593	1	28	29	181
		May 18, 1998
200	HFPCX64	209878	Uni-ZAP XR	697	1154	84	1154	257	257	1594	1	28	29	87
		May 18, 1998
200	HFPCX64	209878	Uni-ZAP XR	698	1197	85	1197	257	257	1595	1	28	29	87
		May 18, 1998
201	HFRAN90	209242	Uni-ZAP XR	211	532	1	532	178	178	1108	1	33	34	54
		Sep. 12, 1997
202	HFTBM50	209300	Uni-ZAP XR	212	762	1	740	158	158	1109	1	20	21	34
		Sep. 25, 1997
203	HFTDL56	209782	Uni-ZAP XR	213	1839	32	1838	93	93	1110	1	20	21	519
		Apr. 20, 1998
204	HFVAB79	209368	Uni-ZAP XR	214	1175	1	1175	133	133	1111	1	15	16	194
		Oct. 16, 1997
204	HFVAB79	209368	Uni-ZAP XR	699	1186	1	1186	139	139	1596	1	15	16	194
		Oct. 16, 1997
205	HFXAM76	209568	Lambda ZAP II	215	947	1	947	213	213	1112	1	24	25	79
		Jan. 06, 1998
206	HFXDJ75	209603	Lambda ZAP II	216	1918	1	1914	44	44	1113	1	26	27	41
		Jan. 29, 1998
207	HFXDN63	209346	Lambda ZAP II	217	1026	1	1026	33	33	1114	1	14	15	53
		Oct. 09, 1997
208	HFXGT26	209965	Lambda ZAP II	218	1757	1	1757	13	13	1115	1	22	23	85
		Jun. 11, 1998
209	HFXGV31	209242	Lambda ZAP II	219	752	1	752	100	100	1116	1	24	25	64
		Sep. 12, 1997
210	HFXHD88	209511	Lambda ZAP II	220	1602	1	1602	130	130	1117	1	41	42	128
		Dec. 03, 1997
211	HFXJU68	209423	Lambda ZAP II	221	712	1	712	141	141	1118	1	26	27	162
		Oct. 30, 1997
211	HFXJU68	209423	Lambda ZAP II	700	1347	1	1347	148	148	1597	1	25	26	66
		Oct. 30, 1997
212	HFXKJ03	209215	Lambda ZAP II	222	941	1	941	179	179	1119	1	33	34	41
		Aug. 21, 1997
213	HFXKY27	209877	Lambda ZAP II	223	945	1	945	44	44	1120	1	19	20	58
		May 18, 1998
214	HGBFO79	209011	Uni-ZAP XR	224	1538	259	1538	273	273	1121	1	23	24	49
		Apr. 28, 1997
215	HGBHE57	209407	Uni-ZAP XR	225	663	1	663	14	14	1122	1	19	20	68
		Oct. 23, 1997
216	HGBIB74	203648	Uni-ZAP XR	226	1816	1	1804	14	14	1123	1	23	24	377
		Feb. 09, 1999
216	HGBIB74	203648	Uni-ZAP XR	701	1821	1	1821	28	28	1598	1	20	21	170
		Feb. 09, 1999
216	HGBIB74	203648	Uni-ZAP XR	702	1094	1	1094		2	1599	1	1	2	151
		Feb. 09, 1999
217	HGLAL82	209242	Uni-ZAP XR	227	406	1	406	144	144	1124	1	19	20	26
		Sep. 12, 1997
218	HHAAF20	203648	Uni-ZAP XR	228	1495	1	1495	141	141	1125	1	18	19	55
		Feb. 09, 1999
219	HHEAA08	209853	pCMVSport 3.0	229	2150	1	2150	88	88	1126	1	38	39	79
		May 07, 1998
219	HHEAA08	209853	pCMVSport 3.0	703	615	1	615		311	1600	1	13	14	20
		May 07, 1998
220	HHEBB10	209568	pCMVSport 3.0	230	1827	141	1810	334	334	1127	1	23	24	99
		Jan. 06, 1998
221	HHEMA59	203364	pCMVSport 3.0	231	3102	1	3099	239	239	1128	1	20	21	76
		Oct. 19, 1998
222	HHEMA75	209179	pCMVSport 3.0	232	865	229	865	569	569	1129	1	35	36	84
		Jul. 24, 1997
223	HHEMM74	PTA-849	pCMVSport 3.0	233	2612	1	2612	94	94	1130	1	27	28	74
		Oct. 13, 1999
223	HHEMM74	PTA-849	pCMVSport 3.0	704	1125	1	1125	121	121	1601	1	27	28	74
		Oct. 13, 1999
223	HHEMM74	PTA-849	pCMVSport 3.0	705	2297	1425	2297		706	1602	1	6	7	33
		Oct. 13, 1999
223	HHEMM74	PTA-849	pCMVSport 3.0	706	482	33	482		7	1603	1	13	14	53
		Oct. 13, 1999
224	HHENK42	209195	pCMVSport 3.0	234	656	1	656	63	63	1131	1	7	8	42
		Aug. 01, 1997
225	HHENP27	203105	pCMVSport 3.0	235	1237	1	1237	12	12	1132	1	22	23	282
		Aug. 13, 1998
226	HHENQ22	209511	pCMVSport 3.0	236	1899	1	1899	115	115	1133	1	36	37	58
		Dec. 03, 1997
227	HHEPD24	209195	pCMVSport 3.0	237	238	1	238	156	156	1134	1	23	24	27
		Aug. 01, 1997
228	HHEPM33	PTA-322	pCMVSport 3.0	238	1459	1	1459	269	269	1135	1	20	21	82
		Jul. 09, 1999
229	HHEPT60	209138	pCMVSport 3.0	239	532	21	532	245	245	1136	1	18	19	36
		Jul. 03, 1997
230	HHEPU04	203648	pCMVSport 3.0	240	1084	116	1084	259	259	1137	1	31	32	163
		Feb. 09, 1999
230	HHEPU04	203648	pCMVSport 3.0	707	1081	124	1081	267	267	1604	1	31	32	163
		Feb. 09, 1999
230	HHEPU04	203648	pCMVSport 3.0	708	720	1	720	45	45	1605	1	31	32	92
		Feb. 09, 1999
231	HHFEC49	PTA-844	Uni-ZAP XR	241	2263	1	2263	30	30	1138	1	24	25	184
		Oct. 13, 1999
232	HHFGR93	209746	Uni-ZAP XR	242	1835	1	1835	132	132	1139	1	29	30	390
		Apr. 07, 1998
232	HHFGR93	209746	Uni-ZAP XR	709	1932	1	1836	130	130	1606	1	29	30	236
		Apr. 07, 1998
233	HHFHJ59	97975	Uni-ZAP XR	243	661	1	661	192	192	1140	1	29	30	112
		Apr. 04, 1997
		209081
		May 29, 1997
234	HHFHR32	97975	Uni-ZAP XR	244	1378	1	1378	58	58	1141	1	25	26	235
		Apr. 04, 1997
		209081
		May 29, 1997
235	HHFOJ29	PTA-2075	Uni-ZAP XR	245	1366	1	1366	117	117	1142	1	31	32	82
		Jun. 09, 2000
235	HHFOJ29	PTA-2075	Uni-ZAP XR	710	1595	513	1595	132	132	1607	1	19	20	95
		Jun. 09, 2000
235	HHFOJ29	PTA-2075	Uni-ZAP XR	711	970	272	970		62	1608	1	1	2	152
		Jun. 09, 2000
236	HHGCM76	97958	Lambda ZAP II	246	711	8	711	270	270	1143	1	22	23	89
		Mar. 13, 1997
		209072
		May 22, 1997
236	HHGCM76	97958	Lambda ZAP II	712	711	8	711	270	270	1609	1			11
		Mar. 13, 1997
		209072
		May 22, 1997
237	HHGDF16	209463	Lambda ZAP II	247	890	215	890	253	253	1144	1	26	27	52
		Nov. 14, 1997
238	HHGDW43	209346	Lambda ZAP II	248	1050	1	1050	107	107	1145	1	40	41	44
		Oct. 09, 1997
239	HHPEC09	209877	Uni-ZAP XR	249	488	1	488	71	71	1146	1	19	20	55
		May 18, 1998
240	HHPG040	209878	Uni-ZAP XR	250	1002	1	1002	116	116	1147	1	26	27	295
		May 18, 1998
240	HHPG040	209878	Uni-ZAP XR	713	973	1	973	68	68	1610	1	37	38	302
		May 18, 1998
240	HHPG040	209878	Uni-ZAP XR	714	984	1	984	74	74	1611	1	37	38	224
		May 18, 1998
241	HHPTJ65	209179	Uni-ZAP XR	251	515	1	515	247	247	1148	1	32	33	48
		Jul. 24, 1997
242	HHSDX28	209346	Uni-ZAP XR	252	1113	1	1113	90	90	1149	1	21	22	56
		Oct. 09, 1997
243	HHSGW69	PTA-855	Uni-ZAP XR	253	1254	1	1254	238	238	1150	1	26	27	55
		Oct. 18, 1999
243	HHSGW69	PTA-855	Uni-ZAP XR	715	826	1	826	231	231	1612	1	26	27	55
		Oct. 18, 1999
243	HHSGW69	PTA-855	Uni-ZAP XR	716	4400	1605	1674		457	1613	1	1	2	314
		Oct. 18, 1999
244	HHTLF25	209125	ZAP Express	254	697	1	661	142	142	1151	1	26	27	111
		Jun. 19, 1997
245	HJABX32	209146	pBLUESCRIPT ™	255	1061	454	1061	557	557	1152	1	18	19	51
		Jul. 17, 1997	SK-
246	HJACA79	209368	pBLUESCRIPT ™	256	887	1	887	84	84	1153	1	28	29	68
		Oct. 16, 1997	SK-
247	HJACG02	209215	pBLUESCRIPT ™	257	575	1	575	66	66	1154	1	22	23	108
		Aug. 21, 1997	SK-
247	HJACG02	209215	pBLUESCRIPT ™	717	553	1	553	47	47	1614	1	23	24	108
		Aug. 21, 1997	SK-
248	HJACG30	PTA-843	pBLUESCRIPT ™	258	1532	1	1532	291	291	1155	1	27	28	44
		Oct. 13, 1999	SK-
248	HJACG30	PTA-843	pBLUESCRIPT ™	718	1614	1020	1614		50	1615	1	1	2	130
		Oct. 13, 1999	SK-
248	HJACG30	PTA-843	pBLUESCRIPT ™	719	1087	491	1087		350	1616	1	1	2	122
		Oct. 13, 1999	SK-
249	HJBAV55	203364	pBLUESCRIPT ™	259	2441	39	2429	238	238	1156	1	26	27	58
		Oct. 19, 1998	SK-
250	HJBCU04	PTA-322	pBLUESCRIPT ™	260	1192	1	1192	96	96	1157	1	49	50	176
		Jul. 09, 1999	SK-
251	HJMBI18	209580	pCMVSport 3.0	261	1021	303	1021	574	574	1158	1	19	20	80
		Jan. 14, 1998
252	HJMBN89	209407	pCMVSport 3.0	262	1064	306	1064	348	348	1159	1	13	14	56
		Oct. 23, 1997
253	HJMBT65	209580	pCMVSport 3.0	263	621	79	621	341	341	1160	1	33	34	42
		Jan. 14, 1998
254	HJMBW30	209146	pCMVSport 3.0	264	884	1	874	110	110	1161	1	18	19	42
		Jul. 17, 1997
255	HJPAD75	209641	Uni-ZAP XR	265	1231	1	1231	60	60	1162	1	29	30	91
		Feb. 25, 1998
256	HKAAE44	209368	pCMVSport 2.0	266	1494	1	1494	113	113	1163	1	39	40	136
		Oct. 16, 1997
257	HKAAH36	209563	pCMVSport 2.0	267	1216	1	1216	128	128	1164	1	29	30	293
		Dec. 18, 1997
257	HKAAH36	209563	pCMVSport 2.0	720	1016	1	1016	295	295	1617	1	29	30	143
		Dec. 18, 1997
257	HKAAH36	209563	pCMVSport 2.0	721	1490	1	1490	182	182	1618	1	29	30	293
		Dec. 18, 1997
257	HKAAH36	209563	pCMVSport 2.0	722	1441	8	1392	184	184	1619	1	29	30	85
		Dec. 18, 1997
257	HKAAH36	209563	pCMVSport 2.0	723	1516	1	1516	254	254	1620	1	29	30	293
		Dec. 18, 1997
257	HKAAH36	209563	pCMVSport 2.0	724	1381	196	1381	129	129	1621	1	29	30	293
		Dec. 18, 1997
257	HKAAH36	209563	pCMVSport 2.0	725	1439	1	1439	189	189	1622	1	29	30	61
		Dec. 18, 1997
258	HKAAK02	209551	pCMVSport 2.0	268	859	1	859	97	97	1165	1	34	35	196
		Dec. 12, 1997
259	HKABI84	209603	pCMVSport 2.0	269	1238	45	1238	274	274	1166	1	16	17	47
		Jan. 29, 1998
260	HKABZ65	209683	pCMVSport 2.0	270	1189	1	1189	77	77	1167	1	17	18	243
		Mar. 20, 1998
260	HKABZ65	209683	pCMVSport 2.0	726	1191	1	1191	69	69	1623	1	17	18	243
		Mar. 20, 1998
261	HKACB56	209346	pCMVSport 2.0	271	496	1	496	27	27	1168	1	23	24	80
		Oct. 09, 1997
262	HKACD58	209346	pCMVSport 2.0	272	3153	1	3153	38	38	1169	1	25	26	301
		Oct. 09, 1997
262	HKACD58	209346	pCMVSport 2.0	727	1626	1	1626	35	35	1624	1	25	26	154
		Oct. 09, 1997
263	HKACM93	PTA-849	pCMVSport 2.0	273	2352	1	2352	218	218	1170	1	30	31	692
		Oct. 13, 1999
263	HKACM93	PTA-849	pCMVSport 2.0	728	549	1	549	189	189	1625	1	30	31	120
		Oct. 13, 1999
263	HKACM93	PTA-849	pCMVSport 2.0	729	1120	1	1120	314	314	1626	1	30	31	269
		Oct. 13, 1999
263	HKACM93	PTA-849	pCMVSport 2.0	730	1893	739	1893		202	1627	1	13	14	17
		Oct. 13, 1999
263	HKACM93	PTA-849	pCMVSport 2.0	731	1187	1	1187		638	1628	1	4	5	45
		Oct. 13, 1999
264	HKADQ91	209568	pCMVSport 2.0	274	1523	30	1517	229	229	1171	1	25	26	275
		Jan. 06, 1998
265	HKAEG43	209965	pCMVSport 2.0	275	1297	1	1297	32	32	1172	1	29	30	70
		Jun. 11, 1998
265	HKAEG43	209965	pCMVSport 2.0	732	1286	1	1286	21	21	1629	1	29	30	70
		Jun. 11, 1998
266	HKAEL80	209423	pCMVSport 2.0	276	1105	1	1105	398	398	1173	1	17	18	79
		Oct. 30, 1997
267	HKAEV06	209627	pCMVSport 2.0	277	2496	1	2496	501	501	1174	1	30	31	438
		Feb. 12, 1998
267	HKAEV06	209627	pCMVSport 2.0	733	2351	1	2351	197	197	1630	1	29	30	57
		Feb. 12, 1998
268	HKAFK41	209300	pCMVSport 2.0	278	549	1	549	243	243	1175	1	30	31	43
		Sep. 25, 1997
269	HKDBF34	209511	pCMVSport 1	279	1432	60	1418	69	69	1176	1	14	15	222
		Dec. 03, 1997
269	HKDBF34	209511	pCMVSport 1	734	1356	1	1356	18	18	1631	1	19	20	104
		Dec. 03, 1997
270	HKGAT94	209126	pSport1	280	1048	1	1048	449	449	1177	1	31	32	99
		Jun. 19, 1997
270	HKGAT94	209126	pSport1	735	1063	1	1063		470	1632	1	20	21	94
		Jun. 19, 1997
271	HKGCO27	209853	pSport1	281	1021	1	1021	313	313	1178	1	26	27	93
		May 07, 1998
271	HKGCO27	209853	pSport1	736	1311	1	1311	57	57	1633	1	26	27	47
		May 07, 1998
272	HKISB57	209603	pBLUESCRIPT ™	282	1492	1	1439	130	130	1179	1	19	20	95
		Jan. 29, 1998
273	HKIYH57	209324	pBLUESCRIPT ™	283	609	156	609	336	336	1180	1	23	24	54
		Oct. 02, 1997
274	HKIYP40	209463	pBLUESCRIPT ™	284	1215	1	1215	43	43	1181	1	32	33	76
		Nov. 14, 1997
275	HKMLK53	209511	pBLUESCRIPT ™	285	1543	1	1543	20	20	1182	1	25	26	69
		Dec. 03, 1997
276	HKMLP68	PTA-845	pBLUESCRIPT ™	286	2784	1	2784	130	130	1183	1	24	25	80
		Oct. 13, 1999
276	HKMLP68	PTA-845	pBLUESCRIPT ™	737	718	1	718	153	153	1634	1	24	25	80
		Oct. 13, 1999
276	HKMLP68	PTA-845	pBLUESCRIPT ™	738	614	1	614		471	1635	1	1	2	47
		Oct. 13, 1999
277	HL2AC08	209580	Uni-ZAP XR	287	1478	1	1478	64	64	1184	1	23	24	280
		Jan. 14, 1998
278	HL2AG57	209746	Uni-ZAP XR	288	1780	349	1780	560	560	1185	1	31	32	80
		Apr. 07, 1998
279	HLCND09	PTA-2076	Uni-ZAP XR	289	1984	1	1984	146	146	1186	1	38	39	110
		Jun. 09, 2000
279	HLCND09	PTA-2076	Uni-ZAP XR	739	465	1	465	38	38	1636	1	38	39	142
		Jun. 09, 2000
280	HLDBX13	203331	pCMVSport 3.0	290	1815	1	1815	303	303	1187	1	39	40	55
		Oct. 08, 1998
281	HLDON23	209628	pCMVSport 3.0	291	1262	208	1256	368	368	1188	1	20	21	113
		Feb. 12, 1998
282	HLDOW79	PTA-1544	pCMVSport 3.0	292	989	1	989	43	43	1189	1	21	22	275
		Mar. 21, 2000
283	HLDQC46	PTA-1544	pCMVSport 3.0	293	632	1	632	163	163	1190	1	34	35	87
		Mar. 21, 2000
284	HLDQR62	203027	pCMVSport 3.0	294	2572	427	2572	520	520	1191	1	18	19	161
		Jun. 26, 1998
285	HLDQU79	203071	pCMVSport 3.0	295	1488	1	1488	99	99	1192	1	23	24	348
		Jul. 27, 1998
286	HLDRM43	209628	pCMVSport 3.0	296	609	1	609	24	24	1193	1	20	21	151
		Feb. 12, 1998
286	HLDRM43	209628	pCMVSport 3.0	740	759	1	759	164	164	1637	1	20	21	151
		Feb. 12, 1998
287	HLDRP33	209641	pCMVSport 3.0	297	612	1	612	215	215	1194	1	26	27	41
		Feb. 25, 1998
288	HLHFP03	209126	Uni-ZAP XR	298	613	1	613	224	224	1195	1	19	20	116
		Jun. 19, 1997
289	HLHFR58	PTA-841	Uni-ZAP XR	299	1015	1	1015		206	1196	1	17	18	21
		Oct. 13, 1999
289	HLHFR58	PTA-841	Uni-ZAP XR	741	733	1	733		205	1638	1	16	17	21
		Oct. 13, 1999
289	HLHFR58	PTA-841	Uni-ZAP XR	742	741	1	741		288	1639	1	1	2	67
		Oct. 13, 1999
289	HLHFR58	PTA-841	Uni-ZAP XR	743	951	12	675		254	1640	1	1	2	91
		Oct. 13, 1999
290	HLIBD68	203071	pCMVSport 1	300	1022	1	1022	186	186	1197	1	35	36	50
		Jul. 27, 1998
291	HLICQ90	203517	pCMVSport 1	301	1766	1	1766	249	249	1198	1	29	30	206
		Dec. 10, 1998
292	HLJBJ61	PTA-848	pCMVSport 1	302	1191	1	1191	158	158	1199	1	29	30	38
		Oct. 13, 1999
292	HLJBJ61	PTA-848	pCMVSport 1	744	628	1	628	227	227	1641	1	29	30	38
		Oct. 13, 1999
293	HLMBO76	209603	Lambda ZAP II	303	815	1	795	43	43	1200	1	43	44	107
		Jan. 29, 1998
294	HLMCA59	209236	Uni-ZAP XR	304	787	1	787	101	101	1201	1	31	32	63
		Sep. 04, 1997
295	HLQBE09	209243	Lambda ZAP II	305	633	1	633	17	17	1202	1	19	20	181
		Sep. 12, 1997
296	HLQDH79	209551	Lambda ZAP II	306	913	1	913	205	205	1203	1	19	20	58
		Dec. 12, 1997
297	HLQDR48	209603	Lambda ZAP II	307	989	1	989	10	10	1204	1	21	22	190
		Jan. 29, 1998
297	HLQDR48	209603	Lambda ZAP II	745	990	1	990	3	3	1642	1	21	22	190
		Jan. 29, 1998
298	HLQEM64	PTA-623	Lambda ZAP II	308	774	1	774	247	247	1205	1	29	30	144
		Sep. 02, 1999
298	HLQEM64	PTA-623	Lambda ZAP II	746	1038	1	702	42	42	1643	1	29	30	132
		Sep. 02, 1999
299	HLTAU74	PTA-163	Uni-ZAP XR	309	1524	1	1524	76	76	1206	1	21	22	62
		Jun. 01, 1999
300	HLTCO33	203071	Uni-ZAP XR	310	1184	1	1184	80	80	1207	1	18	19	64
		Jul. 27, 1998
301	HLTDV50	209243	Uni-ZAP XR	311	770	1	770	74	74	1208	1	17	18	28
		Sep. 12, 1997
302	HLTEJ06	209346	Uni-ZAP XR	312	617	69	617	197	197	1209	1	22	23	55
		Oct. 09, 1997
303	HLTFA64	209628	Uni-ZAP XR	313	1130	1	1130	268	268	1210	1	42	43	43
		Feb. 12, 1998
304	HLTHG37	209965	Uni-ZAP XR	314	3740	1908	3740	50	50	1211	1	1	2	319
		Jun. 11, 1998
304	HLTHG37	209965	Uni-ZAP XR	747	1932	98	1932	313	313	1644	1	35	36	42
		Jun. 11, 1998
305	HLWAA17	209626	pCMVSport 3.0	315	997	246	997	436	436	1212	1	15	16	187
		Feb. 12, 1998
306	HLWAD77	209651	pCMVSport 3.0	316	1167	304	1167	326	326	1213	1	24	25	140
		Mar. 04, 1998
307	HLWAE11	203071	pCMVSport 3.0	317	1618	1	1618	28	28	1214	1	46	47	278
		Jul. 27, 1998
308	HLWAO22	209511	pCMVSport 3.0	318	1338	1	1311	212	212	1215	1	21	22	354
		Dec. 03, 1997
309	HLWAY54	209651	pCMVSport 3.0	319	1892	1	1892	38	38	1216	1	25	26	338
		Mar. 04, 1998
310	HLWBI63	209407	pCMVSport 3.0	320	1038	1	1038	149	149	1217	1	30	31	63
		Oct. 23, 1997
311	HLWBY76	203517	pCMVSport 3.0	321	2081	1	2081	432	432	1218	1	27	28	232
		Dec. 10, 1998
312	HLWCF05	209126	pCMVSport 3.0	322	646	1	646	155	155	1219	1	36	37	58
		Jun. 19, 1997
313	HLYAC95	203071	pSport1	323	312	1	312	92	92	1220	1	16	17	46
		Jul. 27, 1998
314	HLYAF80	209126	pSport1	324	826	1	826	222	222	1221	1	24	25	47
		Jun. 19, 1997
315	HLYAN59	209346	pSport1	325	770	1	770	383	383	1222	1	40	41	77
		Oct. 09, 1997
315	HLYAN59	209346	pSport1	748	729	1	729	254	254	1645	1	39	40	54
		Oct. 09, 1997
316	HLYAZ61	209022	pSport1	326	1237	1	1237	190	190	1223	1	18	19	222
		May 08, 1997
316	HLYAZ61	209022	pSport1	749	997	74	997	205	205	1646	1	18	19	215
		May 08, 1997
317	HLYBD32	209407	pSport1	327	1045	35	1045	98	98	1224	1	23	24	70
		Oct. 23, 1997
318	HMADS41	209563	Uni-ZAP XR	328	1267	1	1267	267	267	1225	1	21	22	88
		Dec. 18, 1997
319	HMADU73	209139	Uni-ZAP XR	329	3194	1	3194	491	491	1226	1	16	17	713
		Jul. 03, 1997
319	HMADU73	209139	Uni-ZAP XR	750	437	1	437	115	115	1647	1	15	16	77
		Jul. 03, 1997
320	HMAMI15	PTA-2075	Uni-ZAP XR	330	1258	1	1258	4	4	1227	1	26	27	340
		Jun. 09, 2000
320	HMAMI15	PTA-2075	Uni-ZAP XR	751	1084	1	1084	3	3	1648	1	26	27	306
		Jun. 09, 2000
321	HMDAE65	209243	Uni-ZAP XR	331	698	1	698	179	179	1228	1	17	18	77
		Sep. 12, 1997
322	HMDAN54	97974	Uni-ZAP XR	332	1856	725	1853	928	928	1229	1	33	34	50
		Apr. 04, 1997
		209080
		May 29, 1997
323	HMDAQ29	209563	Uni-ZAP XR	333	974	1	974	180	180	1230	1	43	44	82
		Dec. 18, 1997
324	HMEAI48	203069	Lambda ZAP II	334	413	1	413	36	36	1231	1	29	30	88
		Jul. 27, 1998
324	HMEAI48	203069	Lambda ZAP II	752	1168	1	1168	95	95	1649	1	29	30	40
		Jul. 27, 1998
325	HMECK83	209853	Lambda ZAP II	335	1010	1	1010	50	50	1232	1	28	29	54
		May 07, 1998
326	HMEED18	209368	Lambda ZAP II	336	1369	28	1369	34	34	1233	1	34	35	221
		Oct. 16, 1997
327	HMEET96	209407	Lambda ZAP II	337	1337	73	1200	121	121	1234	1	30	31	266
		Oct. 23, 1997
328	HMIAL37	209563	Uni-ZAP XR	338	1420	1	1420	49	49	1235	1	13	14	97
		Dec. 18, 1997
329	HMIAP86	209878	Uni-ZAP XR	339	1674	13	1674	182	182	1236	1	19	20	334
		May 18, 1998
330	HMKCG09	209346	pSport1	340	921	60	921	221	221	1237	1	28	29	49
		Oct. 09, 1997
331	HMMAH60	209368	pSport1	341	822	1	822	142	142	1238	1	15	16	50
		Oct. 16, 1997
332	HMQDF12	209407	Uni-ZAP XR	342	706	1	627	63	63	1239	1	27	28	142
		Oct. 23, 1997
333	HMQDT36	209022	Uni-ZAP XR	343	1871	1	1871	157	157	1240	1	32	33	406
		May 08, 1997
333	HMQDT36	209022	Uni-ZAP XR	753	1914	37	1897	192	192	1650	1	32	33	406
		May 08, 1997
334	HMSBX80	209563	Uni-ZAP XR	344	1726	1	1726	169	169	1241	1	19	20	57
		Dec. 18, 1997
335	HMSFS21	209324	Uni-ZAP XR	345	1283	1	1283	28	28	1242	1	17	18	37
		Oct. 02, 1997
336	HMSGB14	209423	Uni-ZAP XR	346	1552	1	1552	138	138	1243	1	18	19	77
		Oct. 30, 1997
337	HMSGU01	PTA-1544	Uni-ZAP XR	347	1617	1	1617	137	137	1244	1	23	24	120
		Mar. 21, 2000
337	HMSGU01	PTA-1544	Uni-ZAP XR	754	1257	1	1257	137	137	1651	1	23	24	235
		Mar. 21, 2000
337	HMSGU01	PTA-1544	Uni-ZAP XR	755	1654	1	1654	135	135	1652	1	23	24	120
		Mar. 21, 2000
338	HMSHM14	209126	Uni-ZAP XR	348	756	1	756	103	103	1245	1	29	30	45
		Jun. 19, 1997
339	HMSHS36	PTA-2070	Uni-ZAP XR	349	1402	1	1402	134	134	1246	1	23	24	103
		Jun. 09, 2000
339	HMSHS36	PTA-2070	Uni-ZAP XR	756	616	30	616	162	162	1653	1	23	24	103
		Jun. 09, 2000
340	HMSJM65	209641	Uni-ZAP XR	350	2270	1	2231	111	111	1247	1	27	28	77
		Feb. 25, 1998
341	HMSJU68	209076	Uni-ZAP XR	351	1123	4	1123	272	272	1248	1	31	32	49
		May 22, 1997
342	HMSKC04	203105	Uni-ZAP XR	352	1417	1	1417	133	133	1249	1	22	23	73
		Aug. 13, 1998
343	HMTAD67	209551	pCMVSport 3.0	353	1173	1	1173	306	306	1250	1	19	20	84
		Dec. 12, 1997
344	HMUAP70	209878	pCMVSport 3.0	354	1965	531	1914	183	183	1251	1	16	17	221
		May 18, 1998
344	HMUAP70	209878	pCMVSport 3.0	757	1842	407	1783	413	413	1654	1	25	26	103
		May 18, 1998
344	HMUAP70	209878	pCMVSport 3.0	758	1963	530	1914	251	251	1655	1	28	29	198
		May 18, 1998
344	HMUAP70	209878	pCMVSport 3.0	759	1487	1	1487	62	62	1656	1	16	17	106
		May 18, 1998
344	HMUAP70	209878	pCMVSport 3.0	760	1653	1	1653	60	60	1657	1	15	16	68
		May 18, 1998
344	HMUAP70	209878	pCMVSport 3.0	761	1830	407	1830	60	60	1658	1			23
		May 18, 1998
345	HMVBN46	209603	pSport1	355	1382	1	1382	10	10	1252	1	19	20	48
		Jan. 29, 1998
346	HMWEB02	209628	Uni-ZAP XR	356	1755	1	1755	106	106	1253	1	23	24	91
		Feb. 12, 1998
347	HMWF002	209324	Uni-ZAP XR	357	547	1	547	7	7	1254	1	37	38	68
		Oct. 02, 1997
347	HMWF002	209324	Uni-ZAP XR	762	708	1	708	20	20	1659	1	38	39	60
		Oct. 02, 1997
348	HMWFY10	209147	Uni-ZAP XR	358	556	1	556	367	367	1255	1	15	16	30
		Jul. 17, 1997
348	HMWFY10	209147	Uni-ZAP XR	763	556	1	556		129	1660	1	9	10	18
		Jul. 17, 1997
349	HMWGY65	203105	Uni-ZAP XR	359	1974	1	1974	42	42	1256	1	21	22	490
		Aug. 13, 1998
349	HMWGY65	203105	Uni-ZAP XR	764	2027	1	1976	42	42	1661	1	21	22	188
		Aug. 13, 1998
350	HNEAC05	209236	Uni-ZAP XR	360	890	1	890	101	101	1257	1	24	25	105
		Sep. 04, 1997
351	HNEEB45	PTA-845	Uni-ZAP XR	361	1043	1	1043	139	139	1258	1	25	26	57
		Oct. 13, 1999
351	HNEEB45	PTA-845	Uni-ZAP XR	765	699	160	699	226	226	1662	1	25	26	57
		Oct. 13, 1999
352	HNFFC43	203027	Uni-ZAP XR	362	2103	209	2058	488	488	1259	1	12	13	68
		Jun. 26, 1998
353	HNFGF20	203071	Uni-ZAP XR	363	1370	38	1370	206	206	1260	1	45	46	143
		Jul. 27, 1998
354	HNFJF07	209463	Uni-ZAP XR	364	616	1	616	86	86	1261	1	21	22	66
		Nov. 14, 1997
355	HNFJH45	97976	Uni-ZAP XR	365	575	1	575	275	275	1262	1	30	31	67
		Apr. 04, 1997
356	HNGAK47	209368	Uni-ZAP XR	366	1144	1	1144	89	89	1263	1	23	24	40
		Oct. 16, 1997
357	HNGAP93	209243	Uni-ZAP XR	367	703	1	703	50	50	1264	1	19	20	33
		Sep. 12, 1997
358	HNGBC07	PTA-844	Uni-ZAP XR	368	1649	1	1647	81	81	1265	1	18	19	249
		Oct. 13, 1999
358	HNGBC07	PTA-844	Uni-ZAP XR	766	1649	1	1647	122	122	1663	1	24	25	44
		Oct. 13, 1999
358	HNGBC07	PTA-844	Uni-ZAP XR	767	1570	1	1570	55	55	1664	1	24	25	44
		Oct. 13, 1999
359	HNGBT31	97976	Uni-ZAP XR	369	639	1	639	224	224	1266	1	28	29	104
		Apr. 04, 1997
360	HNGDJ72	209299	Uni-ZAP XR	370	524	1	524	185	185	1267	1	19	20	113
		Sep. 25, 1997
361	HNGDU40	209563	Uni-ZAP XR	371	1035	1	1035	333	333	1268	1	17	18	51
		Dec. 18, 1997
362	HNGEG08	209179	Uni-ZAP XR	372	660	1	660	94	94	1269	1	35	36	66
		Jul. 24, 1997
363	HNGEO29	209299	Uni-ZAP XR	373	491	1	491	98	98	1270	1	32	33	44
		Sep. 25, 1997
364	HNGEP09	209197	Uni-ZAP XR	374	1042	1	1042	72	72	1271	1	15	16	82
		Aug. 08, 1997
365	HNGHR74	209346	Uni-ZAP XR	375	1095	1	1095	53	53	1272	1	18	19	41
		Oct. 09, 1997
366	HNGIH43	97976	Uni-ZAP XR	376	427	1	427	178	178	1273	1	31	32	40
		Apr. 04, 1997
367	HNGIJ31	209236	Uni-ZAP XR	377	796	1	796	135	135	1274	1	16	17	36
		Sep. 04, 1997
368	HNGIQ46	209243	Uni-ZAP XR	378	527	1	527	221	221	1275	1	21	22	70
		Sep. 12, 1997
369	HNGJE50	209368	Uni-ZAP XR	379	1037	1	1037	77	77	1276	1	36	37	46
		Oct. 16, 1997
370	HNGJO57	209463	Uni-ZAP XR	380	828	1	828	87	87	1277	1	18	19	52
		Nov. 14, 1997
371	HNGJP69	209603	Uni-ZAP XR	381	985	1	985	321	321	1278	1	14	15	74
		Jan. 29, 1998
372	HNGJT54	209215	Uni-ZAP XR	382	1110	1	1110	172	172	1279	1	19	20	34
		Aug. 21, 1997
373	HNGOI12	PTA-847	Uni-ZAP XR	383	2128	1	2128	27	27	1280	1	34	35	57
		Oct. 13, 1999
373	HNGOI12	PTA-847	Uni-ZAP XR	768	774	1	774	27	27	1665	1	34	35	57
		Oct. 13, 1999
373	HNGOI12	PTA-847	Uni-ZAP XR	769	1396	1	1396		596	1666	1	25	26	93
		Oct. 13, 1999
374	HNGOM56	203648	Uni-ZAP XR	384	956	1	956	391	391	1281	1	22	23	55
		Feb. 09, 1999
375	HNHAH01	209180	Uni-ZAP XR	385	905	1	905	328	328	1282	1	41	42	54
		Jul. 24, 1997
376	HNHCX60	209243	Uni-ZAP XR	386	762	1	762	158	158	1283	1	20	21	21
		Sep. 12, 1997
377	HNHCY64	209243	Uni-ZAP XR	387	725	1	725	258	258	1284	1	32	33	44
		Sep. 12, 1997
378	HNHCY94	209243	Uni-ZAP XR	388	606	1	606	78	78	1285	1	25	26	48
		Sep. 12, 1997
379	HNHDW38	209299	Uni-ZAP XR	389	793	1	793	231	231	1286	1	22	23	46
		Sep. 25, 1997
380	HNHDW42	97976	Uni-ZAP XR	390	426	1	426	168	168	1287	1	26	27	71
		Apr. 04, 1997
381	HNHED17	209346	Uni-ZAP XR	391	843	1	843	274	274	1288	1	19	20	51
		Oct. 09, 1997
381	HNHED17	209346	Uni-ZAP XR	770	692	1	692	282	282	1667	1	19	20	48
		Oct. 09, 1997
382	HNHEI42	PTA-844	Uni-ZAP XR	392	2642	1	2642	52	52	1289	1	22	23	36
		Oct. 13, 1999
382	HNHEI42	PTA-844	Uni-ZAP XR	771	1654	1	1654	28	28	1668	1	22	23	36
		Oct. 13, 1999
382	HNHEI42	PTA-844	Uni-ZAP XR	772	447	1	447		166	1669	1	6	7	28
		Oct. 13, 1999
382	HNHEI42	PTA-844	Uni-ZAP XR	773	641	1	641		331	1670	1	3	4	34
		Oct. 13, 1999
383	HNHFO29	209138	Uni-ZAP XR	393	699	1	699	160	160	1290	1	21	22	180
		Jul. 03, 1997
384	HNHFU32	209407	Uni-ZAP XR	394	607	1	607	175	175	1291	1	30	31	52
		Oct. 23, 1997
385	HNHOD46	PTA-1543	Uni-ZAP XR	395	1355	1	1355	12	12	1292	1	20	21	80
		Mar. 21, 2000
386	HNHOG73	203570	Uni-ZAP XR	396	802	1	802	342	342	1293	1	19	20	51
		Jan. 11, 1999
387	HNTBL27	209324	pCMVSport 3.0	397	791	71	791	100	100	1294	1	23	24	115
		Oct. 02, 1997
388	HNTCE26	PTA-1544	pCMVSport 3.0	398	2163	830	2163	111	111	1295	1	30	31	402
		Mar. 21, 2000
388	HNTCE26	PTA-1544	pCMVSport 3.0	774	1763	1	1763	57	57	1671	1	28	29	121
		Mar. 21, 2000
389	HNTNI01	209782	pSport1	399	2087	1	2087	307	307	1296	1	33	34	76
		Apr. 20, 1998
389	HNTNI01	209782	pSport1	775	1274	1	1114	306	306	1672	1	33	34	49
		Apr. 20, 1998
390	HOAAC90	209236	Uni-ZAP XR	400	642	1	642	33	33	1297	1	15	16	104
		Sep. 04, 1997
390	HOAAC90	209236	Uni-ZAP XR	776	652	1	652	38	38	1673	1	15	16	104
		Sep. 04, 1997
391	HOACB38	209243	Uni-ZAP XR	401	606	1	606	63	63	1298	1	21	22	40
		Sep. 12, 1997
392	HOCNF19	203570	pSport1	402	1118	1	1118	166	166	1299	1	20	21	87
		Jan. 11, 1999
393	HODDN65	209244	Uni-ZAP XR	403	755	1	755	251	251	1300	1	14	15	20
		Sep. 12, 1997
394	HODDN92	209012	Uni-ZAP XR	404	1939	294	1939		434	1301	1	26	27	35
		Apr. 28, 1997
		209089
		Jun. 05, 1997
395	HODD008	203364	Uni-ZAP XR	405	1776	138	1284	725	725	1302	1	33	34	106
		Oct. 19, 1998
396	HODDW40	209463	Uni-ZAP XR	406	682	1	682	139	139	1303	1	19	20	40
		Nov. 14, 1997
397	HODFN71	203570	Uni-ZAP XR	407	1126	1	1126		1	1304	1	1	2	159
		Jan. 11, 1999
397	HODFN71	203570	Uni-ZAP XR	777	1124	1	1124	27	27	1674	1	18	19	148
		Jan. 11, 1999
398	HODGE68	203570	Uni-ZAP XR	408	851	1	851	87	87	1305	1	26	27	59
		Jan. 11, 1999
399	HOEBK34	209224	Uni-ZAP XR	409	747	75	747	149	149	1306	1	20	21	165
		Aug. 28, 1997
399	HOEBK34	209224	Uni-ZAP XR	778	660	1	660	68	68	1675	1	26	27	88
		Aug. 28, 1997
400	HOEBZ89	203517	Uni-ZAP XR	410	2520	1	2520	19	19	1307	1	21	22	333
		Dec. 10, 1998
401	HOEDB32	209628	Uni-ZAP XR	411	1462	73	1462	104	104	1308	1	21	22	226
		Feb. 12, 1998
402	HOEDE28	PTA-844	Uni-ZAP XR	412	1635	1	1635	248	248	1309	1	21	22	117
		Oct. 13, 1999
402	HOEDE28	PTA-844	Uni-ZAP XR	779	1424	806	1424		387	1676	1	11	12	20
		Oct. 13, 1999
403	HOEDH84	209965	Uni-ZAP XR	413	2079	1	2079	256	256	1310	1	20	21	404
		Jun. 11, 1998
404	HOFMQ33	PTA-848	pCMVSport 2.0	414	2410	1	2410	49	49	1311	1	24	25	484
		Oct. 13, 1999
404	HOFMQ33	PTA-848	pCMVSport 2.0	780	2409	1	2409	48	48	1677	1	24	25	484
		Oct. 13, 1999
404	HOFMQ33	PTA-848	pCMVSport 2.0	781	876	1	876	78	78	1678	1	24	25	266
		Oct. 13, 1999
404	HOFMQ33	PTA-848	pCMVSport 2.0	782	1586	1	1586		724	1679	1			5
		Oct. 13, 1999
404	HOFMQ33	PTA-848	pCMVSport 2.0	783	1011	873	1011		123	1680	1	1	2	84
		Oct. 13, 1999
405	HOFMT75	PTA-848	pCMVSport 2.0	415	2131	6	2131	83	83	1312	1	20	21	410
		Oct. 13, 1999
405	HOFMT75	PTA-848	pCMVSport 2.0	784	427	1	427	83	83	1681	1	20	21	115
		Oct. 13, 1999
405	HOFMT75	PTA-848	pCMVSport 2.0	785	1500	1	1500		1225	1682	1	9	10	92
		Oct. 13, 1999
405	HOFMT75	PTA-848	pCMVSport 2.0	786	1234	337	1234	129	129	1683	1	20	21	368
		Oct. 13, 1999
406	HOFNC14	PTA-623	pCMVSport 2.0	416	2794	1	2794	79	79	1313	1	13	14	73
		Sep. 02, 1999
406	HOFNC14	PTA-623	pCMVSport 2.0	787	3095	1	3095	155	155	1684	1	13	14	72
		Sep. 02, 1999
407	HOFND85	PTA-1544	pCMVSport 2.0	417	2048	1	2048	167	167	1314	1	22	23	627
		Mar. 21, 2000
408	HOFNY91	PTA-1544	pCMVSport 2.0	418	2406	1	2406	64	64	1315	1	14	15	82
		Mar. 21, 2000
409	HOFOC33	PTA-848	pCMVSport 2.0	419	1669	1	1669	76	76	1316	1	21	22	363
		Oct. 13, 1999
409	HOFOC33	PTA-848	pCMVSport 2.0	788	518	1	518	81	81	1685	1	21	22	112
		Oct. 13, 1999
409	HOFOC33	PTA-848	pCMVSport 2.0	789	518	1	518	81	81	1686	1	17	18	112
		Oct. 13, 1999
409	HOFOC33	PTA-848	pCMVSport 2.0	790	1670	1	1670	76	76	1687	1	21	22	139
		Oct. 13, 1999
409	HOFOC33	PTA-848	pCMVSport 2.0	791	606	1	606		23	1688	1			7
		Oct. 13, 1999
409	HOFOC33	PTA-848	pCMVSport 2.0	792	841	1	841		158	1689	1	6	7	14
		Oct. 13, 1999
409	HOFOC33	PTA-848	pCMVSport 2.0	793	868	1	847		3	1690	1	1	2	288
		Oct. 13, 1999
410	HOGCK20	209853	pCMVSport 2.0	420	2087	1	2087	57	57	1317	1	23	24	522
		May 07, 1998
410	HOGCK20	209853	pCMVSport 2.0	794	2075	1	2054		53	1691	1	22	23	554
		May 07, 1998
411	HOGCK63	PTA-848	pCMVSport 2.0	421	1409	310	1409	514	514	1318	1	29	30	246
		Oct. 13, 1999
411	HOGCK63	PTA-848	pCMVSport 2.0	795	1697	144	1697		1455	1692	1			5
		Oct. 13, 1999
412	HOGCS52	PTA-848	pCMVSport 2.0	422	2571	1	2571	25	25	1319	1	22	23	453
		Oct. 13, 1999
412	HOGCS52	PTA-848	pCMVSport 2.0	796	2645	1	2586	30	30	1693	1	22	23	453
		Oct. 13, 1999
412	HOGCS52	PTA-848	pCMVSport 2.0	797	1098	457	638		2	1694	1	1	2	96
		Oct. 13, 1999
413	HOHBB49	203517	pCMVSport 2.0	423	3080	1	3080	148	148	1320	1	19	20	48
		Dec. 10, 1998
414	HOHBC68	209568	pCMVSport 2.0	424	1837	1	1837	348	348	1321	1	30	31	128
		Jan. 06, 1998
415	HOHBY12	209603	pCMVSport 2.0	425	1188	1	1188	232	232	1322	1	25	26	199
		Jan. 29, 1998
416	HOHCC74	209346	pCMVSport 2.0	426	558	1	558	327	327	1323	1	20	21	48
		Oct. 09, 1997
417	HOHCH55	203331	pCMVSport 2.0	427	2499	1	2499	221	221	1324	1	23	24	494
		Oct. 08, 1998
417	HOHCH55	203331	pCMVSport 2.0	798	2522	1	2522	230	230	1695	1	23	24	469
		Oct. 08, 1998
418	HOSDJ25	209423	Uni-ZAP XR	428	2214	985	2214	1076	1076	1325	1	18	19	40
		Oct. 30, 1997
418	HOSDJ25	209423	Uni-ZAP XR	799	1258	1	1258	146	146	1696	1	18	19	40
		Oct. 30, 1997
419	HOSEG51	209324	Uni-ZAP XR	429	590	48	590	232	232	1326	1	31	32	102
		Oct. 02, 1997
420	HOSEQ49	209551	Uni-ZAP XR	430	1943	280	1935	544	544	1327	1	32	33	51
		Dec. 12, 1997
421	HOSFD58	97957	Uni-ZAP XR	431	2527	290	1747	56	56	1328	1	30	31	624
		Mar. 13, 1997
		209073
		May 22, 1997
421	HOSFD58	97957	Uni-ZAP XR	800	2527	288	1747	477	477	1697	1	32	33	61
		Mar. 13, 1997
		209073
		May 22, 1997
422	HOUCQ17	209086	Uni-ZAP XR	432	4712	1	4693	508	508	1329	1	51	52	967
		May 29, 1997
423	HOUDK26	209423	Uni-ZAP XR	433	1051	1	1051	214	214	1330	1	30	31	174
		Oct. 30, 1997
424	HOUGG12	203071	Uni-ZAP XR	434	1895	1	1895	289	289	1331	1	20	21	314
		Jul. 27, 1998
424	HOUGG12	203071	Uni-ZAP XR	801	1050	1	1050	399	399	1698	1	21	22	114
		Jul. 27, 1998
424	HOUGG12	203071	Uni-ZAP XR	802	1642	35	1642	116	116	1699	1	22	23	61
		Jul. 27, 1998
425	HOVCA92	209299	pSport1	435	707	1	488	181	181	1332	1	20	21	62
		Sep. 25, 1997
426	HPASA81	203181	Uni-ZAP XR	436	1945	1	1945	19	19	1333	1	17	18	600
		Sep. 09, 1998
426	HPASA81	203181	Uni-ZAP XR	803	1971	2	1971	14	14	1700	1	17	18	315
		Sep. 09, 1998
426	HPASA81	203181	Uni-ZAP XR	804	2081	1	2081	124	124	1701	1	17	18	72
		Sep. 09, 1998
427	HPBCU51	97977	pBLUESCRIPT ™	437	599	1	599	86	86	1334	1	27	28	119
		Apr. 04, 1997	SK-
		209082
		May 29, 1997
428	HPDDC77	209012	pBLUESCRIPT ™	438	978	1	978	51	51	1335	1	29	30	131
		Apr. 28, 1997	SK-
		209089
		Jun. 05, 1997
428	HPDDC77	209012	pBLUESCRIPT ™	805	2361	455	1442	510	510	1702	1	29	30	131
		Apr. 28, 1997	SK-
		209089
		Jun. 05, 1997
429	HPDWP28	PTA-2076	pSport1	439	528	1	528	143	143	1336	1	29	30	49
		Jun. 09, 2000
429	HPDWP28	PTA-2076	pSport1	806	510	1	500	133	133	1703	1	29	30	49
		Jun. 09, 2000
430	HPFCL43	209299	Uni-ZAP XR	440	665	1	665	21	21	1337	1	17	18	79
		Sep. 25, 1997
431	HPFDG48	209324	Uni-ZAP XR	441	723	165	700	283	283	1338	1	18	19	47
		Oct. 02, 1997
432	HPIAQ68	203517	Uni-ZAP XR	442	2466	1	2466	20	20	1339	1	22	23	62
		Dec. 10, 1998
433	HPIBO15	209563	Uni-ZAP XR	443	1739	1	1739	128	128	1340	1	18	19	211
		Dec. 18, 1997
433	HPIBO15	209563	Uni-ZAP XR	807	1739	1	1739	127	127	1704	1	18	19	173
		Dec. 18, 1997
434	HPJBK12	PTA-855	Uni-ZAP XR	444	2648	1	2648	126	126	1341	1	18	19	48
		Oct. 18, 1999
434	HPJBK12	PTA-855	Uni-ZAP XR	808	538	1	538	119	119	1705	1	18	19	48
		Oct. 18, 1999
434	HPJBK12	PTA-855	Uni-ZAP XR	809	1346	1	1346		969	1706	1			10
		Oct. 18, 1999
434	HPJBK12	PTA-855	Uni-ZAP XR	810	912	1	912	509	509	1707	1			4
		Oct. 18, 1999
435	HPJCL22	PTA-2071	Uni-ZAP XR	445	3107	1	3107	86	86	1342	1	35	36	80
		Jun. 09, 2000
435	HPJCL22	PTA-2071	Uni-ZAP XR	811	995	58	995	136	136	1708	1	35	36	80
		Jun. 09, 2000
435	HPJCL22	PTA-2071	Uni-ZAP XR	812	751	183	751		232	1709	1	1	2	145
		Jun. 09, 2000
436	HPJCW04	209551	Uni-ZAP XR	446	1466	1	1466	44	44	1343	1	19	20	57
		Dec. 12, 1997
437	HPJEX20	PTA-872	Uni-ZAP XR	447	566	1	566	23	23	1344	1	26	27	174
		Oct. 26, 1999
437	HPJEX20	PTA-872	Uni-ZAP XR	813	1823	1	1823	31	31	1710	1	23	24	115
		Oct. 26, 1999
437	HPJEX20	PTA-872	Uni-ZAP XR	814	1964	1	1964	170	170	1711	1	23	24	174
		Oct. 26, 1999
437	HPJEX20	PTA-872	Uni-ZAP XR	815	769	1	769	84	84	1712	1	23	24	228
		Oct. 26, 1999
437	HPJEX20	PTA-872	Uni-ZAP XR	816	818	1	818		565	1713	1	1	2	84
		Oct. 26, 1999
438	HPMAI22	209683	Uni-ZAP XR	448	1274	334	1274	483	483	1345	1	16	17	59
		Mar. 20, 1998
439	HPMFP40	209628	Uni-ZAP XR	449	1217	1	1217	37	37	1346	1	24	25	44
		Feb. 12, 1998
440	HPMGJ45	203105	Uni-ZAP XR	450	1656	1	1656	119	119	1347	1	25	26	48
		Aug. 13, 1998
441	HPQAC69	97979	Lambda ZAP II	451	990	1	988	82	82	1348	1	19	20	37
		Mar. 27, 1997
442	HPRBC80	209852	Uni-ZAP XR	452	2543	1245	2543	94	94	1349	1	30	31	387
		May 07, 1998
442	HPRBC80	209852	Uni-ZAP XR	817	2052	275	2032	404	404	1714	1	26	27	69
		May 07, 1998
443	HPRSB76	209244	pBLUESCRIPT ™	453	741	1	741	127	127	1350	1	22	23	59
		Sep. 12, 1997
444	HPVAB94	209244	Uni-ZAP XR	454	819	1	819	80	80	1351	1	25	26	44
		Sep. 12, 1997
445	HPWAY46	PTA-843	Uni-ZAP XR	455	1414	1	1414	468	468	1352	1	30	31	52
		Oct. 13, 1999
445	HPWAY46	PTA-843	Uni-ZAP XR	818	891	1	891	474	474	1715	1	30	31	52
		Oct. 13, 1999
445	HPWAY46	PTA-843	Uni-ZAP XR	819	501	120	501		178	1716	1	1	2	86
		Oct. 13, 1999
446	HPWAZ95	209007	Uni-ZAP XR	456	323	1	323	88	88	1353	1	27	28	78
		Apr. 28, 1997
		209083
		May 29, 1997
447	HPWDJ42	209852	Uni-ZAP XR	457	1340	1	1340	149	149	1354	1	18	19	54
		May 07, 1998
447	HPWDJ42	209852	Uni-ZAP XR	820	1340	1	1340	149	149	1717	1	21	22	54
		May 07, 1998
447	HPWDJ42	209852	Uni-ZAP XR	821	813	1	813	161	161	1718	1	18	19	47
		May 07, 1998
448	HPZAB47	209511	pBLUESCRIPT ™	458	1676	1	1676	34	34	1355	1	18	19	47
		Dec. 03, 1997
449	HRAAB15	209651	pCMVSport 3.0	459	1747	1	1747	35	35	1356	1	14	15	159
		Mar. 04, 1998
450	HRABA80	209889	pCMVSport 3.0	460	1251	1	1251	144	144	1357	1	27	28	102
		May 22, 1998
450	HRABA80	209889	pCMVSport 3.0	822	1237	1	1237	130	130	1719	1	27	28	102
		May 22, 1998
451	HRACD15	209852	pCMVSport 3.0	461	1539	24	1539	252	252	1358	1	40	41	53
		May 07, 1998
451	HRACD15	209852	pCMVSport 3.0	823	1681	24	1453	252	252	1720	1	40	41	53
		May 07, 1998
452	HRACD80	209889	pCMVSport 3.0	462	1941	1	1941	196	196	1359	1	16	17	575
		May 22, 1998
452	HRACD80	209889	pCMVSport 3.0	824	1934	1	1934	191	191	1721	1	16	17	575
		May 22, 1998
452	HRACD80	209889	pCMVSport 3.0	825	1958	1	1958	191	191	1722	1	16	17	146
		May 22, 1998
453	HRDDV47	209628	Uni-ZAP XR	463	1510	1	1510	146	146	1360	1	30	31	276
		Feb. 12, 1998
454	HRDFD27	209423	Uni-ZAP XR	464	805	1	805	82	82	1361	1	35	36	83
		Oct. 30, 1997
455	HRTAE58	209241	pBLUESCRIPT ™	465	600	1	600	244	244	1362	1	18	19	58
		Sep. 12, 1997	SK-
456	HSATR82	209299	Uni-ZAP XR	466	777	1	777	74	74	1363	1	15	16	41
		Sep. 25, 1997
457	HSAUK57	209148	Uni-ZAP XR	467	1037	1	1037	322	322	1364	1	26	27	83
		Jul. 17, 1997
457	HSAUK57	209148	Uni-ZAP XR	826	1070	1	1070	327	327	1723	1	26	27	48
		Jul. 17, 1997
458	HSAUL82	209148	Uni-ZAP XR	468	727	1	727	140	140	1365	1	25	26	49
		Jul. 17, 1997
459	HSAVD46	209124	Uni-ZAP XR	469	773	2	767	155	155	1366	1	20	21	58
		Jun. 19, 1997
460	HSAVH65	209651	Uni-ZAP XR	470	600	1	600	104	104	1367	1	21	22	100
		Mar. 04, 1998
461	HSAVK10	209368	Uni-ZAP XR	471	1242	1	1242	131	131	1368	1	32	33	40
		Oct. 16, 1997
462	HSAWZ41	209463	Uni-ZAP XR	472	1388	1	1388	98	98	1369	1	24	25	57
		Nov. 14, 1997
463	HSAXA83	209324	Uni-ZAP XR	473	649	1	649	92	92	1370	1	22	23	74
		Oct. 02, 1997
464	HSAYM40	209139	Uni-ZAP XR	474	433	1	433	190	190	1371	1	19	20	63
		Jul. 03, 1997
465	HSDAJ46	209746	Uni-ZAP XR	475	1537	92	1537	299	299	1372	1	18	19	262
		Apr. 07, 1998
466	HSDEK49	209603	Uni-ZAP XR	476	1782	1	1782	60	60	1373	1	19	20	399
		Jan. 29, 1998
466	HSDEK49	209603	Uni-ZAP XR	827	1590	96	1590	126	126	1724	1	21	22	305
		Jan. 29, 1998
467	HSDER95	209683	Uni-ZAP XR	477	574	1	574	72	72	1374	1	25	26	71
		Mar. 20, 1998
468	HSDEZ20	209852	Uni-ZAP XR	478	795	1	795	58	58	1375	1	41	42	122
		May 07, 1998
468	HSDEZ20	209852	Uni-ZAP XR	828	1540	1	1540	66	66	1725	1	41	42	97
		May 07, 1998
469	HSDJA15	203081	Uni-ZAP XR	479	1443	1	1443	247	247	1376	1	20	21	152
		Jul. 30, 1998
470	HSDSB09	209145	pBLUESCRIPT ™	480	809	1	809	16	16	1377	1	17	18	135
		Jul. 17, 1997
470	HSDSB09	209145	pBLUESCRIPT ™	829	819	1	819	22	22	1726	1	17	18	121
		Jul. 17, 1997
471	HSDSE75	209324	pBLUESCRIPT ™	481	1151	1	1151	160	160	1378	1	18	19	181
		Oct. 02, 1997
472	HSFAM31	209346	Uni-ZAP XR	482	868	1	868	44	44	1379	1			9
		Oct. 09, 1997
473	HSHAX21	209853	Uni-ZAP XR	483	1986	1	1986	177	177	1380	1	13	14	72
		May 07, 1998
474	HSIAS17	209226	Uni-ZAP XR	484	1781	1	1781	431	431	1381	1	22	23	257
		Aug. 28, 1997
474	HSIAS17	209226	Uni-ZAP XR	830	1448	1	1224	108	108	1727	1	23	24	218
		Aug. 28, 1997
475	HSIDX71	PTA-843	Uni-ZAP XR	485	2118	1	2118	200	200	1382	1	41	42	59
		Oct. 13, 1999
475	HSIDX71	PTA-843	Uni-ZAP XR	831	1868	1	1868	200	200	1728	1	41	42	59
		Oct. 13, 1999
476	HSKDA27	PTA-322	Uni-ZAP XR	486	4412	1	4412	786	786	1383	1	24	25	950
		Jul. 09, 1999
476	HSKDA27	PTA-322	Uni-ZAP XR	832	1792	134	1792	127	127	1729	1	21	22	509
		Jul. 09, 1999
476	HSKDA27	PTA-322	Uni-ZAP XR	833	1673	1	1673	12	12	1730	1	21	22	554
		Jul. 09, 1999
477	HSKHZ81	209346	pBLUESCRIPT ™	487	969	1	969	64	64	1384	1	27	28	247
		Oct. 09, 1997
477	HSKHZ81	209346	pBLUESCRIPT ™	834	988	1	967	57	57	1731	1	27	28	247
		Oct. 09, 1997
478	HSLCQ82	209551	Uni-ZAP XR	488	1476	1	1476	226	226	1385	1	28	29	84
		Dec. 12, 1997
478	HSLCQ82	209551	Uni-ZAP XR	835	1501	1	1501	233	233	1732	1	22	23	57
		Dec. 12, 1997
479	HSLJG37	PTA-855	Uni-ZAP XR	489	2126	1	2126	114	114	1386	1	16	17	42
		Oct. 18, 1999
479	HSLJG37	PTA-855	Uni-ZAP XR	836	1083	1	1083	206	206	1733	1	16	17	42
		Oct. 18, 1999
479	HSLJG37	PTA-855	Uni-ZAP XR	837	1904	1	1904		1331	1734	1			6
		Oct. 18, 1999
480	HSNAB12	209300	Uni-ZAP XR	490	630	1	630	151	151	1387	1	27	28	71
		Sep. 25, 1997
481	HSODE04	PTA-855	Uni-ZAP XR	491	1370	1	1370	202	202	1388	1	20	21	41
		Oct. 18, 1999
481	HSODE04	PTA-855	Uni-ZAP XR	838	1937	1	1937	300	300	1735	1	20	21	41
		Oct. 18, 1999
482	HSPBF70	203105	pSport1	492	1397	288	1397	429	429	1389	1	19	20	97
		Aug. 13, 1998
483	HSQCM10	209641	Uni-ZAP XR	493	657	1	654	130	130	1390	1	19	20	62
		Feb. 25, 1998
484	HSSAJ29	209626	Uni-ZAP XR	494	1044	1	1044	103	103	1391	1	25	26	47
		Feb. 12, 1998
485	HSSDX51	209683	Uni-ZAP XR	495	1143	1	1143	133	133	1392	1	20	21	50
		Mar. 20, 1998
486	HSSFT08	209551	Uni-ZAP XR	496	791	1	791	125	125	1393	1	34	35	58
		Dec. 12, 1997
487	HSSGD52	PTA-1543	Uni-ZAP XR	497	2425	1	2425	344	344	1394	1	32	33	606
		Mar. 21, 2000
487	HSSGD52	PTA-1543	Uni-ZAP XR	839	2460	105	2460	338	338	1736	1	27	28	606
		Mar. 21, 2000
488	HSSJC35	209853	Uni-ZAP XR	498	1174	1	1174	62	62	1395	1	28	29	295
		May 07, 1998
488	HSSJC35	209853	Uni-ZAP XR	840	1163	1	1163	55	55	1737	1	30	31	295
		May 07, 1998
488	HSSJC35	209853	Uni-ZAP XR	841	1183	1	1183	66	66	1738	1	30	31	37
		May 07, 1998
489	HSTBJ86	203027	Uni-ZAP XR	499	1766	1	1766	120	120	1396	1	24	25	83
		Jun. 26, 1998
490	HSUBW09	209007	Uni-ZAP XR	500	1021	1	1021	153	153	1397	1	31	32	56
		Apr. 28, 1997
		209083
		May 29, 1997
491	HSVAM10	209244	Uni-ZAP XR	501	433	1	433	46	46	1398	1	27	28	51
		Sep. 12, 1997
492	HSVBU91	209603	Uni-ZAP XR	502	727	1	727	256	256	1399	1	18	19	90
		Jan. 29, 1998
493	HSXCG83	203570	Uni-ZAP XR	503	2112	233	1573	101	101	1400	1	45	46	267
		Jan. 11, 1999
493	HSXCG83	203570	Uni-ZAP XR	842	1938	58	1399	211	211	1739	1	22	23	172
		Jan. 11, 1999
494	HSXEC75	209641	Uni-ZAP XR	504	1112	1	1112	295	295	1401	1	33	34	45
		Feb. 25, 1998
495	HSXEQ06	PTA-847	Uni-ZAP XR	505	1598	1	1598	123	123	1402	1	24	25	60
		Oct. 13, 1999
495	HSXEQ06	PTA-847	Uni-ZAP XR	843	768	21	768	136	136	1740	1	24	25	60
		Oct. 13, 1999
495	HSXEQ06	PTA-847	Uni-ZAP XR	844	1392	1	1392		1271	1741	1	9	10	17
		Oct. 13, 1999
496	HSYAV50	PTA-1544	pCMVSport 3.0	506	2801	1	2801	155	155	1403	1	23	24	672
		Mar. 21, 2000
497	HSYAV66	209746	pCMVSport 3.0	507	1407	1	1407	186	186	1404	1	28	29	69
		Apr. 07, 1998
498	HSYAZ50	PTA-849	pCMVSport 3.0	508	1097	1	1097	131	131	1405	1	18	19	56
		Oct. 13, 1999
498	HSYAZ50	PTA-849	pCMVSport 3.0	845	768	226	768	345	345	1742	1	18	19	56
		Oct. 13, 1999
498	HSYAZ50	PTA-849	pCMVSport 3.0	846	2087	770	875		723	1743	1	1	2	106
		Oct. 13, 1999
498	HSYAZ50	PTA-849	pCMVSport 3.0	847	2096	1767	2050		2	1744	1	1	2	279
		Oct. 13, 1999
499	HSYAZ63	PTA-163	pCMVSport 3.0	509	3466	1655	3347	448	448	1406	1	30	31	434
		Jun. 01, 1999
499	HSYAZ63	PTA-163	pCMVSport 3.0	848	1707	1	1707	215	215	1745	1	21	22	40
		Jun. 01, 1999
500	HSYBG37	209463	pCMVSport 3.0	510	1238	1	1238	47	47	1407	1	24	25	305
		Nov. 14, 1997
500	HSYBG37	209463	pCMVSport 3.0	849	1239	1	1239	48	48	1746	1	24	25	305
		Nov. 14, 1997
501	HSZAF47	209124	Uni-ZAP XR	511	1304	1	1304	106	106	1408	1	16	17	289
		Jun. 19, 1997
501	HSZAF47	209124	Uni-ZAP XR	850	1333	2	1333	107	107	1747	1	18	19	127
		Jun. 19, 1997
502	HT3SF53	PTA-499	Uni-ZAP XR	512	1926	1	1926	184	184	1409	1	27	28	68
		Aug. 11, 1999
503	HT5GJ57	209889	Uni-ZAP XR	513	1773	1	1773	105	105	1410	1	25	26	243
		May 22, 1998
503	HT5GJ57	209889	Uni-ZAP XR	851	1797	92	1797	122	122	1748	1	25	26	190
		May 22, 1998
504	HTADX17	209124	Uni-ZAP XR	514	1147	0	1148	92	92	1411	1	23	24	142
		Jun. 19, 1997
504	HTADX17	209124	Uni-ZAP XR	852	1140	22	1140	84	84	1749	1	19	20	142
		Jun. 19, 1997
505	HTDAF28	97974	pSport1	515	912	1	912	38	38	1412	1	22	23	87
		Apr. 04, 1997
		209080
		May 29, 1997
506	HTEAF65	PTA-322	Uni-ZAP XR	516	563	1	563	135	135	1413	1	19	20	75
		Jul. 09, 1999
507	HTEBI28	209177	Uni-ZAP XR	517	413	1	413	43	43	1414	1	20	21	67
		Jul. 24, 1997
508	HTEDF80	209511	Uni-ZAP XR	518	1306	1	1306	696	696	1415	1	21	22	126
		Dec. 03, 1997
509	HTEDY42	209241	Uni-ZAP XR	519	754	1	754	19	19	1416	1	23	24	233
		Sep. 12, 1997
509	HTEDY42	209241	Uni-ZAP XR	853	810	1	810	19	19	1750	1	23	24	77
		Sep. 12, 1997
510	HTEFU65	209324	Uni-ZAP XR	520	1028	1	1028	231	231	1417	1	24	25	46
		Oct. 02, 1997
511	HTEGI42	PTA-842	Uni-ZAP XR	521	978	1	978	26	26	1418	1	19	20	257
		Oct. 13, 1999
511	HTEGI42	PTA-842	Uni-ZAP XR	854	1092	1	1092	145	145	1751	1	19	20	257
		Oct. 13, 1999
511	HTEGI42	PTA-842	Uni-ZAP XR	855	284	1	133		1	1752	1	1	2	94
		Oct. 13, 1999
511	HTEGI42	PTA-842	Uni-ZAP XR	856	1494	754	937		1081	1753	1	1	2	82
		Oct. 13, 1999
511	HTEGI42	PTA-842	Uni-ZAP XR	857	1014	1	806		670	1754	1	1	2	60
		Oct. 13, 1999
512	HTEHR24	209224	Uni-ZAP XR	522	1075	50	1075	84	84	1419	1	29	30	163
		Aug. 28, 1997
512	HTEHR24	209224	Uni-ZAP XR	858	1038	1	1038	41	41	1755	1	28	29	124
		Aug. 28, 1997
513	HTEHU31	209568	Uni-ZAP XR	523	1113	1	1113	121	121	1420	1	25	26	312
		Jan. 06, 1998
514	HTEHU93	209090	Uni-ZAP XR	524	738	1	738	188	188	1421	1	24	25	142
		Jun. 05, 1997
514	HTEHU93	209090	Uni-ZAP XR	859	745	1	745	187	187	1756	1	24	25	113
		Jun. 05, 1997
515	HTEIP36	209244	Uni-ZAP XR	525	752	1	752	22	22	1422	1	19	20	58
		Sep. 12, 1997
516	HTEIV80	209511	Uni-ZAP XR	526	1748	1	1748	203	203	1423	1	14	15	47
		Dec. 03, 1997
517	HTEJN13	97958	Uni-ZAP XR	527	1094	1	1094	156	156	1424	1	15	16	208
		Mar. 13, 1997
		209072
		May 22, 1997
517	HTEJN13	97958	Uni-ZAP XR	860	1147	1	1147	163	163	1757	1	15	16	159
		Mar. 13, 1997
		209072
		May 22, 1997
517	HTEJN13	97958	Uni-ZAP XR	861	1134	1	1134	155	155	1758	1	19	20	71
		Mar. 13, 1997
		209072
		May 22, 1997
518	HTELM16	203648	Uni-ZAP XR	528	531	1	531	121	121	1425	1	21	22	84
		Feb. 09, 1999
519	HTEPG70	203570	Uni-ZAP XR	529	813	1	813	365	365	1426	1	27	28	89
		Jan. 11, 1999
520	HTGAU75	209563	Uni-ZAP XR	530	1713	1	1713	149	149	1427	1	33	34	142
		Dec. 18, 1997
521	HTGEP89	97977	Uni-ZAP XR	531	703	1	703	285	285	1428	1	29	30	94
		Apr. 04, 1997
		209082
		May 29, 1997
522	HTHBG43	PTA-843	Uni-ZAP XR	532	848	1	848	47	47	1429	1			39
		Oct. 13, 1999
522	HTHBG43	PTA-843	Uni-ZAP XR	862	632	103	632	149	149	1759	1			39
		Oct. 13, 1999
523	HTHCA18	PTA-844	Uni-ZAP XR	533	1818	1	1818	231	231	1430	1	15	16	38
		Oct. 13, 1999
523	HTHCA18	PTA-844	Uni-ZAP XR	863	2036	1	2036	224	224	1760	1	15	16	38
		Oct. 13, 1999
524	HTHDJ94	209746	Uni-ZAP XR	534	1632	20	1632	66	66	1431	1	26	27	292
		Apr. 07, 1998
525	HTHDS25	203071	Uni-ZAP XR	535	1061	1	1061	70	70	1432	1	15	16	90
		Jul. 27, 1998
526	HTJMA95	209853	pCMVSport 2.0	536	1650	198	1569	527	527	1433	1	22	23	181
		May 07, 1998
527	HTJML75	PTA-868	pCMVSport 2.0	537	2762	1	2762	30	30	1434	1	1	2	822
		Oct. 26, 1999
527	HTJML75	PTA-868	pCMVSport 2.0	864	2694	21	2694		335	1761	1	20	21	64
		Oct. 26, 1999
528	HTLBE23	PTA-842	Uni-ZAP XR	538	1216	1	1216	129	129	1435	1	17	18	45
		Oct. 13, 1999
528	HTLBE23	PTA-842	Uni-ZAP XR	865	810	286	810		205	1762	1			5
		Oct. 13, 1999
529	HTLFE42	209138	Uni-ZAP XR	539	712	1	712	116	116	1436	1	22	23	77
		Jul. 03, 1997
530	HTLFE57	PTA-1543	Uni-ZAP XR	540	2248	1	2248	124	124	1437	1	17	18	188
		Mar. 21, 2000
530	HTLFE57	PTA-1543	Uni-ZAP XR	866	2298	1157	2214	189	189	1763	1	18	19	170
		Mar. 21, 2000
530	HTLFE57	PTA-1543	Uni-ZAP XR	867	928	1	928	110	110	1764	1	18	19	170
		Mar. 21, 2000
531	HTLGE31	PTA-2081	Uni-ZAP XR	541	534	1	534	51	51	1438	1	17	18	86
		Jun. 09, 2000
532	HTLHY14	203648	Uni-ZAP XR	542	1032	1	1032	36	36	1439	1	17	18	246
		Feb. 09, 1999
533	HTLIT32	203570	Uni-ZAP XR	543	1074	164	897	288	288	1440	1	26	27	246
		Jan. 11, 1999
534	HTLIV19	PTA-2081	Uni-ZAP XR	544	978	1	978	110	110	1441	1	33	34	84
		Jun. 09, 2000
535	HTNBO91	209241	pBLUESCRIPT ™	545	300	1	300	7	7	1442	1	26	27	40
		Sep. 12, 1997	SK-
536	HTOAK16	209368	Uni-ZAP XR	546	1466	1	1466	87	87	1443	1	18	19	110
		Oct. 16, 1997
537	HTODK73	209244	Uni-ZAP XR	547	1019	4	1019	43	43	1444	1	23	24	59
		Sep. 12, 1997
538	HTODO72	209299	Uni-ZAP XR	548	973	1	973	183	183	1445	1	16	17	24
		Sep. 25, 1997
539	HTOGR42	209603	Uni-ZAP XR	549	1430	1	1430	14	14	1446	1	18	19	56
		Jan. 29, 1998
539	HTOGR42	209603	Uni-ZAP XR	868	1433	1	1433	13	13	1765	1	18	19	60
		Jan. 29, 1998
540	HTOHD42	203081	Uni-ZAP XR	550	946	1	946	155	155	1447	1	24	25	190
		Jul. 30, 1998
541	HTOHM15	PTA-843	Uni-ZAP XR	551	1949	1	1949	30	30	1448	1	20	21	61
		Oct. 13, 1999
541	HTOHM15	PTA-843	Uni-ZAP XR	869	408	1	408	23	23	1766	1	20	21	61
		Oct. 13, 1999
541	HTOHM15	PTA-843	Uni-ZAP XR	870	1299	982	1274		71	1767	1	1	2	322
		Oct. 13, 1999
541	HTOHM15	PTA-843	Uni-ZAP XR	871	1669	1	1622		1555	1768	1	9	10	13
		Oct. 13, 1999
542	HTOHT18	209745	Uni-ZAP XR	552	1499	267	1499	433	433	1449	1	24	25	53
		Apr. 07, 1998
543	HTOIZ02	PTA-843	Uni-ZAP XR	553	549	1	549	243	243	1450	1	16	17	50
		Oct. 13, 1999
543	HTOIZ02	PTA-843	Uni-ZAP XR	872	1369	746	1345		2	1769	1	1	2	240
		Oct. 13, 1999
544	HTOJA73	203105	Uni-ZAP XR	554	1294	1	1294	100	100	1451	1	21	22	41
		Aug. 13, 1998
545	HTOJK60	209324	Uni-ZAP XR	555	904	1	904	217	217	1452	1	18	19	32
		Oct. 02, 1997
546	HTPBW79	209511	Uni-ZAP XR	556	1374	1	1374	178	178	1453	1	22	23	362
		Dec. 03, 1997
546	HTPBW79	209511	Uni-ZAP XR	873	1515	118	1507	302	302	1770	1	24	25	362
		Dec. 03, 1997
546	HTPBW79	209511	Uni-ZAP XR	874	1404	1	1404	92	92	1771	1	22	23	415
		Dec. 03, 1997
547	HTSEW17	209138	pBLUESCRIPT ™	557	652	1	652	170	170	1454	1	34	35	37
		Jul. 03, 1997
548	HTTBI76	209641	Uni-ZAP XR	558	1711	1	1711	133	133	1455	1	22	23	133
		Feb. 25, 1998
549	HTTDB46	203484	Uni-ZAP XR	559	3059	1	3059	55	55	1456	1	17	18	318
		Nov. 17, 1998
549	HTTDB46	203484	Uni-ZAP XR	875	2008	215	2008	153	153	1772	1	17	18	461
		Nov. 17, 1998
550	HTWCT03	209086	pSport1	560	1963	1	1963	334	334	1457	1	26	27	101
		May 29, 1997
551	HTWDF76	209852	pSport1	561	963	1	963	316	316	1458	1	24	25	85
		May 07, 1998
552	HTWJK32	209852	Lambda ZAP II	562	911	211	911	376	376	1459	1	20	21	51
		May 07, 1998
553	HTWKE60	209651	Lambda ZAP II	563	407	1	407	185	185	1460	1	25	26	44
		Mar. 04, 1998
554	HTXCV12	209423	Uni-ZAP XR	564	1134	1	1134	175	175	1461	1	27	28	102
		Oct. 30, 1997
554	HTXCV12	209423	Uni-ZAP XR	876	1162	1	1162	183	183	1773	1	27	28	91
		Oct. 30, 1997
555	HTXDW56	209746	Uni-ZAP XR	565	1583	1	1583	217	217	1462	1	21	22	201
		Apr. 07, 1998
556	HTXFL30	209603	Uni-ZAP XR	566	1991	1	1991	30	30	1463	1	39	40	102
		Jan. 29, 1998
557	HTXKP61	203364	Uni-ZAP XR	567	1209	1	1209	169	169	1464	1	33	34	42
		Oct. 19, 1998
558	HUDBZ89	209407	ZAP Express	568	2135	1	2135	1085	1085	1465	1	17	18	73
		Oct. 23, 1997
558	HUDBZ89	209407	ZAP Express	877	1265	1	1265	197	197	1774	1	17	18	54
		Oct. 23, 1997
559	HUFBY15	PTA-1543	pSport1	569	1193	1	1193	49	49	1466	1	26	27	159
		Mar. 21, 2000
559	HUFBY15	PTA-1543	pSport1	878	1012	1	1012	74	74	1775	1	26	27	145
		Mar. 21, 2000
560	HUFEF62	209852	pSport1	570	518	1	518	190	190	1467	1	28	29	68
		May 07, 1998
560	HUFEF62	209852	pSport1	879	539	1	539	182	182	1776	1	28	29	68
		May 07, 1998
561	HUKAH51	209568	Lambda ZAP II	571	853	1	853	286	286	1468	1	20	21	151
		Jan. 06, 1998
561	HUKAH51	209568	Lambda ZAP II	880	754	1	754	144	144	1777	1	22	23	142
		Jan. 06, 1998
561	HUKAH51	209568	Lambda ZAP II	881	667	1	667	55	55	1778	1	22	23	119
		Jan. 06, 1998
562	HUKBT29	209746	Lambda ZAP II	572	1757	56	1757	74	74	1469	1	19	20	506
		Apr. 07, 1998
563	HUSAT94	209580	Lambda ZAP II	573	2234	269	2234	302	302	1470	1	28	29	45
		Jan. 14, 1998
564	HUSBA88	PTA-623	Lambda ZAP II	574	2733	27	2733	270	270	1471	1	15	16	615
		Sep. 02, 1999
565	HUSIG64	209423	pSport1	575	1010	1	1010	9	9	1472	1	21	22	334
		Oct. 30, 1997
566	HUSXS50	209651	pSport1	576	2561	1	2561	280	280	1473	1	19	20	522
		Mar. 04, 1998
566	HUSXS50	209651	pSport1	882	2025	1098	1997	281	281	1779	1	30	31	462
		Mar. 04, 1998
566	HUSXS50	209651	pSport1	883	1020	1	1020	179	179	1780	1	23	24	174
		Mar. 04, 1998
567	HWAAD63	203570	pCMVSport 3.0	577	3308	1	3308	322	322	1474	1	30	31	168
		Jan. 11, 1999
567	HWAAD63	203570	pCMVSport 3.0	884	3306	1	3306	322	322	1781	1	30	31	53
		Jan. 11, 1999
567	HWAAD63	203570	pCMVSport 3.0	885	2194	1	2194	312	312	1782	1	30	31	169
		Jan. 11, 1999
568	HWABA81	209463	pCMVSport 3.0	578	866	1	866	57	57	1475	1	21	22	48
		Nov. 14, 1997
569	HWABY10	203071	pCMVSport 3.0	579	2950	78	2914	263	263	1476	1	22	23	168
		Jul. 27, 1998
570	HWADJ89	PTA-1543	pCMVSport 3.0	580	1769	529	1769	581	581	1477	1	1	2	43
		Mar. 21, 2000
571	HWBAO62	209603	pCMVSport 3.0	581	1903	1	1903	52	52	1478	1	30	31	212
		Jan. 29, 1998
571	HWBAO62	209603	pCMVSport 3.0	886	1940	1	1940	81	81	1783	1	30	31	101
		Jan. 29, 1998
572	HWBAR14	PTA-867	pCMVSport 3.0	582	3878	1	3878	152	152	1479	1	48	49	371
		Oct. 26, 1999
572	HWBAR14	PTA-867	pCMVSport 3.0	887	432	1	432	287	287	1784	1	33	34	48
		Oct. 26, 1999
572	HWBAR14	PTA-867	pCMVSport 3.0	888	794	1	794		204	1785	1	10	11	12
		Oct. 26, 1999
572	HWBAR14	PTA-867	pCMVSport 3.0	889	1019	1	1019		492	1786	1	1	2	129
		Oct. 26, 1999
573	HWBAR88	PTA-867	pCMVSport 3.0	583	1051	1	1051	156	156	1480	1	18	19	75
		Oct. 26, 1999
574	HWBCB89	PTA-499	pCMVSport 3.0	584	1317	3	1317	37	37	1481	1	19	20	187
		Aug. 11, 1999
574	HWBCB89	PTA-499	pCMVSport 3.0	890	1315	1	1315	35	35	1787	1	19	20	187
		Aug. 11, 1999
575	HWBCP79	209641	pCMVSport 3.0	585	1138	1	1138	243	243	1482	1	21	22	105
		Feb. 25, 1998
575	HWBCP79	209641	pCMVSport 3.0	891	1138	1	1138	233	233	1788	1	21	22	105
		Feb. 25, 1998
576	HWBDP28	209641	pCMVSport 3.0	586	1841	1	1841	1342	1342	1483	1	25	26	67
		Feb. 25, 1998
576	HWBDP28	209641	pCMVSport 3.0	892	314	1	314	132	132	1789	1	25	26	61
		Feb. 25, 1998
577	HWBEM18	PTA-868	pCMVSport 3.0	587	6729	1	6729	75	75	1484	1	25	26	1887
		Oct. 26, 1999
577	HWBEM18	PTA-868	pCMVSport 3.0	893	3599	1	3599	65	65	1790	1	25	26	886
		Oct. 26, 1999
577	HWBEM18	PTA-868	pCMVSport 3.0	894	2924	1	2496		1	1791	1	1	2	498
		Oct. 26, 1999
578	HWBFE57	PTA-868	pCMVSport 3.0	588	1133	36	1133	227	227	1485	1	36	37	302
		Oct. 26, 1999
578	HWBFE57	PTA-868	pCMVSport 3.0	895	5811	3302	5811		3300	1792	1	16	17	37
		Oct. 26, 1999
578	HWBFE57	PTA-868	pCMVSport 3.0	896	1012	1	1012		622	1793	1	10	11	16
		Oct. 26, 1999
579	HWDAC39	209641	pCMVSport 3.0	589	753	1	753	96	96	1486	1	20	21	110
		Feb. 25, 1998
579	HWDAC39	209641	pCMVSport 3.0	897	734	1	734	85	85	1794	1	20	21	117
		Feb. 25, 1998
580	HWDAH38	PTA-868	pCMVSport 3.0	590	1604	1	1604	255	255	1487	1	20	21	40
		Oct. 26, 1999
580	HWDAH38	PTA-868	pCMVSport 3.0	898	796	1	796	319	319	1795	1	20	21	40
		Oct. 26, 1999
581	HWHGP71	203858	pCMVSport 3.0	591	1021	1	1021	389	389	1488	1	51	52	211
		Mar. 18, 1999
581	HWHGP71	203858	pCMVSport 3.0	899	1037	1	1037	394	394	1796	1	18	19	77
		Mar. 18, 1999
582	HWHGQ49	209641	pCMVSport 3.0	592	985	1	985	511	511	1489	1	17	18	90
		Feb. 25, 1998
582	HWHGQ49	209641	pCMVSport 3.0	900	1410	33	1410	306	306	1797	1	22	23	150
		Feb. 25, 1998
583	HWHGU54	209782	pCMVSport 3.0	593	1445	1	1445	145	145	1490	1	19	20	414
		Apr. 20, 1998
584	HWHGZ51	PTA-499	pCMVSport 3.0	594	1699	1	1699	33	33	1491	1	30	31	346
		Aug. 11, 1999
585	HWHHL34	203181	pCMVSport 3.0	595	1529	95	1529	131	131	1492	1	30	31	188
		Sep. 09, 1998
585	HWHHL34	203181	pCMVSport 3.0	901	1796	1	1796	209	209	1798	1	31	32	102
		Sep. 09, 1998
585	HWHHL34	203181	pCMVSport 3.0	902	2136	1	2136	101	101	1799	1	30	31	188
		Sep. 09, 1998
586	HWHQS55	203027	pCMVSport 3.0	596	3282	1	3282	169	169	1493	1	26	27	742
		Jun. 26, 1998
587	HWLEV32	PTA-884	pSport1	597	1218	1	1218	39	39	1494	1	18	19	45
		Oct. 28, 1999
587	HWLEV32	PTA-884	pSport1	903	1203	1	1203	29	29	1800	1	18	19	45
		Oct. 28, 1999
587	HWLEV32	PTA-884	pSport1	904	1144	528	596		3	1801	1	1	2	136
		Oct. 28, 1999
587	HWLEV32	PTA-884	pSport1	905	1120	791	851		1	1802	1	1	2	141
		Oct. 28, 1999
588	HWLIH65	203081	pSport1	598	831	1	831	129	129	1495	1	18	19	165
		Jul. 30, 1998
589	HYAAJ71	203517	pCMVSport 3.0	599	3337	1	3337	190	190	1496	1	31	32	62
		Dec. 10, 1998
590	HYBAR01	209580	Uni-ZAP XR	600	1440	1	1440	157	157	1497	1	26	27	46
		Jan. 14, 1998
591	HYBBE75	203570	Uni-ZAP XR	601	838	1	838	319	319	1498	1	25	26	41
		Jan. 11, 1999
592	HAPSA79	PTA-1543	Uni-ZAP XR	602	4386	1	4386	468	468	1499	1	30	31	310
		Mar. 21, 2000
592	HAPSA79	PTA-1543	Uni-ZAP XR	906	4385	1	4385	468	468	1803	1	30	31	310
		Mar. 21, 2000
592	HAPSA79	PTA-1543	Uni-ZAP XR	907	4386	1	4386	468	468	1804	1	30	31	310
		Mar. 21, 2000

Table 1B (Comprised of Tables 1B.1 and 1B.2)